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Every year more than 75,000 pregnant women are exposed to teratogenic medications 
or general anesthesia during non-obstetric surgery in the US,1'4 and embryonic effects o f  
general anesthesia are o f particular interest in laboratory research and veterinary 
medicine. The mouse system is used to screen potential toxic effects o f anesthetics used 
in egg retrieval for in vitro fertilization (TVF), or those o f pharmacologic agents which 
may come in contact with the egg or early embryo. Mouse preimplantation 2-cell 
embryos were exposed in vitro to incremental concentrations o f common general 
anesthetics within and exceeding the normal clinical dosage range for mice (propofol 50- 
200mg/kg, sodium pentobarbital 50mg/kg, and ketamine hydrochloride 50-100mg/kg) for 
72h to determine the effects o f each anesthetic on subsequent cleavage and development 
during prolonged exposure. The anesthetic dosage ranges were as follows: propofol 0- 
25.0|ig/mL, sodium pentobarbital 0-300pg/mL, and ketamine hydrochloride 0- 
5000pg/mL, embryonic development was evaluated every 24h during the 72h mouse 
embryo assay culture period. Results found propofol (> 2.0pg/mL), sodium pentobarbital 
(>30pg/mL), and ketamine hydrochloride (>40pg/mL) to exert inhibitory effects to the in 
vitro development o f preimplantation mouse embryos. The percentage o f 2-cell embryos 
developing to more advanced stages was decreased by exposure to higher concentrations 
of all three compounds. By the 72h endpoint, blastomeres o f delayed and arrested 
embryos began to degenerate, displaying lysis and/or fragmentation; embryos exposed to 
lower concentrations o f  each anesthetic demonstrated a significant ability to continue 
cleavage and differentiation towards blastocyst formation. Conclusion: Embryotoxic 
effects to preimplantation embryos were observed in a dose-dependent manner after 72h 
of in vitro culture with propofol, sodium pentobarbital, and ketamine hydrochloride.
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CHAPTER 1
INTRODUCTION
Potentially teratogenic medications are prescribed to millions of women of childbearing age (age 14- 
44) in the US each year1 and approximately 0.5-2% of pregnant women are exposed to general anesthesia 
during non-obstetric surgery in the United States each year.2'4 For some women, surgery is performed 
before detection of pregnancy, for others surgery may be necessary in spite of the pregnancy.3,5 
Unavoidable surgery may be directly related to a patient’s pregnancy, such as in the case of cervical 
cerclage placement, or indirectly related to a patient’s pregnancy, such as ovarian cystectomy; but may also 
include completely unrelated emergency procedures such as appendectomy, biliary tract disease, cardiac 
disease, cancers, or treatment of injuries such as bone fracture.3'5'6
The use of potentially teratogenic medication is sometimes necessary, since for some applications 
effective nonteratogenic medications do not exist.1 The teratogenic risk of anesthetics in humans is 
difficult to assess,5 however numerous studies suggest exposure to anesthesia may have potential 
detrimental effects on development.6' 16 In addition to utilization for typical non-obstetric surgical 
procedures,2-4 anesthesia is necessary for assisted reproduction procedures such as in vitro fertilization 
(IVF) and gamete intrafallopian transfer.13 Ideally, if a surgical procedure must be performed during 
pregnancy, it should occur during the second trimester to avoid the period o f  organogenesis during the first 
trimester, and to minimize the risk of inducing preterm labor during the third trimester.17 Adequate 
information is not available to definitively ascertain which anesthetics used for these procedures could be 
toxic to the oocyte or the developing embryo,13 making the study of the effects of anesthetics to early 
embryonic development an area of particular interest.
Anesthesia is defined as the absence of sensation, contrasting with analgesia, the relief o f pain.18 
Anesthesia may be classified as either local/regional (in a specific area of the body), or general (absence of 
sensation in the entire body).18 The general anesthesia state is a balance of numerous effects including 
unconsciousness, analgesia, immobility, and suppression o f reflexes and stress response.19 The four stages 
of general anesthesia consist o f induction, maintenance, emergence, and recovery.20 Induction of general 
anesthesia involves the safe and rapid passage of a patient from the conscious to the unconscious state.20 
Induction may be accomplished by intravenous (IV), inhalational, and less commonly intramuscular (IM), 
or intraosseous (IO) means, to achieve adequate concentrations of anesthetic agent within the brain.20
History O f Anesthesia
The father of chemistry and founder of medicinal chemistry and toxicology, Renaissance physician 
Paracelsus anticipated the practice of anesthesia with his philosophy that “no thing is without poison; solely 
the dose determines that a thing is not a poison.21,22” Until the discovery of anesthesia, surgical patients
Anesthesiology
were fully conscious during what can only be described as quick and brutal p rocedures.T hroughout 
history, numerous agents have been used for hypnotic or sedative properties, such as alcohol, opium, and 
narcotic plants such as hemp, jimsomweed, belladonna, henbane,24 and coca.23
Modem anesthesia emerged with the discovery of the effects of two gases, diethyl ether and 
chloroform.21-23 Boston dentist William Morton, the founder of modem anesthesia, investigated diethyl 
ether inhalation after discovering that significant anesthesia was produced by topical application of ether to 
the teeth of a patient teeth before extraction.23 After great success with inhalation of volatile ether for 
unconscious, painless tooth extraction, in 1846 Morton assisted the Chief of Surgery at Harvard, John 
Collins Warren, in performing the first surgery using general anesthesia.23 Concurrently, Scottish 
obstetrician James Young Simpson was determined to find a better anesthetic than ether, and once 
introduced to chloroform, he was inspired to promote its use as a volatile anesthetic.23 Chloroform 
anesthesia became widely accepted and its use remained prevalent for decades;23 chloroform was so 
popular that it was used anesthetize Queen Victoria for the birth o f Prince Leopold in 1853 .25
During the development of anesthesia in the late 19th and early 20th centuries, several hundred 
anesthetic gases were discovered and used, however almost all were be explosive (except chloroform and 
nitrous oxide),23 and inhalation of these gases often resulted in slow, unpleasant, and occasionally 
dangerous inductions.21 The discovery that fluorination of volatile gases reduced its flammability led to the 
developm ent o f  superior volatile anesthetics.23 V olatile agents such as isofluorane and  sevoflurane 
continue to be used extensively as general anesthetics,20-23 and desflurane or halothane may also be used 
occasionally.20
Although anesthesia transformed modem medicine, the necessary inhalation of vapors seemed 
unpleasant to many patients,23 as well as sometimes causing slow or dangerous inductions.21 Little 
alternative to inhalation anesthesia was available prior to development of the IV route, following the mid- 
19th century technological advancement of hollow needles and syringes.19-21 Drug administration through 
direct access to the bloodstream allowed the rapid induction and maintenance of general anesthesia .19-21 
The first IV anesthetic successfully used was chloral hydrate in 1872.23-24-26 Various other intravenous 
drugs were experimented with, but most were abandoned once side effects became apparent,23 and IV 
anesthesia did not become popular until the 1930s with the clinical introduction of barbiturates.26
Originally synthesized by Volwiler and Tabem in 1930,24 pentobarbital and its sulfur derivative 
thiopental revolutionized intravenous anesthesia.23-24 John Lundy and colleagues of the Mayo Clinic 
introduced pentobarbital and thiopental anesthesia for clinical use, and barbiturates use as IV anesthetics 
quickly gained popularity.23- 24 During this time, many barbiturates were developed, however the only one 
to offer any significant challenge to thiopental and pentobarbital was the ultrashort-acting hexobarbital.21-27 
Hexobarbital use was limited due to the fact that induction was not as smooth27 and it allowed some 
myoclonic movement.21-24 Derivation of thiopental by the addition of a sulfur group to pentobarbital 
increased the lipid solubility to alleviate problems caused by slower acting pentobarbital,24 and thiopental
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lacked excitatory movements manifested by hexobarbital.21 Barbiturates had many undesirable properties 
though, including cardiovascular depressant action,23 instability o f solutions, irritant effects at the site 
injection, absence of analgesia, and unfavorable pharmacokinetics for extended use,27 ultimately 
contributing to the development of new induction agents.21'27
The first non-barbiturate IV anesthetics such as dolitrone and hydroxydione had undesirable properties 
as well.2' The development of etomidate in 19742' demonstrated an agent which had several benefits over 
barbiturates, including minimal cardiovascular depressant effects.23'27 In addition, several of its undesirable 
effects were minimized with prior use o f fentanyl, for “balanced anesthesia.” 2' Balanced anesthesia, a 
concept first theorized by Lundy in 1926, uses a combination of premedication, local anesthetic, and 
general anesthetic to reduce the dose of each agent to minimize side effects and improve safety.21,23
Ketamine (Ketalar) was synthesized in 196223'28 and was quickly adopted by the American military 
during the Vietnam War for its favorable hemodynamic effects, and was later released for civilian use.29 At 
the time, ketamine was believed to be the perfect anesthetic because it provided loss of consciousness and 
antegrade amnesia28 as well as good analgesia even at subanesthetic concentrations,30 however emergence 
from ketamine anesthesia produced undesirable psychotomimetic side effects,31,32 leading to the continued 
search for an ideal anesthetic. Later work with ketamine showed the retention of desirable and absence of 
undesirable properties of the pharmacologically available racemic mixture with use of enantiomers of 
ketam ine; how ever the in troduction  o f  o ther agents such as propofol overshadow ed these potential 
benefits.27 Propofol (Diprivan) was clinically introduced in 1977 as a highly lipophilic short-acting IV 
anesthetic.15’23,33"43 Compared to other anesthetics, propofol is advantageous due to its rapid action with 
short, predictable duration, and rapid, antiemetic, clear-headed recovery, making propofol arguably the 
most frequently used IV induction agent.15,23'30'33"43
Anesthetic General Information
General anesthetics are highly selective, only binding to a small number of targets in the central 
nervous system (CNS).44 Drug transport to vessel-rich tissues such as the brain is necessary for rapid onset 
of action, and IV administration allows immediate introduction of a dose to the bloodstream.45 The primary 
targets of IV anesthetics are CNS ion channel-linked receptors for the either the endogenous 
neurotransmitter glutamate, the main excitatory neurotransmitter in mammals, or gamma-aminobutyric acid 
(GABA),21 the most abundant inhibitory neurotransmitter.19'21'46"50 GABA is synthesized by glutamic acid 
decarboxylase from L-glutamic acid,51 and GABA modulates inhibition in the CNS by activating two 
classes of receptors, ionotropic (GABAa /GABAc) and metabotropic (GABAB).47'50'52'53 Metabotropic 
GABAb receptors couple to G proteins (guanine-nucleotide-binding proteins) to influence the movement of 
potassium and calcium ions and modulate synaptic transmission through intracellular effector systems.52"55 
Ionotropic GABAa receptors are ligand-gated ion channels that convey fast synaptic transmission,53 and
most IV anesthetics (except ketamine) exert their primary action by enhancing inhibitory signaling at 
GABAa receptors.19,21,44
The GABAa receptor is a pentameric transmembrane glycoprotein of about 275 kDa47 composed of 
phylogenetically related subunits (al-6 , pi-4, y l-3 ,8, e, p l-3)56 assembled around an integral 
transmembrane chloride (Cl ) channel.19,47,56 GABA facilitates inhibition47,50 by binding to GABAa 
receptors, regulating the gating of the C f channels47,48,57 to hyperpolarize neuron membranes .21 In addition 
to the GABA recognition site, the GABAa receptor includes a variety of allosteric modulatory sites through 
which many pharmacological agents can influence receptor function58 by enhancing the binding of GABA, 
while inhibiting the binding of GABA antagonists.50,58,59 The GABAa receptor is the primary target of a 
diverse group o f anxiolytic, sedative, anticonvulsant, and anesthetic pharmacological agents, including 
barbiturates, benzodiazepines (midazolam, valium, diazepam, clonazepam), ethanol, neurosteroids 
(pregnenolone, dehydroepiandrosterone), and general anesthetics such as halothane and 2-6- 
diisopropylphenol (propofol).48,50,58'60
Na- Ca; '








Fig. 1. Key targets of intravenous anesthetics. GABAa receptors are critical targets for benzodiazepines, 
barbiturates, etomidate, and propofol. Although it is possible for the drugs and ligands to interact with this 
protein in multiple areas, it is generally agreed that the endogenous ligand GABA binds to the receptor in a 
pocket between the a and P subunits. Many of the intravenous anesthetics have their main influence on the 
activity of this protein in the transmembrane portion of the p subunit, while the benzodiazepines modulate 
the protein through interactions with transmembrane amino acids between the a  and y subunits near the 
intracellular side. NMDA receptors are activated by the agonist glutamate and co-agonist glycine only 
when voltage changes displace Mg2+ from the ion channel pore. Ketamine also acts primarily by a pore- 
blocking mechanism.19 Reprinted from Pharmacology and Physiology for Anesthesia, edited by Hemmings 
HC, Egan TD, Intravenous Anesthetics, Garcia P, Whalin MK, Sebel PS, Pages 137-158, Copyright 2013, 
with permission from Elsevier.
The excitatory signaling in the adult mammalian CNS is primarily dependent upon the 
neurotransmitter glutamate acting on A’-methyi-D-aspartate (NMDA) and non-NMDA receptors.46,61 The 
glutamate NMDA receptor is a heteromeric, integral membrane protein subclass of the excitatory L-
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glutamate family of neurotransmitter receptors, acting via the receptor-gated cation channel, which is 
permeable to Ca2+ and some monovalent cations48,61 such as sodium, to depolarize neuronal membranes and 
activate signaling pathways.21 The name “NMDA receptor” is attributed to the fact that NMDA stimulates 
these receptors under experimental conditions; however NMDA is not endogenous, it is a synthetic 
chemical used to probe the activity o f this class of receptors.62 Anesthetic effects are achieved by the 
blockade of NMDA receptors19 when agents such as ketamine HC1,63 phencyclidine (PCP),11,64 
dextromethorphan,65 and nitrons oxide66 act to antagonize the binding of glutamate.11,63"66
GABA Receptor Agonists: Propofol
The GABAa receptor agonist propofol is a short-acting IV anesthetic,15,23,30,33"43 advantageous for its 
rapid action with short, predictable duration, in addition to rapid, antiemetic, clear-headed 
recovery.15,23,30,33"43 The anesthetic effects of propofol are attributed to its high lipophilicity43,67 allowing 
rapid penetration of the blood-brain barrier and distribution to the central nervous system.38,67 The 
lipophilic nature of propofol in addition to the steric effects it exerts act to suppress excitatory synaptic 
transmission and synaptic plasticity, and facilitate long-term depression by increasing Cl" conductance at 
the GABAa receptor.43,46,49 Propofol is a non-chiral isopropylphenol68"70 chemically distinct from all other 
IV induction agents.70 Propofol has a pH of around 7.0, a pKa of 11, is stable at room temperature, and is 
not sensitive to light,26,30 and due to high lipid solubility with only slight water solubility, propofol 
(Diprivan) is formulated as 1 % w/v of oilAvater emulsion of soybean oil, glycerol and purified egg 
phosphatide.21,43 Propofol induces narcosis and suppression of withdrawal reflexes in a dose-dependent 
manner,71 and in addition to antiemetic properties, propofol has antioxidant, immunomodulatory, 
neuroprotective, and analgesic effects,43 and it is the only induction agent, with the exception of ketamine, 
with good analgesic properties in addition to its anesthetic action.28
Propofol may have other sites of action in addition to the GABAa receptor; the glycine receptor has 
been suggested to contribute to analgesia and anesthesia,60 and some o f the analgesic effects o f propofol 
may be modulated through opioid receptors and the release of p-endorphin; serum levels of P-endorphin 
have been found to be increased during peak propofol action.72 The cardiovascular and respiratory effects 
of propofol are similar to those produced by other injectable anesthetics such as barbiturates,35 including 
brief periods o f apnea, and reduction o f arterial blood pressure and cardiac output. IQ',,p4° Some adverse 
effects of propofol include pain on injection30,73 (often mitigated with lidocaine), apnea, hypotension, and 
occasional excitatory effects such as myoclonus.30
Propofol does not accumulate significantly after repeat boluses, making it is especially suitable for 
long-term infusions during surgery, and for long-term sedation in the ICU.I9-21-26-30-73 Propofol is widely 
used as an anesthetic for gastrointestinal endoscopy and minor surgical procedures, as well as in obstetric 
and gynecologic practices for assisted reproduction procedures.37 The most common obstetric procedures 
during which propofol is used are Caesarean sections36,41 and transvaginal oocyte retrieval during in vitro
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fertilization (IVF).28,34,3 When used for IVF, propofol allows relatively painless puncture on an out-patient 
basis,37 making it one o f the most common anesthetics used in ultrasound-guided transvaginal oocyte 
retrieval.15,34,37,39 Propofol is also a popular agent to reduce intracranial pressure (1CP)73 and for 
neuroanesthesia19 for its ability to decrease the cerebral metabolic oxygen requirement, allowing cerebral 
vasoconstriction.19,73
The anesthesia induction dose of propofol for human adults ranges from between 1.5- 
2.5mg/kg19,26,30,43,67,74 with maintenance provided by continuous infusion of 4-12mg/kg/h or intermittent 
repeat bolus injections of 20-50mg,43,67 and for mice, dosages range from 50-200mg/kg (IP) (50- 
200pg/mL).75 In humans, the propofol distribution half-life for a single bolus or an infusion has been 
shown to be approximately 2 to 4 minutes, with total clearance between 77 and 156 L/h.43,67 Metabolism of 
propofol is rapid30,39,40,43,67 and primarily hepatic30,40,43,67,76 and 88% of propofol metabolites have been 
recovered in the urine, with less than 0.3% excreted as unchanged propofol.77 The major metabolites are 
inactive glucuronide metabolites,43 the glucuronic acid propofol conjugate and the glucuronic acid and 
sulphate conjugates of its hydroxylated derivative, 2,6-diisopropyl-l,4-quinol.30 77
GABA Receptor Agonists: Barbiturates
Barbiturates are general central nervous system depressants used clinically for their anesthetic, 
sedative-hypnotic and anticonvulsant effects.50,78,79 Barbiturates are substituted derivatives of barbituric 
acid, a condensation product of urea and malonic acid.80 Barbiturates are neuromodulators which 
potentiate presynaptic inhibition by acting as agonists at the GABAa receptor47,50,58,79,81 Barbiturates such 
as pentobarbital also act to enhance postsynaptic inhibitory responses to GABA by enhancing sodium (Na ) 
independent binding of GABA to synaptic membranes at clinically relevant concentrations (100- 
lOOOpM).78 Some common barbiturates include amobarbital, secobarbital,24 methohexital, thiopental, 
phenobarbital (Luminal) and pentobarbital (Nembutal).24,56,82 Although it has been largely displaced by 
benzodiazepines (BZDs), phenobarbital is still occasionally used for certain types o f epilepsy and 
emergency convulsion treatment.24,59 The more potent pentobarbital56,58,71 was once a widely used general 
anesthetic, however the development of other anesthetic agents such as etomidate and propofol24 in 
response to some of the negative anesthetic properties of barbiturates such as toxic effects including tissue 
irritancy or high mortality83 has led to the reduction of the anesthetic use of barbiturates.15-23-30-33-43 
Pentobarbital anesthesia remains prevalent in some areas however,82 and additional applications include 
treatment of insomnia as a sedative-hypnotic, emergency anticonvulsant treatment,24,82,84,85 and treatment of 
intracranial pressure in patients with head injury, encephalitis, cerebral ischemia,24,73,86 for sedation and 
treatment of ICP and epilepsy in pediatric intensive care,13 and has been frequently used in pediatrics alone 
or combined with other agents for sedation during MRI procedures.87 Pentobarbital also continues to be a 
common agent used for numerous applications in veterinary medicine and for laboratory animals68,82,85,88
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The oxybarbiturale pentobarbital26’68 is formulated the by the alkylation of a-ethylmalonie ester with 2- 
bromopentane.89,90 The pentobarbital Nembutal solution is formulated as a sterile 6.5%82 racemic mixture
8^  89  90  *of s te re o is o m e rs ,’ containing propylene glycol for minor preservative action and to increase 
miscibility with water,82'91 and like most barbiturates, it is formulated as a sodium salt to increase solubility 
and stability in solution.19,21,82,92 Once reaching the plasma, barbiturates become lipophilic, leading to rapid 
profound anesthesia after bolus injection.19 The recommended anesthetic dosage for pentobarbital is 
between 100-200mg (2-4mg/kg) for induction in humans.24'73 For anesthesia in rodents, doses range from 
30mg/kg (IV) for the rabbit93 and 50mg/kg (50pg/mL) for mice (IP),94 to the wide range of the rat, from 
60mg/kg95 to as much as SOOmg/kg.96 Pentobarbital is metabolized by liver microsomal P450 primarily by 
hydroxylation, resulting in four 5-ethyl-5-(3’-hydroxy-l’methylbutyl)-barbituric acid metabolites.97
NMDA Receptor Antagonists: Ketamine
D, l-2-(o-ChlorophenyI)-2-(methyIamino) cyclohexanone hydrochloride (ketamine HC1)63 is a non­
competitive antagonist of glutamate NMDA receptors.21,28,29,68,98'100 Ketamine is an 
arylcyclohexylamine30,101 PCP derivative, and a general parenteral anesthetic agent with unique 
pharmacological properties.11,64 The ketamine molecule is chiral and is prepared as a racemic mixture of S 
(+) and R (-) enantiomers.19,27,29,73,102 Ketamine HC1 solution is freely water-soluble, slightly acidic (pH 
3.5-5 5), with a pKa of 7.5,26,29,30 and benzethonium chloride is added as a preservative.26 The rapid 
anesthetic action of ketamine HC1 is attributed to its high lipid solubility and relatively low molecular 
weight (274.19).29,31
Ketamine is considered to be safe, nontoxic, and potent, with short duration of action.7,100 Ketamine is 
widely used for anesthesia in pediatric patients,29,103 and has been previously used in obstetrics for its rapid 
induction o f profound anesthesia.31,64 Currently, ketamine anesthesia is also common for patients suffering 
hemodynamic compromise due to the positive hemodynamic effects it exerts,23,29 making its use is 
prevalent in military field hospitals,27,29 and for emergency Caesarean sections with heavy blood loss.104 
The positive hemodynamic pharmacokinetics also make ketamine anesthesia useful for cardiovascular 
compromised patients with acute hypovolemia, hypotension, cardiomyopathy, pericarditis, congenital heart
21 29  21 73disease, bronchospastic disease, cardiac tamponade, acute hemorrhage, or acute asthma. ’ Ketamine 
has relatively low protein binding19,82 much less than that of barbiturates or propofol, making it useful for 
hypoproteinaemic patients.82 In addition, ketamine remains a common anesthetic in developing nations for 
its low cost,19,27,29 and for veterinary surgery,29,101 as well as being frequently used for sedation during 
regional techniques,33 repeated dosage for analgesia in bum victims,27,33 postoperative pain relief in patients 
with chronic symptoms,33 and in pediatric patients.19-26-27
A unique attribute of ketamine is that it is one of the few anesthetics capable producing analgesia,73 
making its selection more desirable for certain applications than propofol or barbiturates.26 The versatility 
o f ketamine administrative routes (IV, IM, oral, rectal) also make its use advantageous,21,26 especially in
pediatrics,26 and it remains the only induction agent which can be administered intramuscularly (IM) as 
well as intravenously (IV).23 CNS depression is the predominant effect produced by ketamine, and a broad 
range of doses can be injected to induce anesthesia without convulsions or danger of death from respiratory 
arrest,63 and there is a low incidence of vomiting in the recovery phase.31 Ketamine has a vasopressive 
effect on peripheral circulation31 and has a short-lasting effect on the cardiovascular system causing 
tachycardia and an increase in arterial blood pressure. I2|,1'6,'6‘t
The main disadvantage of ketamine is a strong tendency to undesirable physiologic reactions that 
typically occur after awakening from anesthesia (emergence reactions).28 These reactions are characterized 
as psychotomimetic side effects31'32 and include vivid peculiar dreams, hallucinations, and delirium during 
recovery.28- 31 Emergence reactions are less intense in children,29 but the psychotomimetic effects in adults 
have led to the decreased use o f ketamine as a lone agent.23 Adverse reactions may be reduced by 
preoperative discussion with patients, but ketamine may also be used in combination with other drugs (such 
as BZDs)26 for balanced anesthesia to significantly reduce hallucinations and other side effects.23
The recommended anesthetic dosage and for adult humans dosage ranges from between 0.5-2.0mg/kg 
(IV) and 4-10mg/kg (IM)20,29 (maintenance with 10-30pg/kg IV infusion); and for sedation and analgesia, 
from 0.2-0.75mg/kg (IV) and 2-4mg/kg (IM) (with 5-20pg/kg IV infusion for maintenance).29 For mice, 
the recommended anesthetic dosage is 50-100mg/kg (50-1 OOpg/mL) administered via intraperitoneal (IP) 
injection.105 Clearance o f ketamine is rapid, resulting in a relatively short elimination half-life due to both 
the high hepatic extraction ratio and limited protein binding.30 Ketamine is quickly metabolized by 
cytochrome P450 enzymes19,61,64 by demethylation and hydroxylation of the cyclohexanone ring, with 
metabolites excreted in the urine.29 The main metabolite of ketamine, norketamine, is one-third as potent 
as ketamine19 and may contribute to the analgesic effects,61 but also may be involved with the undesirable 
side effects.30
Choice O f Anesthetic
Injectable anesthetic agents may be used either to induce anesthesia prior to maintenance with a 
volatile inhalant, or as the sole anesthetic agent.82 The most common inhalation agent is sevoflurane, 
however inhalation induction in is rarely used for anesthesia of adults.20 Volatile anesthetic agents exhibit 
less specificity than IV agents,19 but an ideal injectable anesthetic is yet to be developed.82 For human 
anesthesia, use of a single agent is predominately achieved by IV injection, followed by infusion to extend 
anesthesia duration.82 This anesthetic technique is known as total intravenous anesthesia (TIVA), and its 
development is largely attributed to the popularity of propofol as an efficacious monoanesthetic agent.23 
TIVA provides good general anesthesia and eliminates the need for volatile agents,20'23however it is 
necessary that drugs used for TIVA possess short half-lives to prevent accumulation.20
Rapid induction of anesthesia is the main advantage of IV agents, but all o f the desired properties of an 
anesthetic may be unachievable with a single IV agent.26 Some of the properties of a single agent may be
9
contradictory, such as the high lipid solubility of a rapid acting drug reducing its water solubility.26 Some 
of these drawbacks may be addressed by presenting the agent as a salt to improve solubility such as in 
ketamine hydrochloride and sodium pentobarbital,82'92 Solubility issues may also be alleviated by addition 
of other compounds, such as in the case of sodium pentobarbital, which contains propylene glycol to make 
it miscible with water,82'91 or the lipid emulsion used to formulate propofol.19 The addition of compounds 
to the anesthetic formulation can sometimes have important clinical implications, such as in the case of 
propofol, in which the lipid formulation can promote rapid microbial growth.19 Other indications of 
anesthetic agents such as the positive antiemetic effects o f propofol19 and the analgesic effects73 and 
versatility of ketamine,21'26 or negative effects such as cardiovascular depression by propofol causing 
hypotension in some patients,19 emergence reactions of ketamine,28 or potential toxic effects of 
pentobarbital83 influence the selection of an agent for a specific procedure. The availability of an agent is 
also an important factor influencing selection; the recent shortage of drugs such as propofol and thiopental 
has made the choice of an induction agent be more dictated by availability rather than by pharmacology.21
When available, the most ideal agents for TIVA include the alfentanil, as an analgesic and propofol as 
an anesthetic.20 TIVA with propofol has advantages over anesthetic maintenance with volatile agents in 
some patient populations.19 The rapid effects and antiemetic qualifies of propofol make it a frequent choice 
for sedation in monitored anesthesia care, as well as for induction and maintenance o f general anesthesia,19 
and it is especially suitable for long-term infusions during surgery and on the ICU for long-term sedation 
since it does not significantly accumulate.26
Many synthetic agents used for anesthesia are chiral drugs, and nearly all of these agents are 
distributed as racemic mixtures rather than in pure enantiomeric formulations.102 One enantiomer is often 
be responsible for therapeutic action, and the other may offer different properties, be pharmacologically 
inert, or even have undesirable effects.102 Ketamine and pentobarbital are produced as racemic mixtures, 
and most clinical preparations continue to be a racemic mix of the R and S enanfiomers.19,73 Enantiomers 
of ketamine have been found to retain desirable and lack undesirable properties of the racemic mixture,27 
and trials have been conducted with the (S+) enantiomer, which is more potent106 and has been shown to 
limit potential adverse effects such as emergence reactions.73’106 The The S(-)-enantiomorph of 
pentobarbital is more potent than the corresponding R (+)-isomer,58'97 and future use of pentobarbital may 
be expanded by application of one stereoisomer if clinical experimentation shows promise. The 
disadvantage to use of single enantiomers is the availability of these isomers, which are expensive and 
scarce, which may also restrict identification of molecular targets of action.107
Preoperative Assessment, Pregnancy Testing, And Abuse
In addition to being one of the first physicians to adopt the practice of anesthesia, John Snow also 
introduced the importance of pre-anesthesia physical examination.25 Between 0.5-2% of pregnant women 
are exposed to general anesthesia during non-obstetric surgery in the United States each year,2-4 and this
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percentage does not include patients who are not yet aware o f their pregnancy at the time of surgery.4 
Basic standards exist for pre-anesthesia evaluations which apply to patients undergoing all techniques of 
anesthesia established by The American Society o f Anesthesiologists.25 These guidelines are periodically 
revised25 to standardize the preoperative assessment and reduce the risk o f critical incidents.20
The preoperative assessment is as important as the anesthetic procedure itself.108 Preoperative 
assessment is the part o f patient management before induction, and it establishes the extent of any co­
morbidity, in addition to current medication, and potential complications which may arise in response to
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anxiety states, allergies, difficult airways or venous access, ’ diseases, or pregnancy. Careful history 
evaluation and physical examination constitute routine preoperative assessment,25'108 followed by further 
tests only if the indicated appropriate by patient medical history.25 Routine tests may have shortcomings 
such as failure to uncover pathologic conditions, or inadequate follow-up and false positives may lead to 
patient distress and provoke further invasive testing.25 One such test is the hCG pregnancy test, the most 
widely used immunoassay,109 which is reliable but only necessary if  indicated by the patient medical 
history.25 Women of child-bearing age are asked about their last menstrual period and only if their 
pregnancy status is uncertain, pregnancy testing is performed.4 The anesthesiologist must consider if the 
pregnancy would be affected by the anesthetic agents or if the pregnancy is desired or unintended, such as 
in the case o f detection of pregnancy in teenager wishing to hide her condition from her parents.25 If 
pregnancy is diagnosed, concerns are raised whether surgery or anesthesia may endanger the developing 
embryo or fetus by increasing the risk of congenital abnormalities or spontaneous abortion.4
The accurate establishment of the pregnancy duration and timing of conception is essential for 
optimum care.110 First trimester anesthesia exposure has been found to increase the risk of spontaneous 
abortion and lower birth weight.4 This is the period of maximum sensitivity to teratogenicity, during which 
organogenesis occurs.4 To minimize potential miscarriage or congenital defects, elective surgery during 
this time should be deferred,4 however surgery may sometimes be necessary in spite of the pregnancy.3'5 
Pregnancy may also be endangered by other factors in addition to surgery. 85% of prescriptions of 
potentially teratogenic medications to women of childbearing age are by outpatient physicians such as 
family/general practitioners, internists, psychiatrists, and dermatologists.1
Establishment of pregnancy relies upon several factors. Historically, pregnancy has been dated by 
using the first day of the last menstrual period (LMP), which is usually the only data available for very 
early pregnancy, but the LMP method is frequently inaccurate.110 During early pregnancy, the rise in hCG 
concentration is uniform, so the measurement of hCG levels provides the most accurate early estimation of 
gestational age.110 Home pregnancy testing using the hCG immunoassay offers the advantages of privacy 
and early detection necessitating a clinical visit.111 More than 20 brands of home pregnancy tests (HPTs) 
are commercially available, and home pregnancy testing continues to be a dominant method for early 
detection despite about problems with interpretation or results and false pregnancy detection.111 In a study 
of over-the-counter HPTs, only 1 of 18 HPTs tested was found to have the sensitivity needed to detect 95%
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of pregnancies at the time of missed menses, and 2 gave false positive or invalid results.111 Women with 
intended conceptions are more likely to recognize early signs of pregnancy than those with unintended 
pregnancies,112'113 however the sensitivity limitations of HPTs causing false-negative tests can mislead 
women and result in avoidance of positive pregnancy behaviors.109 The behavior of a woman during 
pregnancy may be influenced by their attitude toward the pregnancy.112 This can affect the health of their 
infant by either compelling a woman to seek early prenatal care, or to avoid detrimental behaviors such as 
smoking,112 use of fetotoxic drugs, or consuming alcohol.109
Nearly 90% of drug-abusing women are of childbearing age; consequently it is not unusual to 
encounter pregnant women who abuse illicit drugs.114 Drug use may be explained by addiction or an 
individual’s desire for novel experiences or changes in mood.115 The diverse clinical manifestations of 
drug abuse in combination with physiologic changes of pregnancy or of a coexisting pregnancy-related 
disease may lead to significant complications.114 The most extensively studied agent of abuse, alcohol, is 
well documented to have profound deleterious effects on embryonic and fetal development.115'118 Heavy 
use of alcohol can also alter the effects of other drugs and may even increase euphorigenic effects.115'116
Drug abuse is not limited to illicit drugs with no recognized medical use; it also encompasses misuse 
and intentional abuse of pharmaceuticals and over-the-counter medicines. Legal pharmaceuticals may be 
illicitly obtained for misuse,119 and even if a drug is obtained legally from a physician it may become 
subject to abuse.119,120 While state and Federal law classifies (Schedules) and restricts access to controlled 
substances according to their medical use and potential for abuse, many of these substances continue to be 
abused.121 In 2005, the National Survey on Drug Use and Health found 6.4 million people to have used 
prescription pharmaceuticals for nonmedical reasons during the past month, with use of pain relievers by 
4.7 million, tranquilizers by 1.8 million, and stimulants by 1.1 million people,122 and women have 
previously been found to have a higher rate of sedative and tranquilizer abuse.123 Those granted access to 
controlled substances include chemical distributors, pharmacies, hospitals and clinics, physicians, 
veterinarians, and researchers;121 however professionals that prescribe or work around restricted 
pharmaceuticals are at risk of abusing these readily available medications.122 Professionals working in 
anesthesia,119'124'125 emergency medicine, and psychiatry have the highest rates o f pharmaceutical drug 
abuse,119 and physicians in general also have a higher rate o f psychoactive substance abuse than the general 
population.124
The increased abuse of substances by people working in medical and veterinary occupations may first 
attributed to access to controlled substances.122'124’125 Many of these professionals administer these potent 
drugs and directly observe their effects on a daily basis, and often the routine of the process can make one 
desensitized to the importance and danger of controlled substances.125 In addition, it takes a relatively 
short period of time to leam the technical skill to administer many of these substances, and often the 
application of these drugs is performed with minimal supervision.125 This can cause some individuals 
without prior risk factors or history of abuse to develop a curiosity about these drugs, a sentiment which
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may rapidly progress to experimentation and addiction.125 In addition to anesthetics, some drugs 
commonly abused by medical professionals include opiates, amphetamines, barbiturates, and 
benzodiazepines.119
Even if some drugs such as veterinary medications are not approved for human use, they may be 
abused by individuals with easy access, including veterinarians or veterinarian assistants,126"128 horse 
trainers, or farmers.127 Like many physician and dental offices, veterinary offices maintain pharmacies to 
fill out-patient prescriptions and carry an inventory of drugs for on-site procedures.129 Veterinary offices 
differ from most clinical medical offices, though, since they also serve as surgical centers, performing 
invasive procedures requiring large quantities of pharmaceuticals used for both human and veterinary 
medicine as well as drugs specific for animal use.128 129 Veterinary offices are also unique in that they also 
perform euthanasia procedures requiring highly potent medications.128'129
Although the abuse of controlled substances may be higher in individuals working in occupations 
where these drugs are more readily accessible, many of these medications may be obtained by the general 
public by alternative means. Some individuals with access to controlled substances contribute to abuse 
through the illegal sale o f pharmaceuticals.122 In a recent survey o f over 4,000 respondents, individuals 
were asked the source from which they illegally acquired their drug of choice. The three most frequently 
reported sources for illicitly acquiring a pharmaceutical drug were drug dealers, friends or relatives, and 
physician prescriptions.130 Additional sources for illegally obtaining pharmaceuticals include theft,130,120 
forged prescriptions, and the Internet.130 While the Internet is currently a relatively minor source for the 
illicit purchase of prescription pharmaceuticals, many of these drugs are available on the Internet.130 Most 
websites provide adequate control of the purchase of pharmaceuticals but the legality of some online sales 
is questionable and some websites are completely illegal.131 Disadvantages of using the internet to acquire 
pharmaceuticals include fear of possible detection by authorities, scams, and price considerations 
(prescription drugs are less expensive on the street).130
Pharmaceuticals may also be illegally obtained in other countries where the restriction of certain agents 
is much less stringent than in the United States. An example of such an agent is pentobarbital, currently 
only used in the United States as a veterinary anesthetic68,82'85'88' 128 and as a sedative/hypnotic in human 
medicine,115 but its anesthetic use for humans continues in many countries.82 In addition being subject to 
abuse, pentobarbital use for assisted suicide is advocated by the Exit International Association.128 Exit’s 
mission is to aide individuals experiencing chronic painful disease or severe physical degradation.128 
Information intended to assist individuals wishing to commit suicide is available in “The Peaceful Pill 
Handbook,” written by the founder of the Exit Association, Philip Nitschke. In addition to containing 
extensive instructions for self-euthanasia, this publication also describes how to illegally obtain substances 
such as pentobarbital.132 Nitschke cites Mexican pharmacies to be the preferred source to easily obtain 
pentobarbital and devotes an entire chapter detailing how to acquire and transport the drug back to the
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US.132 This information can be accessed in minutes following a simple web search by any individual 
lacking “street connections” with a desire to obtain pentobarbital.
Some of the side effects o f anesthetics which have limited their use in the medical field can make them 
desirable to abusers. Anesthetic use of pentobarbital is prevalent in veterinary medicine ' ‘ but is 
limited in humans;24 '3'82'84'87’" 5 however it has a high potential for abuse115'121'122'133 in addition to 
possessing strong addictive properties.119,121,133 Common street names pentobarbital may be identified by 
include Nembutal, Nembies, yellow jackets, or yellows.119 Another anesthetic used for both veterinary and 
clinical anesthesia, ketamine, is also highly addictive119'121 and may possess an even higher potential for 
abuse.7'11'29'101 Ketamine is considered to have unique euphoric hallucinogenic properties7'119'134 that enable 
the abuser to experience effects similar to PCP, cocaine, or lysergic acid diethylamide (LSD) with varying 
doses; and it is frequently used in combination with other drugs and as an ingredient in MDMA (ecstasy).' 
Alternative names ketamine may be identified by include Special ^  71,'29-10l-n6 Ket,711'29'101 K, Vitamin 
K,29'101 or c a t " 9
Propofol is currently a preferred general anethestic in human medicine19-20’26 as well as being prevalent 
in veterinary medicine.76'82 Recreational use of propofol has become an issue due to the mild euphoria and 
hallucinations it induces.135 The abuse potential for the anesthetic propofol has not been completely 
defined, but numerous case reports exist in the literature.70 Abuse of propofol is more prevalent among 
anesthesiologists due to its widespread use in clinical practice, and the short duration of action of propofol 
allows easy concealment of its abuse.70 Recreational use o f propofol is also significant among celebrities 
or patients who have become addicted following numerous elective surgeries, and a high incidence of death 
has been documented due to propofol misuse and abuse.1,5
Animal Use/Model
In humans, the teratogenic risk of dmgs is difficult to assess,5 and the teratogenic risk in human 
pregnancy is undetermined for over 90% of drug treatments.136 Although drugs must undergo preclinical 
animal testing, these studies are not always predictive of effects in human pregnancy, and most clinical 
trials required for by the United States Food and Drug Administration (FDA) approval focus on immediate 
adverse effects and exclude pregnant women.136 While consideration of potential harmful effects to a 
pregnancy is ubiquitous, prescriptions of potentially teratogenic medications to women of childbearing age 
by outpatient physicians is frequent.1 Pregnant woman may also be exposed potentially harmful dmgs 
during surgery spite of her pregnancy.3'5’136 Women such as those with intended conceptions are more 
likely to recognize early signs o f pregnancy than those with unintended pregnancies,112'113 and their attitude 
toward the pregnancy can influence the health of the embryo by avoiding detrimental behaviors such as use 
of potentially fetotoxic dmgs or postponing elective surgical procedures.109 Negligence of early pregnancy 
due to the sensitivity limitations of HPTs109 or disregard of potential harmful effects due to attitude or 
addiction may cause some women to continue to abuse illicit dmgs.114 Though teratogenic studies may not
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find an anesthetic to pose significant risk, exposure conditions of these studies are not comparable to binge 
exposure conditions.137 In addition, procedures of assisted reproduction such as in vitro fertilization (IVF) 
require the use of anesthetic drugs with potential toxic effects when exposed to the oocyte or early 
embryo.10'138
Consideration of the potential teratogenic effects of drugs used in veterinary medicine and for 
laboratory animals is also important. In laboratory animals and veterinary anesthesia, injectable agents are 
preferred for a variety of reasons including the minimization of equipment, ease of administration, and 
fewer safety concerns than those posed by use of inhalants.139 Common injectable anesthetics used for 
laboratory animals and in veterinary medicine include pentobarbital,68’88 ketamine, and propofol.76'82 The 
decades of use of pentobarbital, in addition to its generalized availability, low cost, relatively rapid onset of 
anesthesia, and ease of injection (IP or IV) to a variety of animals contributes to its continued widespread 
use in laboratory animals and in veterinary medicine,88 and its use is especially prevalent for rodent 
anesthesia.68’88 The use of ketamine is widespread throughout veterinary anesthesia, and propofol is 
commonly used for feline and canine anesthesia.76’82
Human IVF programs require continuous quality controls for the maintenance and improvement of 
reagents and methods.I40 ,4:! Due to the complex nature of IVF, an animal model which allows for the 
testing o f drugs, routine preparations of reagents, skills o f technicians, and innovative methods is 
required.140'141’143"146 The most common animal model for this purpose is the mouse embryo growth and 
development bioassay, in which the development of in vitro and in vivo fertilized 2-cell mouse embryos to 
the hatching blastocyst stage is tested.144’145 While lower order species such as the zebrafish,147,148 frog 
(Xcnopus),149 and sea urchin are occasionally utilized for studying teratogenesis, fertilization, and embryo 
development, the mouse is advantageous for mammalian reproductive studies.138 The mouse is a superior 
animal model for mammalian embryonic study since the mouse embryo divides slowly after fertilization,138 
contributing to the collection of abundant knowledge of mouse genetics.138’150 The mouse system is also 
valuable for the fundamental similarities between mouse and human preimplantation development and 
implantation processes.150 Collection of embryos at the 2-cell stage is performed because embryos at this 
stage are much more resilient in culture than those collected at the zygotic pronucleate stage.151 Like 
human embryos, mouse embryos are able to develop in simple defined media in vitro,150 allowing the 
mouse embryo to be studied extensively as a model for mammalian embryogenesis.152 For this reason, the 
mouse embryo growth and development bioassay is preferentially used for the screening of drugs, and is 
considered to be by the clinical reproductive industry and the FDA, the preferred assay for quality 
assurance/quality control (QA/QC) determination and validation of gamete and embryo research,153 as well 
as to improve pregnancy rates.141-154 Although the FDA has not prescribed a standard procedure for test 
performance and design, it has described the mouse embryo assay to be the most appropriate indicator of 
potential toxicity o f materials used for assisted reproduction.143
15
All aspects o f laboratory procedures require meticulous attention to increase the chance for a patient to 
successfully obtain pregnancy.145 IVF technologists must be trained and experienced in proper tissue 
culture techniques for handling mammalian gametes and embryos before working with human tissues.145 
The mouse embryo culture system is utilized to compare the ability o f different media and supplements to 
support mammalian preimplantation embryogenesis, or other components used in IVF programs such as 
culture dishes, collection devices, pipettes, surgical instruments, and surgical gloves;'41,142'144 or to test the 
effectiveness of instrument sterilization procedures.142 144 Media is required to support at least 75% morula 
or blastocyst Development of 2-cell mouse embryos following a 72h culture period to be approved for use 
in human jv f ,,4' 144 H5 with no more than 15% degenerating or fragmenting.144 This does not offer direct 
proof that human fertilization or embryogenesis would be impaired, and is not able to predict success for 
human IVF,141 rather the mouse bioassay assists in screening and identifying potentially failure-causing 
problems before the media are used with human gametes or embryos.144
The in vitro culture mouse embryo assay may also aid assessment of safety of drugs155 and can be used 
to screen potential toxic effects o f anesthetics used in egg retrieval for IVF,10, 138 143 or those of 
pharmacologic agents that may come in contact with the egg or early embryo.10 138 146 Prediction of the 
safety risk of drugs is challenging due to the limited and restricted availability of human cells for toxicity 
evaluation.156 The preimplantation mouse embryo in vitro development bioassay helps to elucidate the 
effect of a pharmacologic agent on cellular differentiation;138,146 and the zygotic and early embryonic stages 
provide indications of possible experimental induction o f fetal and postnatal defects.157 In addition to 
economic benefits of the in vitro mouse embryo assay, 155,158 it assists the expansion of the range of data 
obtained by toxicological assessments.146,155 Numerous attempts to culture embryos continuously from the 
preimplantation to post-implantation developmental phases have been made,149,158’162 but these tests have 
not been widely adopted for the study of mammalian embryogenesis.148,155 These tests are relatively 
complex, require high technical skills, and are costly.149
Developmental toxicity testing is expensive, time-consuming,147,148 and requires a large number of 
animals.148 163 The necessity to improve testing methods has led to development of a number of 
alternatives, but the complexity of embryogenesis has made development of less animal-intensive 
alternatives challenging.147,148,163 Aside from culture of non-mammalian and mammalian embryos to test 
for developmental toxicity,138,146,148,149,162,163 alternatives include testing of sperm motility and viability,145 
mammalian micromass (MM) cultures162 and embryonic stem cells.147'148,156,162 16'1 The MM culture test is 
based on detection of the ability of a particular chemical to inhibit the formation of foci o f differentiating 
cells within a background of undifferentiated mesenchymal cells.162 MM culture allows detection o f cell 
division, differentiation, adhesion, movement, and communication, and the MM culture represents a 
promising model for the study of teratogenesis.162
The embryonic stem cell test (EST) is one of the most extensively studied alternative in vitro methods 
for testing developmental toxicity.148,164 In the EST, mouse blastocyst-derived pluripotent embryonic stem
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cells to assess teratogenic risk.162 The EST makes use of an established permanent cell line14 ,162 and is 
designed as an alternative to animal testing.156 Compared to other in vitro embryotoxicity tests, the 
advantage of EST is that it does not require animal use after cell line establishment,147 and consequently no 
additional animals are sacrificed to obtain embryonic cells or tissues.148162 The disadvantage o f the EST is 
it gives a reductionist representation of embryonic development and evaluates an effect on only a single 
endpoint.14' Although it has been validated, the applicability and predictability o f the EST model requires 
further study for successful implementation as an alternative toxicity testing method.164 E>ue to the 
complexity of the reproductive cycle, the hundreds of signaling pathways involved,163 and the multiple 
steps involved in embryonic development such as cell proliferation and differentiation, pattern formation, 
and organogenesis, it is impossible to develop an alternative test that can encompass the entire 
developmental process with a single comprehensive test.147-148,149
Preimplantation Embryo Development
Fertilization in mammals initiates a series of cleavage divisions which partitions the zygotic 
cytoplasmic mass into successively smaller cells.165 The zygote is enclosed in an acellular glycoprotein 
envelope, the zona pelfucida,166,167 and cleavage division to the blastocyst stage occurs within the zona 
pellucida.167 Early embryogenesis consists of two distinct phases separated by the event o f uterine 
implantation,155 which occurs during the final period o f  the cleavage phase, the blastocyst stage.167-168 The 
cleavage phase of development leads to the separation of two tissue types, the inner cell mass (ICM or 
embryoblast), and the trophoblast (trophectoderm).169 The ICM differentiates into two layers, the epiblast, 
from which cells will develop to form the body of the embryo, and the hypoblast, responsible for extra- 
embryonic tissues.155 Additional extra-embryonic tissues responsible for providing support for uterine 
development are derived from the trophoblast.155
Within 24h of fertilization, male and female pronuclei replicate their DNA in the 1 -cell zygote, their 
chromosomes congress at syngamy, followed by mitosis, cytokinesis, and formation of the 2-cell 
embryo.170 Division of cells (blastomeres) is asynchronous, but initially each division is completed before 
the next round begins, giving rise to intervals of 2-, 4-, and 8-cell stages.165 In mice, the first round of 
cleavage occurs 1 day after fertilization to produce 2 -cell embryos, at which time researchers typically 
collect embryos.171 Each blastomere is totipotent during the 2-cell stage.172 In the 2-cell embryo, each 
blastomere has an oval shape with clearly defined polar bodies.171 During the next two cleavages, each 
blastomere is easily distinguished and has a spherical shape,173 and blastomeres are only loosely 
associated.166 During divisions at the 8-cell stage, adhesion o f blastomeres begins,171 blastomeres change 
shape and spread over each other to maximize intercellular contact, and the embryo begins to compact to 
form a morula.165 Adhesion occurs by the formation of adhesion complexes such as adherens, gap and tight 
junctions,170 and allows physical attachment, cell-cell communication, and signaling for cellular 
differentiation.171
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During the Ca2+-mediated compaction1 3 of the momla (16-cell embryo), outer and inner cells begin to 
develop,169’171 causing a major change in embryonic physiology. This change is due to the formation of 
epithelium and initiation of a more somatic cell physiology by the embryonic cells.151 Small fluid-filled 
cavities formed by active transport of water and ions begin to develop, and these cavities converge to form 
a space called the blastocoel.169171 The outer cells of the trophectoderm are responsible for this Na+/K+- 
ATPasc dependent170 internalization of fluid which generates the blastocoel,165,169 to form the blastocyst 
and help prepare the embryo for implantation.165 This blastulation event coincides with the completion of 
the fifth round of cleavage (at the 32-cell stage) in the mouse, approximately 4 days after fertilization,165,170
Formation and expansion of the blastocoel is crucial to the differentiation of the ICM and “hatching” 
of the embryo from the zona pellucida for further development to occur to prepare for uterine 
implantation.152,174 Implantation has been found to occur when mouse blastocysts exceed approximately 
140 cells,168 usually within 36-48h of blastulation.167 In vitro culture of mouse embryos is possible for 
nearly one-third of the 19 day gestation period, until the end of the cleavage stage at which time the 
blastocyst is prepared for implantation,152-159,160 however without embryonic contact with a living uterus, 
further culture is extremely difficult,151,155, 159,175 and continuous culture of mammalian embry os throughout 
pre- and post-implantation phases has not been widely adopted.155
Physiology O f Mouse Preimplantation Embryo Development
During the preimplantation period of mammalian development, the embryo undergoes significant 
changes in physiology, metabolism, and genetic control.151 Within 24h of fertilization, DNA of the male 
and female pronuclei is replicated in the 1 -cell zygote.170 This is followed by syngamy, when 
chromosomes of the pronuclei congress, then mitosis and cytokinesis occurs to form the 2-cell embryo.170 
In the initial stages following fertilization, transcription from the embryonic genome is essentially absent, 
and embryogenesis is regulated by maternally inherited components.176 177 Encoded by matemal-effect 
genes, these maternal proteins and mRNAs accumulate during oogenesis and regulate the activation of the 
embryonic genome and subsequent cleavage stages of embryogenesis.170-177-178 This period o f post- 
transcriptional maternal control extends from fertilization to the mid 2-cell stage in mice,178,179 (4-cell stage 
in humans)178 when the embryonic genome is activated.151,176,180
18
Fig. 2. Summary of the preimplantation mouse development, 2-cell to morula stage. After fertilization, the 
1st round of cleavage yields the 2-cell stage (A). The 2nd round results in the 4-cell embryo (B), and the 3rd 
cleavage results in the 8-cell (C). During the 8-cell stage, cell-cell adhesion increases and each blastomere 
is not easily distinguished (beginning of compaction). During the next two rounds of cleavage (morula, 16- 
to 32-cell stage) (D), small cavities develop and fuse to form the blastocyst cavity. Photomicrographs 
taken using DIC Optics at 400x.
Fig. 3. Normal blastocyst development. Early (A), normal/compact (B), hatching (C-E), and hatched 
blastocyst (F). Cavities between blastomeres fuse to form a space termed the blastocoel (dark arrows in A 
and B). Contractions of the blastocyst within the zona pellucida contribute to its “hatching,” embryo 
eruption from the glycoprotein coat (dark arrow in C). The blastocyst contains two cell types, the ICM 
(evident at tip of hollow arrow in C), and the trophectoderm, the surrounding outer layer of cells. 
Photomicrographs taken using DIC Optics at 200x.
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Fig. 4. Preimplantation mouse embryo development. (A)Oogenesis and early development. Maternal RNA 
and proteins accumulate within individual oocytes during a ~2 week growth phase, but many are degraded 
during meiotic maturation and ovulation. The zona pellucida surrounds growing oocytes and ovulated eggs 
(green) and is modified following fertilization (red) to prevent polyspermy and to protect the embryo as it 
passes through the oviduct. At embryonic day 0.5 (E0.5), 1 -cell embryos can be recovered from the oviduct 
and, by the 2-cell stage (E l.5), there is robust embryonic genome activation. Following the third cell 
division, embryos undergo a Ca2+-mediated compaction to form morulae (E2.5), and develop a fluid-filled 
blastocoel cavity from the 32-cell stage to become blastocysts (E3.5) that implant in the uterus wall (E4.5). 
(B) Late preimplantation development. At four cells, blastomeres with distinct cell boundaries are encased 
within the protective confines of the zona pellucida. Individual cells remain pluripotent. Following the 8- 
cell stage, the embryo compacts to form the morula, with increased cell contact that morphologically 
obscures cell boundaries. Symmetric cell divisions result in similar daughter cells. Asymmetric divisions 
provide topologically distinct outer cells, which are trophectoderm precursors (forming the placenta), and 
inner cells, which establish the inner cell mass (ICM) of the fetus. Blastocoel formation defines the 
blastocyst, and the eccentric localization of the ICM localizes the polar and mural trophectoderm, the latter 
of which initiates uterine implantation.170 Reproduced with permission, Development. Li L, Zheng P, 
Dean J: Maternal control of early mouse development. Development 2010; 137: 859-870
The critical event that governs the transition from maternal to embryonic control o f development, 
known as zygotic genome activation (ZGA),’81 is arguably the first event following fertilization necessary 
for further successful development to occur.177 ZGA initiates the endogenous transcription of the 
embryonic genome during the late 1 -cell stage176'177 l-2h following initiation of S phase in the 1 -cell 
embryo.182 Transcription steadily increases thereafter,182 with the rate of transcription dramatically 
escalating during the 2-cell stage.177 ZGA is involved in replacing maternal transcripts that are common to 
both the oocyte and embryo, as well as generating new transcripts that are unique to the developing 
embryo.177 Transcriptional reprogramming during ZGA at the transition from the 2-cell to the 4-cell stage 
is also particularly important in preimplantation embryos.183 Some of the gametic genes are regulated
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during reprogramming by noncoding RNAs or CCCTC-binding factor-dependent insulators.184 ZGA also 
requires chromatin remodeling, during which proteins restructure or move nucleosome transcription 
constraints, making the genome accessible to transcription factors such as heat shock factors (HSFs), and 
zinc-finger proteins such as basonuclin 1 and CCCTC binding factor.170 HSFs encode heat shock proteins 
(HSPs), highly conserved cellular stress proteins.178 HSPs are a critical component of a cellular defense 
mechanism in response to adverse environmental conditions such as physical or chemical insults; however 
under physiological conditions, HSPs act as molecular chaperones178 which help to regulate cellular 
homeostasis.185 Basonuclin is a transcription factor170,186 abundant in germ cells, affecting RNA 
polymerase-mediated transcription, and CCCTC-binding factor is a DNA-binding protein ubiquitously 
expressed in mice.170
Differentiation, compaction, and blastocoel development are dependent upon the transcription of 
appropriate embryonic genes, and all o f these processes require an increase in the level o f total biosynthesis 
and energy demands of the embryo.166 Metabolic control during preimplantation development may be 
either intrinsic to the embryo or extrinsic, mediated by the environment within the female tract.187 
Preimplantation embryos exhibit metabolic adaptation, in which their metabolism responds to changes in 
the external environment.187 One of the characteristics of metabolic adaptation displayed by 
preimplantation mouse embryos is the metabolic shift from a dependence on the TCA cycle during the pre­
compaction stages to a metabolism based on glycolysis between the late morula and late blastocyst 
stages.179,188,189 Like the oocyte, the zygote possesses low metabolic activity, low levels of oxygen 
consumption, and low Q 0 2,151 and prior to compaction, glucose is not utilized as the main energy source.166 
Instead, uptake of pyruvate and amino acids such as glutamine is necessary for ATP production, and this 
remains dominant until the 8-cell/morula stage, when glucose consumption increases dramatically.179,190 
Embryonic glucose uptake increases through blastocyst compaction, and by the blastocyst stage, glucose is 
utilized as the primary energy substrate.166 This transition is largely attributed to the marked increase in 
ATP requirements necessary for blastocoel production, due to the active transport of ions mediated by the 
trophectoderm sodium pump (Na+, K+, ATPase).191 While not utilized as the main energy source until 
compaction,166,190 glucose uptake has been detected in earlier stages.179 Several glucose transporter 
(GLUT) isoforms have been detected in early mouse embryos;192,193 these GLUT isoforms exist to mediate 
a facilitated-diffusion glucose transport system.194 The isoform present in nearly every tissue, GLUT 1, is 
expressed throughout preimplantation development, and is thought to provide the embryo with its basal 
glucose requirements;193 however additional GLUT isoforms including GLUT2, GLUT3, and GLUT8 are 
intrinsically expressed from the 8-cell stage to the blastocyst stage.195
Mitochondrial function is also critical to the initiation and progression of early development.190 
Mitochondria are responsible for providing the energy required to maintain cellular activity through 
oxidative phosphorylation and provision o f intermediates for glycolysis; as well as affecting ion 
homeostasis, participating in amino acid metabolism, signal transduction, and apoptosis.196 Mitochondria
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also regulate the redox-balanee;19' however free radicals can damage mitochondrial membranes, causing 
new sources of harmful reactive oxygen species (ROS) to be generated.198 Apoptosis is the physiological 
process o f regulated cellular destruction,199 and is responsible for the normal turnover of somatic cells,200 as 
well as removal o f excess, misplaced, damaged, or genetically abnormal cells in the embryo.178 Unlike 
necrosis, apoptosis affects individual cells;178 cells undergoing apoptosis fragment into membrane-bound 
apoptotic bodies, which are eventually phagocytized by surrounding cells or macrophages without 
inflammatory response.69,178 Apoptosis is a necessary process for early embryo survival, and the first 
apoptosis in the preimplantation embryo may take place as early as during the activation of the embryonic 
genome.178 Anti-apoptotic BCL2 and pro-apoptotic BAX proteins have been detected in zygotes and every 
subsequent stage of preimplantation development,201 but the early preimplantation embryo is resistant to 
pro-apoptotic signals due to biochemical properties of the mitochondrion and nucleus.202
Anesthetic Effects On Development
Teratogenic effects may result from exposure to environmental factors such as radiation, dietary 
exposure such as alcohol, or pharmaceutical exposure to drugs.1 Numerous studies document the potential 
detrimental effects to development following exposure to alcohol and anesthetics.2'6,7'15,116,117 Most 
anesthetics are lipophilic with low molecular weight, increasing their ability for placental transfer.76 Early 
embryonic development may be disrupted by exposure to exogenous agents, particularly anesthetics used 
for emergency surgery, obstetrics, or assisted reproduction procedures such as IVF. Ultrasonically-guided 
transvaginal oocyte retrieval for IVF is one such procedure during which xenobiotic agents may have 
effects on development. Oocyte retrieval can be accomplished with either heavy intravenous sedation or 
spinal anesthesia,203 however since oocyte retrieval is a relatively short procedure (normally completed 
within 30 minutes), rapid and short-acting anesthetic drugs are preferred.204 Some of the commonly used 
drugs for IVF, including midazolam,138 alfentanil,204 and propofol10,37,39,204'205 have been detected in the 
follicular fluid of patients, demonstrating their ability to come in contact with an oocyte or a 
preimplantation embryo in uterine fluids. In addition, as many as 2% of pregnant women require surgery 
not related to IVF,3 and many of the common induction agents used during these surgeries have the 
capacity to come in contact with a developing embryo. During early pregnancy, the risks o f anesthetic 
embryotoxicity and teratogenicity are much greater depending on the stage of embryogenesis and exposure 
duration.76 Exposure to harmful agents may also occur as a result of substance abuse during pregnancy.116 
Therefore, it is necessary to investigate the profound effects which may be exerted upon fertilization, 
cleavage and proliferation, differentiation, implantation, and subsequent embryonic and fetal development 
in the presence of exogenous compounds.
Some drugs, such as the very short-acting opioid alfentanil,204 or the benzodiazepine anesthetic 
midazolam, seem to offer ideal properties with little adverse effect on in vitro development.138 During the 
oocyte retrieval procedure, the alfentanil concentrations in follicular fluid are about ten-fold smaller than
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serum alfentanil concentrations at the same time points.204 Although oocytes are exposed to alfentanil,204 it 
has not been found to produce adverse effects on fertilization or embryo quality.206 Midazolam provides 
conscious sedation for patients undergoing egg retrieval for IVF, and has also been found in patient 
follicular fluid.138 In a 72h study where midazolam was cocultured with 2-cell mouse preimplantation 
embryos, no adverse effects were found on in vitro development of 2-cell to blastocyst stage embryos at 
concentrations approximating and exceeding those at which ova are exposed to during clinical 
anesthesia.138
Other anesthetics which may come in contact with the oocyte or embryo, such as the local anesthetic 
lidocaine, have also been found to adversely affect in vitro development o f mouse embryos.9 In studies of 
72h mouse preimplantation embryo exposure effects, the percentage of 2 -cell embryo cleaved and 
developed to more advanced stages was found to be significantly reduced by prolonged exposure to 
lidocaine.8,9 Development to the blastocyst stage was inhibited by all lidocaine doses tested in vitro, and 
most affected embryos showed arrest, degeneration, and clastogenic damage.8
Even brief exposure of preimplantation embryos to anesthetics may be deleterious to subsequent 
embryo cleavage, and effects are highly dependent on the developmental stage during which exposure 
occurs.2 Nitrous oxide has long been used as an inhalation anesthetic,23 and like ketamine, acts as an 
NMDA receptor antagonist.66 First trimester nitrous oxide exposure has demonstrated an increased 
incidence of skeletal defects and spontaneous abortions.76 Nitrous oxide has also been shown to inhibit 
preimplantation mouse embryo development. Nitrous oxide was used to expose 2-cell, 4-cell, and morula 
stage embryos to determine effects on subsequent development after short durations of exposure.2 All 
groups were exposed to 60% nitrous oxide/40% oxygen for 30 minutes, but 2-cell embryos treated within 
4h o f  expected cleavage were the only group where effects were observed. At 3 -4h and 0- lh  prior to the 
anticipated onset of cleavage, exposure of 2-cell embryos to nitrous oxide resulted in blastocyst 
development in 27.7% and 4.7% of embryos, respectively, while 75%-77% of control embryos reached the 
blastocyst stage.2 In addition, most affected embryos were halted at the 2-cell stage, with no further 
cellular division.2 Similar effects were obtained with 80% nitrous oxide/20% oxygen, leading to the 
conclusion that even short-term nitrous oxide treatment o f 2-cell mouse embryos significantly inhibited 
subsequent cell division.2
Isoflurane, another inhalation anesthetic, also has shown increased incidence of skeletal defects and 
spontaneous abortion following first trimester exposure.76 Isoflurane was also found to adversely affect 
subsequent prcimplantation development when 2-cell mouse embryos were exposed just before the onset of 
their first cleavage in vitro.6 Development to the blastocyst stage was inhibited by 3% and 5% isoflurane 
when 2-cell embryos were exposed 3-4h or 0 -lh before the onset o f cleavage.2 Most of the affected 
embryos were found to arrest at 3- to 4-cell stage, but the development to blastocyst of embryos exposed to 
isoflurane at the 4-cell or morula stage was unaffected.6 Another study found the combination of 
isoflurane/nitrous oxide to affect fertilization and prcimplantation development as well.13 Patients
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undergoing bilateral laparoscopic tubal sterilization were subjected to inhalant general anesthesia with 
isoflurane/nitrous oxide.13 Sera was collected lh  after anesthetic induction, and its addition to the in vitro 
culture media was found to significantly reduce the amount of 2 -cell mouse embryos developing to the 
blastocyst stage, as well as being associated with a significantly decreased fertilization rate of mature 
oocytes.13
Propofol has been shown to display similar pharmacokinetics to alfentanil when used as an 
anesthetic,204 but the two act via different mechanisms, alfentanil is an opioid204 and propofol is a GABAa 
receptor modulator.207 While propofol is one of the most common IV anesthetics for general anesthesia15-23' 
30,33- 43 an(j jn ultrasound-guided transvaginal oocyte retrieval,15-34-37,39 little is known about the effects of 
propofol on embryo development and pregnancy.15 Conflicting reports of the impact of propofol on 
oocytes and early embryos leave questions about the effects o f exposure to during early development. 
Although concentrations in the follicular fluid have been found to be approximately ten-fold smaller than 
serum concentrations,2-204 propofol use has been found to have no detrimental effect on assisted 
reproduction outcome.208 One study found no significant evidence to support a negative impact of propofol 
on oocytes, measured by cumulative embryo scores, probability of clinical pregnancy, and implantation 
rate following administration during IVF procedures.209
Propofol has been shown to negatively affect fertilization and subsequent cleavage, interfering with the 
ability of the oocyte to fuse with spermatozoa, without affecting post-fusion events such as sperm 
decondensation and cell cycle resumption.15 Treatment o f 1-cell embryos for 14h with propofol 
concentrations ranging from 0.01 to lOgg/mL was found to result in the inhibition of cleavage to the 
blastocyst stage, but 14h exposure o f embryos at the 2-cell stage to even lOpg/mL did not impair 
subsequent development to blastocyst.15 Embryos at the 2-cell stage are more robust in culture than the 1 - 
cell zygote,151 and these effects were attributed to cell cycle differences between the 1-cell and 2-cell 
embryos. The G1 phase is much longer in the zygote (4-8h) than in the 2-cell embryo (l-2h),15-210 and since 
cells at the G 1 phase of the cell cycle are particularly susceptible to environmental factors, a prolonged 
period of sensitivity may have contributed to the inhibition of differentiation in the 1 -cell embryos.15
A second in vitro study of mouse oocytes found short-term exposure to propofol deleterious to 
fertilization in a dose-dependent manner,37 even during brief exposure.10 Mouse oocytes were exposed in 
vitro to propofol concentrations ranging from 50ng/mL to 5,000ng/mL for 30 minutes, then washed, 
inseminated, and assessed for ability to fertilize and subsequently develop to the blastocyst stage.10 When 
fertilization did occur, propofol was found to significantly affect subsequent embryo cleavage and 
development to the blastocyst stage.10 Propofol exposure was also found to result in parthenogenetic 
activation of 33% to 60% of oocytes.10
Exposure of early mouse embryos to propofol has been found to produce an adverse effect on 
embryonic development,10-15 but later effects on the fetus have yet to be determined.35 Propofol has the 
ability to cross the placenta,67 making the study of fetal exposure an area of interest. During the postnatal
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period, a high dosage of propofol (25mg/kg) was found to induce complex physiological changes in the 
developing rat brain, accompanied by age-dependent neurodegeneration in the cortex and thalamus at 
postnatal day 7,211 but no evidence of teratological effects has been found in the rat or rabbit at lower doses 
ranging from 5-15mg/kg.43
When extrapolating the results o f fetal and postnatal exposure from animal studies, it is important to 
consider the timing o f  development. Like the development of most tissues, the primary period of 
neurodevelopment differs between species.212 In rodents such as rats, synaptogenesis occurs mostly during 
to the postnatal period, from 1 day before birth until approximately postnatal day 14 day; whereas in 
humans, this period occurs during the third trimester into the first several postnatal years.212-213 Many 
environmental agents such as ethanol, phencyclidine, ketamine, nitrous oxide, barbiturates, 
benzodiazepines, halothane, isoflurane, propofol, and nitrous oxide, as well as pharmaceuticals used in 
obstetric and pediatrics medicine as sedatives, anti-convulsants, or anesthetics have the potential to induce 
neurodegeneration during development, and it is likely that development of other tissues may also be 
afTected.118-214
Barbiturate degenerative effects on neurological development84-85-116,215'218 and induction of congenital 
deformities are well documented,216-219 but reports of effects on the development o f the preimplantation 
embryo are sparse. The anesthetic thiopental has not been reported to produce negative effects to human 
development,76 but sodium pentobarbital has demonstrated potential for embryotoxicity. In a study to 
evaluate the reproductive effects of sodium pentobarbital on the early embryo, female rabbits were injected 
intravenously at either 15 minutes or 6h after mating.14 Unlike mice, rabbits are induced ovulators, 
releasing their ova approximately 12h post coitus.220 At 17h or 24h post-coitus, oviducts were flushed and 
the developmental stage of the zygotes was observed and recorded, and blastocysts were also recovered 
from females on gestation day 6. A greater frequency of chromosomally abnormal blastocysts was found 
to develop in animals injected with pentobarbital than that found in controls.14
Ketamine is a widely used anesthetic in pediatrics,103 and has been commonly used in obstetrics for 
Caesarean sections,104 and ketamine abuse is prevalent,116 making study of its effects on embryonic and 
fetal development essential. Although ketamine has not been reported to have negative effects on human 
fetuses,76 it easily crosses the placenta and is rapidly distributed in the fetal tissues.31-64 The rapid 
transplacental passage of ketamine may be attributed to its relatively low molecular weight, and ketamine 
concentration in the umbilical cord has been found to be higher than in the blood o f the mother.31 
Ketamine has also been found to produce uterine artery vasoconstriction, a fall in uterine blood flow, and 
eventual fetal deterioration.12 Administration of the drug has stimulating effects on the fetus causing rise in 
fetal arterial pressure and heart rate;64 however, no evidence of fetal hypoxia, metabolic acidosis, or 
arrhythmia has been found following ketamine application.12
Ketamine and its metabolites have been found to contribute to developmental defects in rodents; 
however toxicity of ketamine in the preimplantation embryo is unreported. Observations of anatomical
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effects of ketamine on development in CF-1 mice have shown daily 50mg/kg doses from gestation day 6- 
15 to produce insignificant skeletal and visceral defects, as well as no increased resorptions, dead fetuses, 
or decreased fetal weight.7 Histological examination of the heart, liver, and kidney, however, has revealed 
focal nuclear hypochromatosis, interfibrillary edema, parenchymal cell degeneration, and proximal 
convoluted tubule degeneration.7-11 The degenerative effects of ketamine have also been found to be 
dependent on the dose and duration of treatment, including effects in liver, kidney, and heart of rat pups 
exposed to daily doses o f 25mg/kg, 50mg/kg, and lOOmg/kg on days 1-15 and days 5-15 o f gestation."
Fig. 5. Degenerating 2-cell mouse embryo following 72h of culture with lOOOpg/mL ketamine HC1. 
Irregular shape of blastomeres and cellular fragments smaller than normal-size blastomeres are indications 
of degeneration and apoptosis. Photomicrograph taken using DIC Optics at 200x.
Mechanisms O f Embryotoxicity
Drugs must act upon or cross cell membranes to produce their effects,45 and one of the qualities o f a 
rapid-acting IV anesthetic, high lipid solubility24-26-45 produces transfer across the cell membrane more 
readily.45 While the primary action of anesthetics involves interaction at the lipid bilayer and some effects 
of anesthetics on cellular activity are attributed to ability to perturb cell membrane phospholipid 
organization,221 the effects of anesthetics on the lipid bilayer of the cell membrane are minimal.48-222 
Anesthetic activity has also been attributed to ability to perturb membrane protein conformation,221 and 
several studies support that anesthetics primarily act directly on proteins rather than on lipids.44 The role of 
second messengers on anesthetic action remains uncertain,44-222 and other tissues may be affected by contact 
with lipid-soluble drugs in the absence of ligand gated receptors or changes in membrane protein 
conformation and interaction with cytoskeletal components, even if relatively little transport across the 
lipid bilayer occurs.44-221'223
During the cleavage stage in the preimplantation embryo, environmental insults to the embryo may 
result in embryonic death and miscarriage, or in some cases, intact survival.4-122 This “all or none” result is
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due to the largely undifferentiated cells of the early embryo, making repair possible through multiplication 
of the still omnipotent cells.4 Even when survival is possible, non-lethal insults to the embryo may still 
have the ability to compromise development.151'224 Physical or chemical insults have the potential to 
irreversibly damage a developing embryo and embryotoxicity may be influenced by numerous 
mechanisms.225 Oxidative stress is a predominant contributor to developmental complications; oxidative 
stress has been found to cause a developmental block in early preimplantation embryos,224 and exposure to 
oxidants during the first trimester is associated with an increased risk of congenital defects.226 Oxidative 
stress is caused by an imbalance between ROS generation and antioxidant defense systems, which results in 
cell damage either directly or by altering cell signaling pathways69-226 or a number of additional secondary 
processes. ROS may alter signal transduction, damage cellular macromolecules,226 oxidatively cause DNA 
or RNA damage and affect repair, or increase lipid peroxidation, protein oxidation,190'227 and ATP 
depletion.224 Exogenous factors such as drug exposure and radiation may result in ROS production,69'190'227 
or cause and imbalance in antioxidant defense mechanisms in the embryo,69'226 but ROS levels may also be 
elevated by endogenous factors such as increased mitochondrial respiration or inflammation and 
infection.69 Free oxygen or nitrogen radicals can also damage mitochondrial membranes, which can have 
an autocatalytic effect in which oxidative stress is intensified by generation of new sources of ROS.198 This
224 * 190damage is capable of inducing a developmental block, as well as causing apoptosis or necrosis. Once 
free radical damage is initiated, this damage can become autocatalytic; for example by damaging 
mitochondrial membranes new sources o f ROS may be generated.198
Expression of approximately 10,000 genes must be expressed in a well-orchestrated manner for regular 
development of the preimplantation embryo and early fetus,228 and exposure to teratogens may directly or 
indirectly perturb the expression of genes critical for normal development.229 Chemical insults and 
oxidative stress are capable of causing DNA or RNA damage,190,227 which may affect a number of 
embryonic genes depending on the timing o f exposure. Prior to ZGA, oxidative stress to the embryo has 
been found to cause permanent developmental arrest.190 Mutations of matemal-effeet genes or interference 
with embryonic genome activation and transcription have the potential to result in arrested or delayed 
embryonic differentiation. A number of embryonic genes with maternal effects have been identified 
(Mater, Hsfl, Zarl, Basonuclin1), and mutation of maternal-effect genes has been found to induce partial 
or total developmental arrest in embryos at different developmental stages (e.g. in 1-cell H sfl and 2-cell 
M ater)'91 Failure to activate the embryonic genome has also been found to arrest preimplantation 
development.170'177 The preimplantation embryo is particularly sensitive to mutagenic agents or oxidative 
stress during ZGA,190'198 and any condition which enhances ROS accumulation during ZGA may be 
detrimental.190 Under normal conditions, ROS increase has been found to culminate during ZGA, 
suggesting that during this transition, oxidant defense is depleted and must be replenished by ZGA.190 This 
relatively weak antioxidant defense in the early embryonic stages227 often results in defective development 
when exposed to oxidative stress from exogenous agents.224
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Culture conditions can alter the rate of degradation of mRNAs, and the degraded products can affect 
methylation and gene expression.228 Alteration of the methylation pattern can lead to silencing or induction 
of a specific gene, and is a primary candidate for gene expression deviations .228 Extracellular conditions 
may also cause signal transduction pathways target transcription factors, transcriptional coregulators and 
chromatin-modifying factors, leading to their phosphorylation by protein kinases or dephosphorylation by 
protein phosphatases.230 These modifications facilitate gene expression by directly regulating distinct 
aspects of transcription factor function, including cellular localization, protein stability, protein-protein 
interactions, and DNA binding.230 Any teratogen-influenced alteration during chromatin remodeling could 
cause incomplete reprogramming of transcription factor genes and result in abnormal gene expression.202 
Abnormal gene expression can affect a number o f critical processes including transcription, mRNA 
processing, oxidative phosphorylation, metabolism, transmembrane solute transport, or protein 
biosynthesis, modification and degradation.231
The embryonic cell cycle can be modified by introduction of new components, substrates, or pathways, 
or altered interactions between them.232 The precise cell cycle stage during which the development of 
embryos will arrest or delay coincides with initiation early embryonic gene expression,198 and at different 
phases of the cell cycle, the embryo may be more resistant or sensitive to environmental factors.15 During 
the G1 phase o f the cell cycle, preimplantation embryos are particularly susceptible to environmental 
stress.ls The timing of teratogen exposure during the cell cycle is thus very important to embryonic 
survival. In the mouse embryo, mitosis o f the first cleavage division and the G 1 phase of the second cell 
cycle has previously been found to start 16-18h after insemination and reach 90% by 22-24h.233 First 
blastomeres of 2-cell embryos complete DNA synthesis 20-22h after insemination and by 28-30h 80% of 
blastomeres emerged from this phase.233 The G2 phase lasts 12-15h in 2-cell embryos, and similar to the
6 233 234other phases of the cell cycle, is reduced sharply in subsequent cycles. ' ' Since the sensitive G 1 phase
is much longer in 2-cell embryos than subsequent cell cycles, the second cleavage division may be more 
susceptible to environmental factors than subsequent divisions.6 233'234
Cytotoxic agents have the potential to prevent cell division by disrupting the mitotic spindle,6 and 
antimitotic effects may be exerted directly or indirectly by oxidative stress. Antimitotic effects may be 
produced by destruction of the spindle and impaired chromatid separation during mitosis, or by the 
inactivation o f Cdc25 phosphatases. During mitosis, improper attachment of kinetochores to microtubules 
triggers the spindle assembly checkpoint (SAC), which regulates progression of mitosis, preventing the 
onset of anaphase and potential incorrect segregation of the genetic material into daughter cells.210 The 
local anesthetics dibucaine, tetracaine, procaine, and lidocaine have been found to significantly affect the 
organization of cytoskeletal components and their plasma membrane attachment points.223 Electron 
microscopy found evidence of structural alterations in microtubule and microfilament organization 3T3 
cells treated with these anesthetics, and the effects o f these local anesthetics were duplicated by treating 
cells with colchicine (a microtubule polymerization inhibitor) together with cytochalasin B (a
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mierofilament formation blocker).223 Other cell cycle control mechanisms such as Cdc25 phosphatases 
may be affected by anesthetic exposure. Cdc25 phosphatases are cell cycle control proteins,235 essential as 
checkpoint response mediators under normal conditions, and in response to DNA or oxidative damage.235, 
236 When DNA is damaged or incompletely replicated, Chkl and Chk2 checkpoint kinases inactivate 
Cdc25 phosphatases to halt cell cycle progression.237 ROS catalyzed Cdc25 phosphatase inactivation have 
also been found to lead to a block of the cell cycle progression.236
Mitochondria are responsible for many processes critical to the initiation and progression of early 
development,190 such as oxidative phosphorylation and provision of intermediates for glycolysis; as well as 
affecting ion homeostasis, participating in amino acid metabolism, signal transduction, and apoptosis.196 
Mitochondria also regulate the redox-balance;197 however if free radicals damage mitochondrial 
membranes, many processes can be disrupted and new sources of harmful ROS may also be generated.198 
Apoptosis is necessary to early embryo survival, and the first apoptosis in the preimplantation embryo may 
take place as early as during the activation of the embryonic genome, however apoptosis may have 
detrimental effects including embryonic arrest if the number of apoptotic cells is elevated,178 or if the 
balance of pro-apoptotic and anti-apoptotic proteins is affected.201 In vitro causes of apoptosis may be 
attributed to suboptimal culture conditions, lack of survival factors such as growth factors, chromosomal 
abnormalities, or excessive reactive ROS production.178 In preimplantation embryos in vitro, cells that 
begin to undergo or have died by apoptosis display characteristic visible cellular and nuclear fragmentation, 
as well as DNA fragmentation which can be detected by a number of methods.238
Since elevated apoptosis has previously been detected in fragmenting preimplantation embryos,238 
consideration of the potential induction of apoptosis by environmental factors is necessary. In vitro study 
of neurons differentiated from human embryonic stem cells found ketamine to increase ROS production 
and induce differential expression of oxidative stress-related genes; as well as dose- and time-dependently 
cause cell death.103 Ketamine was also found to induce mitochondrial ultrastructural abnormalities, 
decrease inner mitochondrial membrane potential (A’Pm), and increase cytochrome c release from 
mitochondria.103 The consequences of cytochrome c release depend on the cell type, but cytochrome c is a 
caspase activator and is essential part of the apoptosome, which activates caspase-9 and then activates other 
caspases to orchestrate apoptosis.173 In cells containing large amounts of endogenous caspase inhibitors, 
cytochrome c release may be down regulated, resulting in failure to induce apoptosis and the eventual loss 
of electron chain transport, which can contribute to necrosis.173
Like ketamine, other general anesthetics such as pentobarbital or propofol may also have profound 
effects on ROS and mitochondrial function, however further investigation is necessary. Future study to 
compare the effects o f ROS in somatic cells with those of the preimplantation embryo would also have 
significant implications. Pentobarbital has been found to suppress ROS generation and increase 
endogenous antioxidant ability in the rat hippocampus,239 but at high concentrations, pentobarbital was 
found to be unable to protect hcpatocytes from hydrogen peroxide induced oxidative stress; rather it
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intensified stress damage.240 Pentobarbital was also unable to significantly decrease oxidative stress- 
induced apoptotic and necrotic cells, however under the same conditions, propofol showed an ability to 
decrease the number oxidative stress-induced apoptotic and necrotic cells.240
Similar to several phenol-based antioxidants, propofol has been found to possess free radical 
scavenging properties,241 as well as anti-inflammatory effects in vivo.242 Though propofol possesses anti- 
apoptotic properties, stimulation of in vivo enzymatic systems such as the heme oxygenase (HO) pathway 
is important to this protective effect.69 In a study investigating the potential protective effects of propofol, 
dosages were shown to decrease ROS-mediated caspase-3 activation and DNA damage in hepatocytes by 
stimulation o f the HO pathway .69 Additional in vivo study of propofol effects have also found it to reduce 
inflammatory responses in macrophages by inhibiting ROS-regulated Akt/KKp/NF-icB signaling,242 as 
well as to protect against mitochondrial dysfunction and decrease production of mitochondrial ROS 
following induction of cerebral ischemia-reperfusion.243 The protection against mitochondrial dysfunction 
was suggested to be the result of inhibition of mitochondrial membrane permeability and the reduction 
mitochondrial ROS production,243 however the protective effect o f propofol is uncertain.69 In vitro effects 
of propofol require further investigation, most o f the protective effects of propofol in response to ROS have 
been shown to result from stimulation of physiological pathways absent in the preimplantation embryo.69'242
Metabolism, nutrient uptake, and water transport play a critical role in the development of the embryo, 
and in addition to oxidative damage to mitochondrial membranes, metabolism may be altered or damaged 
in many ways.198 Glucose uptake is a critical process in the embryo, being especially important during later 
stages o f preimplantation development.48 Uptake o f glucose has previously been found to be interrupted by 
anesthetics,48'244 and interference with facilitators of glucose uptake has also been shown to result in a high 
rate of apoptosis in murine blastocysts.244 General anesthetics pentobarbital, ketamine, etomidate, and 
propofol have previously been compared for effects on and interactions with GLUT1 in murine fibroblasts 
(which predominately express GLUT l).48 Pentobarbital and ketamine were found to interact directly with 
GLUT 1; and all four compounds inhibited glucose transport.48 The inhibition of GLUT 1 and associated 
decreased glucose transport previously found to be induced by pentobarbital and ketamine may also have a 
similar effect on the mouse embryo. Since GLUT1 is expressed throughout preimplantation development, 
extended exposure to anesthetics may suppress adequate glucose transport to either delay or altogether 
arrest differentiation. Although glucose is not utilized as the primary energy substrate of the 2-cell 
embryo,179'188'189 glucose uptake has been detected during the first several cleavage divisions.179-193
Glucose transporter inhibition can increase cellular apoptosis in the preimplantation embryo,244 which 
may produce detrimental effects such as arrested differentiation.178 Inhibition of GLUT 1 expression in 
mouse blastocysts has previously been found to significantly lower the function of GLUT 1, resulting 
decreased glucose transport and hyperglycemia.244 Apoptosis was initiated in response to the 
hyperglycemia, which was found to act as a cell death signal triggering a BAX-dependent apoptotic 
cascade.244 The result of this study supported the assumption that increased apoptosis at the blastocyst
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stage due to maternal hyperglycemia may result in loss of key progenitor cells and manifest as a resorption, 
malformation, or if a significant cell loss occurs, as a miscarriage,244 an adverse pregnancy outcome with 
elevated risks in diabetic women.245 Increased apoptosis during early embryonic development may also 
contribute to numerous manifestations of developmental defects following anesthetic exposure,2'6,7"15,116 as 
well as congenital malformations associated with barbiturate (phenobarbital) exposure during pregnancy, 
such as midface and digit hypoplasia,219 and microcephaly ;216,219 however further study of necessary to 
support any significant correlation.
Teratogens can affect the preimplantation embryo by directly altering cellular processes or increasing 
oxidative stress,225 and since the early embryo has limited regenerative capacity,4 chemical or oxidative 
insults may cause irreparable damage. Due to relatively weak antioxidant defense especially during early 
stages,227 stress from environmental insults often results in defective development.224 Multiple mechanisms 
are present in the preimplantation embryo to protect against exogenous compounds and ROS, however the 
activity of these responses varies during development. During the final stages of maturation, the oocyte 
stockpiles antioxidant defense against oxidant insults which may arise in the embryo during early 
development.190,224 Endogenous protection against ROS within the embryo is served by antioxidant 
enzymes superoxide dismutase, glutathione peroxidase and y-glutamylcysteine synthetase.224 In addition, 
non-enzymatic antioxidants such as hypotaurine, taurine, ascorbic acid are present in follicular and 
oviductal fluids in vivo.224 In vitro embryo culture media often contains antioxidants such as pyruvate and 
albumin (Appendix 1) to compensate for absence of in vivo protective mechanisms, since follicular and 
oviductal non-enzymatic antioxidants are not present in vitro.224
Additional resistance to environmental insults may be attributed to processes occurring during ZGA, 
and this resistance may be dependent upon the activation of the embryonic genome.182 Previous study of 
propofol effects on zygotes and 2-cell embryos in vitro found differences in sensitivity between the two, 
suggesting resistance to environmental may vary at different stages even during early development.15 This 
was thought to be the result of differences in stages of the cell cycle during the timing of initial exposure,15 
but may have also been the result of the development of a transcriptionally repressive state within the 2-cell 
embryos, which has been suggested to develop in the 2 -cell embryo.182 This repressive state may involve 
some aspect of chromatin remodeling coupled to the second round of DNA replication,182 causing the 2-cell 
embryo to be more resistant to nuclear degradation since modifications such as DNA methylation and 
histone deacetylation mask intemucleosomal sites for DNA cleavage.202
Another cellular response to oxidative stress or chemical insult is increased expression of cell stress 
proteins such as heat shock proteins (HSPs).225 HSPs225 and stress-inducible genes170,246 are regulated by 
heat shock factors,225 some of first transcription factors expressed in the mouse preimplantation 
embryo.170-225 Heat Shock Factor 1 (HSF1) is a major transactivator o f stress-inducible genes in response to 
environmental changes,246 and HFS1 function is required by early embryos for defense against oxidant 
insults and maintenance of redox-homeostasis and mitochondrial function.197 Loss o f HSF 1 function
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results in developmental arrest as early as the 1 - to 2-cell stage in embryos expressing the H sfl ' 
trait,197'225,246 perhaps due to the fact that several HSP genes are down-regulated in H sflv" oocytes.197 HSF 1 
is not necessary to initiate zygotic transcriptional activity, however; H sfl"/" zygotes have been found to 
express HSPs, showing that zygotic transcriptional activity can begin in the absence of HFS1 and its 
protective effects.246 Hsp70.1 is one of the earliest genes constitutively expressed in the early embryo 
beginning with the onset of embryonic transcription.228 Induced expression of HSPs due to suboptimal 
culture conditions and constitutive HSP expression may both represent essential mechanisms for successful 
embryo growth in an adverse environment, but inducible expression o f Hsp70.1 is delayed until the morula 
or early blastocyst,178 offering little protection in earlier developmental stages.
Specific Aims
The focus of this study was to evaluate the toxicity of IV general anesthetics to the preimplantation 
embryo. Potentially teratogenic agents may contact the early embryo in a number of ways including 
elective or emergency surgery, assisted reproduction procedures, or drug abuse, necessitating the 
investigation o f possible deleterious effects during preimplantation development. Numerous studies 
document the potential detrimental effects to development following exposure to alcohol and 
anesthetics.2’6’715116117 General anesthetics were selected as representatives for their mechanism of action, 
with additional consideration to the potential for abuse and prevalence of use in humans and laboratory 
animals. The primary targets o f IV general anesthetics are CNS ion channel-linked receptors for the either 
glutamate (NMDA receptors), or GAB A (GABAa receptors).21 The GABAa receptor is the primary target 
o f a diverse group pharmacological agents, including barbiturates, benzodiazepines, and general anesthetics 
halothane and propofol. 48-50-58'60 Agents such as ketamine HC1,63 phencyclidine (PCP),11-64 
dextromethorphan,65 and nitrous oxide66 antagonize the binding of glutamate11’63"66 by blockade of NMDA 
receptors to achieve anesthetic effects.19 Examples of common injectable anesthetics used for laboratory 
animals and in veterinary medicine include pentobarbital,68’88 ketamine, and propofol,82 however these 
agents are also used for human anesthesia.
A majority of drug-abusing women are of childbearing age; consequently it is not unusual to encounter 
pregnant women who abuse illicit drugs, either due to negligence or disregard to the potentially harmful 
effects of this behavior.114 Many studies found to refute the deleterious potential o f drug exposure only 
investigate effects of short term exposure, and do not test binge conditions under which an abuser may 
expose an embryo to high concentrations for extended durations.122 Pentobarbital has a relatively high 
potential for abuse for the same sedative/hypnotic effects for which it is clinically implemented.115 The 
more widespread use of ketamine increases its availability, which in combination with its psychomimetic 
effects28,31,32 may influence its even higher potential for abuse.7'11,29'101 The abuse potential for propofol has 
not been completely defined, but its abuse is not uncommon among people working in the medical field 
and in certain areas of the world where celebrities have popularized its misuse.70’135
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The perfect injectable anesthetic is yet to be developed,82 but propofol is currently the most ideal 
anesthetic agent for TIVA.20 Propofol is also a commonly used drug for IVF,10'37'39,204'205 and since it has 
been detected in the follicular fluid of patients,2-204 it has demonstrated an ability to make contact with an 
oocyte or an early embryo in uterine fluids. In recent years, the shortage of drugs such as propofol and 
thiopental has made the choice of an induction agent be more influenced by availability,21 requiring 
investigation of alternative agents. While some of the emergence reactions of ketamine are undesirable,28
21 26 23 29 73 19 27 29its versatility, ’ positive hemodynamic profile, - analgesic effects, and low cost - ' contributes to its 
continued use in humans,19 and the use of ketamine is widespread for veterinary anesthesia.82
The development o f other anesthetic agents such as propofol24 in response to some o f the negative 
anesthetic properties of barbiturates has led to the reduction of the anesthetic use of barbiturates,15-23,30’33'43 
however the long history of barbiturate use and research, as well as utilization for selective procedures or 
conditions, and potential for abuse compels continued study of this class of drugs. Pentobarbital anesthesia 
remains prevalent in many undeveloped countries,82 and additional use of pentobarbital continues in the
24 73 82 g-1-87 *first-world as a second or third-line agent for a number of applications - 1 - Pentobarbital is currently 
approved by the FDA,247 and its economic benefits and the promising potential o f its stereoisomers may 
contribute to future widespread use. The decades of use of pentobarbital, in addition to its generalized 
availability, low cost, relatively rapid onset o f anesthesia, and ease of injection to a variety o f animals 
contributes to its continued widespread use in laboratory animals and in veterinary medicine,68-82-85-88 and its 
use is especially prevalent in rodents.68-88 Few barbiturates are currently used, however pentobarbital and 
thiopental are common agents in veterinary medicine, and the availability issues of thiopental82 influenced 
the selection of sodium pentobarbital as a representative of barbiturates for this study.
The study of the preimplantation embryo is important to understand the mechanisms of embryotoxicity 
during early pregnancy.138 The in vitro culture embryo assay is a valuable model for the assessment of the 
safety of drugs155 and to screen potential toxic effects o f pharmacologic agents which may come in contact 
with the egg or early embryo.10-138 The preimplantation mouse embryo in vitro development bioassay 
elucidates the effect of a pharmacologic agent on cellular differentiation;138 and the early embryonic stages 
provide indications of potential induction of fetal and postnatal defects.157 Extended drug exposure periods 
are necessary in this system since some components causing failure of the bioassay may compromise 
embryo development, without being outright lethal.151 Later development may also be assessed during 
extended exposure since components have the ability to affect the development o f the inner cell mass 
directly.151 The potential of embryos developing into blastocysts may relate to factors within the embryos 
which may be affected by contact with exogenous compounds,152 and the timing during which development 
may be interrupted or delayed is necessary to establishing mechanisms by which effects are observed. 
Extended exposure may also assist in evaluation of potential embryotoxicity of pharmaceutical agents 
subject to habitual abuse.
The window of the prcimplantational period, and the dosage and severity of embryotoxic effects which
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may be exerted by sodium pentobarbital, ketamine HC1, or propofol has not been established. To observe 
potential adverse effects of these drugs, preimplantation 2-cell mouse embryos were cultured in three 
separate studies o f 72h extended exposure. The objective o f this study was to establish the window of 
preimplantation development during which each anesthetic agent affects cleavage through the normal 
progression of in vitro embryonic development, the concentration at which inhibitory effects are 
significant, and the extent to which this damage may be exerted. Embryos were exposed to incremental 
concentrations of sodium pentobarbital, ketamine HC1, or propofol, and development was monitored and 
evaluated. Incremental concentrations of these agents exceeding normal clinical concentrations found in 
follicular fluids and surpassing the normal clinical time of exposure were used to assess embryotoxicity for 
this study. Embryotoxicity was evaluated by analysis of the morphology, early cleavage, and subsequent 
differentiation of prcimplantation mouse embryos subjected to prolonged exposure of sodium 
pentobarbital, ketamine HC1, or propofol from the 2-cell stage until blastocyst formation at the 72h 
endpoint. In the mouse model, blastocyst morphology provides a good indicator of embryonic potential for 
implantation, and the role o f blastocysts hatching from the zona pellucida has been shown to be more 
important to this potential than the number or volume of cells.152 Embryonic manifestations of abnormal 
appearance with evidence of fragmentation (appearance of fragments o f cells within an embryo that are 
smaller than normal-sized blastomeres),238 granulation, and degeneration of blastomeres were indications of 
embryotoxic and clastogenic damage, potentially contributing to delayed and inhibited differentiation or 





The potential detrimental effects to development following exposure to alcohol and anesthetics is well 
documented,2'6'7'15'116'117 however exposure is sometimes unavoidable; as many as 2% o f pregnant women 
require surgery.3 Exposure to harmful agents may also occur as a result of substance abuse during 
pregnancy.116 Investigation of xenobiotics which could come in contact with an oocyte or early embryo is 
necessary, exogenous compounds may be potentially detrimental to fertilization, embryonic cleavage and 
differentiation, and subsequent development.1 Propofol is a short-acting IV anesthetic, advantageous for its 
rapid action with short and predictable duration, with rapid, antiemetic, clear-headed recovery.15’23’30'33-43 
Propofol is highly lipophilic,43'67 non-chiral,68-70 and chemically distinct from all other IV induction 
agents.70 Since its development, propofol has been widely accepted as the most ideal agent for TIVA as a 
general anesthetic,20 and propofol TIVA has numerous advantages over anesthetic maintenance with 
volatile agents19 for human and veterinary anesthesia.82 Propofol is a frequent choice for sedation in 
monitored anesthesia care, as well as for induction and maintenance of general anesthesia19 for 
gastrointestinal endoscopic procedures and minor surgical interventions,37 for long-term infusions during 
surgery and on the ICU since it does not significantly accumulate,26,30 and its rapid, short-acting effects 
make propofol a preferred agent for assisted reproduction procedures. l0-15-,7-w-75-204-205 the abuse potential 
for propofol has not been completely defined,70 however its mild euphoric and hallucinogenic effects 
makes the recreational use of propofol desirable.135 Abuse of propofol is also thought to be higher among 
anesthesiologists and medical technicians since its widespread use in clinical practice makes propofol 
available, and concealment of abuse is easy due to its short duration of action.70
When used during transvaginal oocyte retrieval, propofol has been detected in follicular fluid10’39’205 
and has been found to accumulate at levels proportional to the total dose.37 Previous studies have shown 
that even low concentrations of propofol during short-term exposure have the potential to interfere with 
normal fertilization, as well as being deleterious to preimplantation cleavage.1015 In a study to assess the 
ability of mouse oocytes to fertilize and subsequently develop to the blastocyst stage following 30 minute 
in vitro exposure to concentrations ranging from 50ng/mL to 5.0pg/mL, propofol was found to have 
significant effects.10 When fertilization occurred, subsequent embryonic cleavage and development to the 
blastocyst stage was significantly impaired, and propofol was also found to result in parthenogenetic 
activation of cumulus-enclosed oocytes.10 Propofol has been shown to negatively affect the ability of 
oocytes to fuse with spermatozoa without interfering with post-fusion events such as sperm decondensation 
and cell cycle resumption following post-fertilization exposure, however propofol may also inhibit zygotic
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differentiation.15 Comparison of 14h exposure to propofol concentrations ranging from 0.01 to lOpg/mL in 
zygotes and 2-cell embryos found inhibition of cleavage to the blastocyst stage in zygotes, however even at 
lOpg/mL, subsequent cleavage of 2-cell embryos was not significantly impaired.15 This effect was thought 
to be a result o f  cell cycle differences at the time o f exposure between zygotes and 2-cell embryos; cells at 
the G1 phase of the cell cycle are particularly susceptible to environmental factors, and the G1 phase is 
much longer in zygotes than in 2-cell embryos,15,210 leading to a prolonged period of sensitivity in the 1-cell 
embryos.15
Although propofol has no known teratogenic effect in humans,248 it carries and undetermined FDA 
teratogenic risk rating,136 and has the ability to cross the placenta.67’165 No evidence of teratological effects 
in rat and rabbit at lower doses ranging from 5-15mg/kg,43 however neural development has been found to 
be significantly affected by higher doses.211'249 Propofol at 25mg/kg has been found to induce complex 
changes in the developing rat brain, accompanied by age-dependent neurodegeneration in the cortex and 
thalamus at postnatal day 7,211 and even 25% anesthetic effective dose (ED) (200mg/kg) has been found to 
induce neuroapoptosis in the developing mouse brain.249
Short-term exposure of early mouse embryos to propofol has been found to produce an adverse effect 
on embryonic development;10,15 but extended exposure to the preimplantation embryo and effects on later 
embryonic and fetal development have yet to be determined.35-36 The mouse system is valuable for 
screening the potential toxic effects of any xenobiotic compound which may come in contact with a 
developing embryo,138 and the mouse embryo growth and development 72h bioassay is considered to be by 
the clinical reproductive industry the preferred assay for quality assurance/quality control (QA/QC) 
determination and validation of gamete and embryo research.153 The window during preimplantation 
development, and the dosage and severity of embryotoxic effects which may be exerted by propofol has not 
been previously evaluated. Early embryonic stages provide indications of potential induction of fetal and 
postnatal defects,157 and extended exposure allows determination o f effects of later preimplantation 
development since some components have the ability to affect the development of the blastocyst and inner 
cell mass directly.151 Evaluation o f extended drug exposure is necessary since some components causing 
failure of the bioassay may compromise embryo development without being outright lethal.151 Extended 
exposure may also assist in evaluation o f potential embryotoxicity of pharmaceutical agents subject 
prolonged use or habitual abuse.
This study was performed with the objective of evaluating the potential o f propofol to impair cleavage 
through the normal progression of in vitro embryonic development from the 2-cell to the blastocyst stage, 
and the developmental timing and extent to which damage may be exerted. Potential adverse effects o f 
propofol were assessed by individual culture of preimplantation 2-cell murine embryos with incremental 
concentrations o f propofol, starting with normal clinical concentrations and surpassing the normal clinical 
time o f exposure. Initial experimentation showed extreme embryotoxicity at concentrations between 10- 
25pg/mL, well below the murine 50-200mg/kg75,250 (50-200pg/mL) anesthetic induction ED. Inhibitory
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effects were detected even at concentrations similar to the human ED dose range of 1.5-2.5mg/kg (1.5- 
2.5ng/mL)19'26,30'43-67'"1 during propofol anesthesia. Concentrations were modified during follow-up 
experimentation to l.Oug/mL increments between l-10.0ug/mL, and then further refined to 0.5pg/mL 
increments from 0.5-5.0gg/mL. Embryotoxicity was assessed by analysis of early cleavage and subsequent 
differentiation of 2-cell preimplantation embryos subjected in vitro to prolonged 72h exposure o f propofol. 
Detection of abnormal embryo morphology including fragmentation, granulation, and degeneration of 




Embryos used in the study were produced on Institutional Animal Care and Use Committee (IACUC) 
protocol #12-017. Embryos were obtained from female mice 6-18 weeks old (B6CBAFjF, purchased from 
Jackson Laboratories, Bar Harbor, Maine) crossed with outbred CD-I males 2-10 months old (Harlan Lab, 
Indianapolis, IN). This F2 hybrid mouse strain has proved to produce consistently high numbers of 
embryos with 100% development to blastula stage in 72h if all culturing variables are at an optimum. Mice 
were 4-6 weeks old when received and acclimated to the animal facility for at least 48h before use and were 
used within 12 weeks o f purchase. Mice were maintained on a lighting regime of 14h light, lOh dark at 
21°-25°C and given water and laboratory rodent chow (Harlan) ad libitum. Euthanasia was performed by 
cervical dislocation, approved by the Panel on Euthanasia of the American Veterinary Medical Association.
Superovulation And Mating
Female mice were selected at random for exogenously driven superovulation. Superovulation was 
achieved by intraperitoneal (IP) injection o f gonadotropic hormones. IP injection was performed through 
the lower right quadrant o f the abdomen using a lmL syringe with a 'A inch 30 gauge needle. Beginning 
four days prior to use, the injection cycle consisted of two injections separated by 48h. The first injection at 
Oh was 0. lmL of a 50 international units (RJ)/mL (5 IU) of pregnant mare serum gonadotropin (PMSG) 
(SIGMA, G4877, 106K1171; St. Louis) in phosphate buffered saline (PBS). At 48h after PMSG injection, 
0. lmL of a 50 IU/mL (5 IU) solution of human chorionic gonadotropin (hCG) (SIGMA, CG5,075K1442; 
St. Louis) in PBS was administered. At the time of hCG injection, each female was caged with one proven 
fertile male CD-I mouse. Female mice go into estrous and mate within 6h of hCG injection, with ovulation 
occurring between 10 and 12h after hCG injection. Between 8 AM and 10 AM (16h after hCG injection) 
the following morning, female mice were inspected for vaginal copulatory plugs and the result of the 
performance o f each male was recorded. At this time mated and unmated females were segregated and 
marked appropriately with cage cards; only mated animals were used. Unmated animals were submitted to 
the same injection cycle after a two-week recovery period during which the pituitary gland is less sensitive
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to gonadotropins. Females cycled three times without successful mating were removed and euthanized by 
cervical dislocation.
Collection O f Embryos
Females with vaginal copulatory plugs were euthanized using cervical dislocation starting 
approximately 42h after the hCG injection (pregnancy day 0) and immediately prior to embryo collection. 
The abdomen of the mouse was entered by producing a small hole above the umbilicus then retracting the 
skin simultaneously down over the hind legs and over the forelegs in a process known as de-gloving. This 
technique leaves a sterile field for entry without any mouse hair and obviates use of antiseptic agents that 
may compromise embryo viability. Bilateral celiotomy was performed to expose the oviducts o f pregnant 
animals. Salpingectomy was performed by gently stretching and tearing the mesosalpinx and mesomctrium 
away from each oviduct and uterine horn, and then cutting between the oviduct and ovary at the cephalad 
end and the oviduct and the intramural junction at the caudal end with microsurgical scissors. The two 
oviducts were then placed in each sterile 35 x 10mm polystyrene culture dish (Nalge Nunc International) 
containing 2mL of modified Krebs-Ringer-bicarbonate (mKRB) medium (See Appendix 1). A Zeiss 
dissecting stereomicroscope (Eastern Microscope Co, Raleigh, N.C.) at 20x magnification, watchmaker 
forceps (Dumont and Fils, Switzerland) was used to slide the fimbriated end of the oviduct onto a 30-gauge 
(FineJect, Henke Sass Wolf) sterile needle attached to a 1 mL sterile syringe (Norm-Ject). Embryos were 
irrigated from the oviducts with medium lightly expressed from the syringe. Each animal can be expected 
to produce an average of 15 embryos per successful mating (successful mating is approximately 1 per 2 
stimulated females = (Vi))
Embryos
Individual morphologically normal (judged by oval, bilateral symmetry of the two blastomeres with 
narrow perivitelline space and presence of two small polar bodies) 2-cell embryos was evaluated at 32x 
magnification and collected from the petri dish with a lOpL micropipette (Eppendorf) fitted with a sterile 
tip (Avant) and aseptically dispensed into 96 well U-bottom culture plates (Falcon, 35-3077) with one 
embryo per well. Embryos were cultured in a NuAire Autoflow IR Water Jacketed C 0 2 Incubator at 37°C, 
5% C 0 2 for 72h. Differentiation was evaluated every 24h at 40x and IOOx using a Nikon Diaphot inverted 
microscope. Each test medium was evaluated in triplicate cultures.
Solutions And Media
Media used was modified Kreb’s ringer solution (mKRB) supplemented with 4mg bovine serum 
albumin (BSA) per ml. (See Appendix 1) and conditioned at 37°C 18~24h. Propofol (2-6- 
Diisopropylphenol 97%, Sigma Aldrich D126608-5G) was dissolved in mKRB media at various 
concentrations and equilibrated in the C 02 incubator for at least 12h before use. The control solution for
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the propofol experiments was mKRB media. Test concentrations of media containing propofol were 0.5, 
1.0, 1.5, 2.0, 2.5, 3.0, 3.5,4.0, 4.5, 5.0,6.0,7.0, 8.0, 9.0, 10.0, 15.0, and 25.0pg/mL.
Statistics
A 72 hour embryo culture endpoint with minimum development of 65% blastula and combined 80% 
morula + blastula embryo morphology is necessary to report a passing score on the mouse embryo assay.251 
Cell number and overall developmental stage o f embryos in specific treatments were analyzed using one- 
factor fixed-effects randomized block analysis o f variance (ANOVA) performed using IBM SPSS 20 to test 
for overall significance among treatments. This was followed by Tukey’s HSD (honestly significant 
difference) test for differences between means of specific treatments. The Shapiro-Wilk test of normality 
and Levene’s test of equality of variance were also used to evaluate whether samples were normally 
distributed and if there was statistically significant variation between treatments. The significant groups 
were then tested with ■£ for homogeneity and difference of proportions. Culture of at least 15 embryos is 
performed with each item that we test to meet the CLIA ‘88 federal law to establish toxicity for the tested 
item. This embryo number (15) was established by the R.J. Swanson Mouse Embryo Laboratory as the 
standard for their testing protocol.
RESULTS
The results of propofol experiments are presented in Table 1 and fable 2. Preliminary testing included 
concentrations of 0.1, 1.0, 2.5, 5.0, 10.0, 15.0, and 25.0pg/mL propofol. All concentrations exceeding 
5.0pg/mL propofol yielded 100% degeneration and fragmentation with arrest of cleavage at the 2-ccll 
stage. Test concentrations were then modified to l .Opg increments between 1.0-10.0pg/mL propofol to 
evaluate dosage range allowing differentiation. After development past the 2-blastomere stage was 
inhibited in 100% of embryos at all concentrations exceeding 5.0pg/mL, the dosage range was further 
refined to increments o f 0.5pg/mL between 0.5-5.0gg/mL, to determine the range within which embryonic 
development was inhibited but not entirely arrested.
Propofol significantly induced degeneration at concentrations exceeding 2.0pg/mL (Table 2), and 
inhibition of differentiation to blastocyst was significant at concentrations above 1.5pg/mL. Degeneration 
and nuclear fragmentation was observed in 79% of embryos within the 5.0|ig/mL propofol group (^2, 
pO.001). In addition, 87% of embryos displaying degeneration at this concentration were arrested at the 2- 
cell stage (Fig. 8), and only 21% were able to reach the blastocyst stage. At 4.5pg/mL, 17.6% of embryos 
reached the blastocyst stage, with 70.6% degenerating before reaching the morula stage, and 50% of 
degenerating embryos were arrested at the 2-cell stage (Fig. 8). At 4,0gg/mL, 88.5% of embryos exhibited 
fragmentation and degeneration, with 57.7% arrested at the 2-cell stage. The 3.5pg/mL concentration 
resulted in the least amount o f variance between groups (developmental stage reached) o f any
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concentration tested (9.333); 50% of embryos at this concentration degenerated with 20% arrested at the 2- 
cell stage (Fig.7; Table 2), 20% reached the morula stage, and 30% reached the blastocyst stage.
At 3.0|ig/ml , propofol, 19.4% of embryos displayed degeneration; however of those degenerating,
86% were arrested at the 2-cell stage. 3.0pg/mL propofol also halted 25% of embryos at the morula stage, 
and allowed only 55.6% reached the blastocyst stage. At 2 .5pg/mL propofol, 76% of embryos achieved 
the blastocyst stage. Those unable to reach blastocyst at 2.5pg/mL degenerated prior to the morula stage, 
resulting in a failing embryo score, though 50% of degenerating embryos completed at least one additional 
cleavage division (Table 2; Fig. 8). Below 2.5pg/mL, propofol did not significantly inhibit differentiation 
to at least the morula stage. This effect was especially evident in groups below 2.0pg/mL. In every group 
below 2.0|ig/mL, the blastocyst stage was reached in over 80% of embryos, with less than 10% 
degenerating and/or fragmenting.
Results of the one-factor fixed-effects randomized block ANOVA for overall significance among 
treatments found the means of all treatment groups to be significantly different (F=3.9831; d/=3,56; 
P=0.012136). Analysis of groups from Ofig/ml (control) to S.Opg/ml propofol also found significantly 
different means (F=6.555761; d/=3,36; P=0.001189), however a significant effect was not found between 
these lower concentrations. Analysis was followed by Post Hoc Tukey’s HSD test to evaluate differences 
between specific treatments. The Tukey’s HSD test did not reveal significant effect between specific 
blocks suggesting that lower concentrations did not significantly inhibited differentiation. The Shapiro- 
Wilk test o f normality indicated that the samples were not normally distributed in control groups, 1 5pg/mL 
propofol, and 6.0-10.0jig/mL propofol (P=0.047,0.00,0.00). Levene’s test o f equality o f variance was 
statistically significant (P=0.002), indicating a significant effect on differentiation between the 
concentrations tested.











•  fC orto f) o% 0% 0% o% 100% 10
O.lpg/mL 0% 10.0% 0% 0% 90.0% 10
0% 0% 0% 0% 100% 10
2.5ng/mL 0% 16.7% 16.7% 0% 83.3% 12













25fig/mL 100 % 0% 100% 0% 0% 12
Propofol buffered with mKRB media+BSA was tested at the above concentrations to ascertain potential for 
embryotoxicity. A control solution containing mKRB+BSA embryo culture media, with no (Ong/mL) 
propofol was used. Degenerating refers to abnormal development or deterioration of the embryo before 
reaching the compact morula stage.
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72h Differentiation of 2-Cell Mouse Embryos Exposed to  Propofol
■  2-Cell
■  4- 12-Cell 
□  Blastocyst
0 0.1 1.0 2.5 5.0 10.0 15.0 25.0
Concentration Propofol (|ig/mL)
Fig. 6. 72h differentiation of 2-cell mouse embryos exposed to propofol: preliminary results. Percentage 
of embryos reaching specific stage of differentiation during preliminary experiments. Embryonic arrest 
prior to morula, or completed differentiation to blastocyst rendered reporting morula stage not applicable 
for preliminary studies (see Table 1). A control solution containing mKRB+BSA embryo culture media, 
sans propofol was used. All concentrations exceeding 5.0pg/mL were found to be 100% toxic to 
embryonic development.
Table 2. Propofol 72h effects on embryonic development: percentage of embryos reaching specific stage 
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Propofol buffered with mKRB media+BSA was tested at the above concentrations in follow up 
experiments. This phase was performed within range of inhibition o f differentiation found by preliminary 





















■  4 - 12-Cell 
□  Morula
E3 Blastocyst
0.5 1.0 1.5 2.0 2.5 3.0 3.5
Concentration Propofol
Fig. 7. 72h in vitro culture effects o f propofol on 2 -cell mouse embryo development: percentage of 
embryos reaching specific differentiation stages. A control solution containing mKRB+BSA culture media, 
sans propofol was used. Exposure to higher concentrations (6.0, 7.0, 8.0, 9.0, and lO.Opg/mL) was found 
to be 100% toxic to embryonic development. See Table 2.
72h DifftrMitiation ProgrM* of Dogtnoratlng Embryo* 
ExpoMdto Propofol
2.5Mf/mL 3.0p*/mL 3.5pc/mL ■  2-Cel 
□  4-12Cell
4 .0pf/m l 4.5pg/mL 5.0pc/mL
Fig. 8. Differentiation progress of degenerating embryos following 72h exposure to propofol. Percentages 
of embryos arrested at the 2-cell stage in comparison to embryos able to undergo at least one cleavage 
division before degenerating and/or fragmenting (4- 12-cell).
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Fig. 9. Photomicrograph o f propofol 72h in vitro culture effects. Hatching blastocyst (A) in control 
solution (mKRB media + BSA), 8-cell embryo (B) cultured at 4.0pg/mL propofol; arrested 2-cell embryo 
(C) cultured at lO.Ogg/mL propofol. Photomicrograph taken at 200x using DIC Optics.
DISCUSSION
The results of this study suggest that extended propofol exposure produces dose-dependent inhibitory 
effects to the differentiation of preimplantation murine embryos in vitro. Propofol significantly decreased 
72h differentiation to the blastocyst stage at the highest concentrations tested (6.0-10.Opg/mL propofol), 
with 100% of embryos within these groups degenerating at the 2-cell stage. Blastomeres o f embryos within 
these treatment groups displayed substantial fragmentation indicative o f apoptotic damage and no evidence 
of further differentiation was exhibited. Caution should be exercised when forming conclusions about 
degenerative effects though; it is not uncommon to find a few embryos fragmenting or degenerating, even 
in culture with Kreb’s media preparations alone.14'1
Degeneration and nuclear fragmentation was significant at 5.0pg/mL propofol, where 68.9% of 
embryos exhibited a 2-cell block. 10.3% of embryos degenerating at 5.0pg/mL propofol were able to 
complete one cellular division before arresting at the 4 -cell stage (Fig. 8); however all surviving embryos 
that did not degenerate at this concentration completed differentiation to blastocyst (20.8%). Significant 
inhibition of differentiation to the blastocyst stage was also observed between 2.0-4.5pg/mL, with an 
overall trend of increased inhibition at progressively rising concentrations. This generalization was 
deviated from by embryos cultured at 4.0pg/mL. At 4.0pg/mL, propofol exerted effects (89% 
degeneration) resembling those found at concentrations exceeding 5,0gg/mL (100% degeneration). 
However, like embryos cultured at 4.5pg/mL, cleavage was not entirely blocked at 4.0pg/ml, and 35% of 
arrested embryos completed at least one mitotic division (Fig. 8).
By the 72h conclusion of the culture period, concentrations between 2.5-4.5pg/mL propofol resulted in 
significant variation in the stage of differentiation reached. Although 2-cell block was significant at 
concentrations above 2.0pg/mL, embryos degenerating at 2.5pg/mL and between 3.5-4.5pg/mL propofol 
were able to complete at least one cleavage division before fragmenting and cleavage arrest (Fig. 8). Later 
embryonal delay was significant in groups exposed to 2.0, 3.0, 3.5, and 4.5|ig/mL propofol; at these 
concentrations, a significant percentage of embryos were halted at the morula stage and unable to undergo 
further differentiation to blastocyst. Embryos cultured at concentrations below 3.0pg/ml, propofol
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exhibited significant capacity for differentiation to at least the morula stage. This effect was especially 
evident in groups cultured at concentrations below 2.0pg/mL. Although a significant percentage of 
embryos exposed to 2.5pg/mL propofol reached the blastocyst stage, 24% degenerated to result in a failing 
embryo score. For human IVF, media is not recommended for use when less than 75% of the embryos 
develop to morula or blastocyst, or more than 15% appear to be degenerating or fragmenting after 72h 
culture,144 but minimum development of 65% blastocyst and combined 80% morula + blastocyst embryo 
morphology is necessary to report a passing score on the mouse embryo assay.251 Failing embryo scores 
were recorded for embryos cultured at all concentrations exceeding 2.5pg/mL propofol.
The embryotoxicity of propofol exposure in the current study may be attributed to a variety of 
biochemical mechanisms or a combination of deleterious effects. Exogenous compounds can affect 
development of the preimplantation embryo by increasing oxidative stress, and due to relatively weak 
antioxidant defense during early developmental stages,227 this stress often results in defective 
development.224 Oxidative stress has previously been found to produce a developmental block in mouse 
embryos cultured from the 2-cell stage,224 and propofol-induced oxidative stress is a likely factor 
contributing to the observed fragmentation and inhibited embryonic differentiation at higher 
concentrations. Oxidative stress is also capable of affecting development via numerous secondary effects 
such as directly causing DNA or RNA damage,190’227 as well as affecting nutrient uptake and metabolism,198 
mitosis,236 and apoptosis.178 Oxidative stress may be intensified by autocatalytic effects; free radicals can 
damage mitochondrial membranes and generate new sources of ROS.198 Environmental agents that elevate 
levels o f free radicals may also affect the developing embryo by increasing lipid peroxidation and protein 
oxidation.227 Although propofol has been shown to exhibit antioxidant69 and free radical scavenging 
properties,241 previous results have shown many of the protective effects of propofol to be the result of 
stimulation of later developing enzymatic pathways such as the HO pathway,69 or by reduction of 
macrophage inflammatory response.242
In the current study, the survival of embryos able to complete at least one cellular division, or of those 
exhibiting delayed differentiation suggests that at lower concentrations, embryos were resilient enough to 
stagger through at least one additional cleavage division before degenerating. This embryonic survival may 
be attributed to modest toxic effects at lower concentrations affecting few cellular processes, perhaps in 
combination with the capacity of embryonic endogenous mechanisms to preserve some normal functions in 
the presence of environmental insult. During the cleavage stage in the preimplantation embryo, 
environmental insults to the embryo may result in embryonic death or survival.4 Even when survival is 
possible, development may still be compromised by non-lethal insults to the embryo.151'224 The 
undifferentiated cells of the early embryo can enable repair through multiplication o f the still omnipotent 
cells,4 but because the embryo has limited regenerative capacity, oxidative injury may result in irreparable 
damage.151'224
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A cellular response to oxidative stress or chemical insult is increased expression of cell stress proteins 
such as HSPs.225 Induced expression of HSPs due to suboptimal culture conditions and constitutive HSP 
expression both represent an essential mechanism for successful embryo growth in an adverse 
environment.178 Along with other stress-inducible genes, HSPs are regulated by heat shock factors, but loss 
of heat shock factor function has been shown to result in developmental arrest as early as the 2-cell 
stage. l70’I97>225’246 Hsp70.1 is one of the earliest genes constitutively expressed in the early embryo 
beginning with the onset of embryonic transcription;228 however inducible expression is delayed until the 
morula or early blastocyst.178 Inadequate HSP expression may have contributed to inability of 2-cell 
embryos to recover from the chemical insult of exposure to greater than 4.5pg/mL propofol. HSP 
expression may have also assisted in the significant survival o f embryos at 2.5-4.5pg/mL and lower 
concentrations.
If propofol exposure directly altered HSP transcripts or proteins, or oxidatively induced down-regulation of 
HSP expression, the intracellular redox-balance may have been affected.
Apoptosis is a necessary process in normal embryonic development, however apoptosis may have 
detrimental effects including embryonic arrest if the number of apoptotic cells is elevated,178 or if the 
balance of pro-apoptotic and anti-apoptotic proteins is affected.201 Aside from excessive ROS exposure, 
additional in vitro causes of apoptosis may be attributed to suboptimal culture conditions or chromosomal 
abnormalities.178 High levels of apoptosis have previously been detected in fragmenting preimplantation 
embryos,238 and the fragmentation of blastomeres observed in degenerating embryos in this study was 
indicative of apoptosis. Cellular death and fragmentation characteristic o f apoptosis was significantly 
increased in embryos exposed to concentrations exceeding 2.0pg/mL propofol, and increased apoptosis or 
an imbalance of apoptotic proteins may have also contributed to the delayed differentiation in embryos 
exposed to 2.0-4.5pg/mL propofol.
Although propofol has previously been shown to have a protective effect against mitochondrial 
dysfunction by inhibiting mitochondrial membrane permeability and reducing mitochondrial ROS 
production,243 significant alteration of the redox-balance may still result in mitochondrial dysfunction and 
induce oxidative damage to cellular proteins.198 Mitochondrial damage or alteration o f membrane and 
intracellular proteins can perturb metabolism, which could affect nearly every process critical to early 
development. Propofol has the ability protect against mitochondrial dysfunction,243 but excessive propofol 
exposure could potentially affect the intracellular redox balance to damage organelles, DNA, RNA, and 
proteins. Disruption of mitochondrial function would primarily affect metabolism during pre-compaction 
stages, when energy production is nearly entirely dependent on the mitochondrial tricarboxilic acid fl'CA) 
cycle.179 188,189 Oxidative stress has previously been found to cause cells to shift from oxidative use of 
pyruvate in the full TCA cycle to use of the segment of the TCA cycle involving succinate and succinate 
dehydrogenase.198 Alteration of the TCA cycle would significantly interrupt the main mechanism of ATP 
production during early embryonic differentiation, possibly contributing to the significant degeneration and
45
2-cell block in embryos cultured at concentrations exceeding 2.5pg/mL propofol, as well as embryonal 
delay at concentrations between 2.5-4.5ug/mL propofol.
Embryonic dependence on the TCA cycle during the pre-compaction stages shifts to a metabolism
179 188 189based on glycolysis between the morula and blastocyst stages. ' ' Between the 8-cell stage and
morula, glucose consumption increases dramatically as embryo metabolism transitions to depend on 
glycolysis,179 190 and by the blastocyst stage glucose is the primary energy substrate.166 Glucose is not 
utilized as the main energy source prior to compaction,166 but glucose uptake has been detected in earlier 
stages.179 Though propofol inhibition glucose transport may not be directly involved the cleavage block at 
higher concentrations, it may have contributed to delayed differentiation. While the TCA cycle is dominant 
during early cleavages, the glucose transporter GLUT 1 is expressed throughout development and is thought 
to provide the embryo with its basal glucose requirements.193 Glucose uptake has previously been found to 
be interrupted by propofol,48 and if propofol has similar effects in the embryo, deprivation o f the primary 
energy substrate during later cleavage stages and compaction166'179,190 would significantly affect many 
processes critical to development. Interference with facilitators of glucose uptake such as GLUT 1 has been 
shown to result in a high rate of apoptosis at the blastocyst stage,244 and inhibition of GLUT 1 and 
associated decreased glucose transport previously found to be induced by propofol may have a similar 
effect. Inhibition o f glucose transport may significantly slow cellular processes to significantly affect 
further cleavage, resulting in arrest prior to the blastocyst stage similar to that found to be elevated in 
groups exposed to concentrations exceeding 1.5pg/mL propofol. Increased apoptosis resulting from 
interference with facilitators of glucose uptake by propofol may have also contributed embryonal delay 
demonstrated by embryos cultured at 2.5, 3.0, 3.5pg/mL and 4.0pg/mL propofol; a significant percentage 
were halted at the morula stage, indicating that an exogenous factor inhibited differentiation to the 
blastocyst stage. Furthermore, at least 30% of embryos at concentrations between 3.5-4.5pg/mL propofol 
were arrested between 4-cells and 12-cells, a period of differentiation during which embryonic metabolism 
begins to transition from a reliance on the TCA cycle to glycolysis (Table 2).
The embryonic cell cycle can be modified either by introduction of new components, substrates, 
pathways, or altered interactions between them.232 Inhibitory effects found in embryos arresting at the 2- 
cell stage suggest significant modification to the cell cycle occurred, especially at concentrations greater 
than 5.0fig/mL where 2-cell block was recorded in 100% of embryos. The cell cycle may have been 
affected by antimitotic activity exerted either directly or by propofol-induced oxidative stress. Later 
divisions may also be interrupted by exposure to exogenous factors.232 Antimitotic effects resulting from 
propofol exposure could be exerted by a number of mechanisms, including destruction of the spindle and 
impaired chromatid separation during mitosis, or inactivation of Cdc25 phosphatases. Cell cycle control 
proteins Cdc25 phosphatases235 may be inactivated by ROS, which has been found to lead to a block of the 
cell cycle progression.236 Propofol may also have induced improper attachment of kinetochores to 
microtubules, which could trigger the spindle assembly checkpoint (SAC), and prevented the onset of
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anaphase to arrest mitosis.210 Several anesthetics (dibueaine, tetracaine, procaine, and lidoeaine) have 
previously been found to significantly affect the organization of cytoskeletal components and plasma 
membrane attachment points223 and similar effect may be produced by an anesthetic such as propofol.
The significant variation in sensitivity to propofol at the 3.0pg/mL and 3.5pg/mL concentrations 
(Table 2; Fig. 8) may be attributed in part to differences in sensitivity between embryos at various points 
within the cell cycle during initial exposure. During the G 1 phase o f the cell cycle, preimplantation 
embryos are particularly susceptible to environmental factors.15 The timing of teratogen exposure during 
the cell cycle is consequently very important to embryonic survival. At first contact, affected embryos may 
have been at a transition in stages of the cell cycle, depending on the timing of insemination possibly 
contributing to the difference in sensitivity to propofol at the 4.5pg/mL concentration. At this 
concentration, 70.6% of embryos arrested and degenerated, and 50% degenerating embryos were able to 
complete at least one cellular division (Fig. 8), but a significant percentage still reached the morula and 
blastocyst stage.
Propofol exposure may have interfered with zygotic gene activation (ZGA), contributing to arrested or 
delayed embryonic differentiation. The failure to undergo ZGA often results in arrested progression,170'177 
similar to that observed in treatment groups exposed to concentrations greater than 2.0pg/mL propofol, 
where significant arrest of 2-cell embryos was observed. Direct mutagenic activity has not been found to 
result from propofol exposure, though. Previous tests of propofol have found neither direct mutagenic 
activity in the Salmonella mutation test, nor cause genetic mutation or gene conversion in Saccharomices 
cerevisiae43 Instead, oxidative stress exerted by propofol may be a more likely factor affecting ZGA in 
this study. The preimplantation embryo is particularly sensitive to oxidative stress during ZGA, and any 
condition which enhances ROS accumulation during ZGA can have detrimental consequences.190 Under 
normal conditions, ROS increase has been found to culminate during ZGA, suggesting that during this 
transition, oxidant defense is depleted and must be replenished by ZGA.190 Future experimentation is 
necessary to determine whether the higher doses of propofol (>2.0fig/mL) directly affected ZGA, or if 
oxidative damage to transcription was responsible for the developmental block at the 2 -cell stage or altered 
the embryonic genome to delay differentiation.
Chromatin remodeling is necessary for the initiation of ZGA and the onset of embryonic 
transcription.170 Chromatin remodeling uses energy from ATP hydrolysis to restructure or move 
nucleosome constraints to transcription to make the genome accessible to transcription factors, however 
defective transcription factor function can result in developmental arrest.1!>7-225-246 Interference with 
chromatin remodeling or transcription factors may have contributed to the inhibition observed in the 
embryos exposed to greater than 2.0pg/mL propofol. Culture media has previously been found to directly 
affect gene expression (actin, G-3PDH, and Na /K ATPase housekeeping genes), transcription factors, and 
growth factors, as well as impacting the rate of degradation of mRNAs which can affect methylation and 
expression,228 but further study of propofol effects is necessary.
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The results of this study suggest that exposure to propofol affects preimplantation murine embryo 
development by delaying or arresting cleavage. At propofol concentrations well below the clinical ED, in 
vitro preimplantation embryonic progression to blastocyst was inhibited; all concentrations exceeding 
1.5 |ig/mL propofol significantly delayed or arrested differentiation. Further testing concentrations within 
the range of embryonal delay (2.0-5.0fig/mL propofol) should enable detailed analysis of potential 
molecular mechanisms contributing to the inhibition of preimplantation embryonic development by 
propofol. Detailed examination of propofol effects on preimplantation embryo biochemistry is necessary to 
confirm that apoptosis is indeed activated by propofol exposure, that increased apoptosis contributed to 
inhibited differentiation, and to elucidate the mechanism(s) by which apoptosis is initiated. Additional 
mechanistic study is needed for characterization of the significant 2-cell block recorded at propofol doses 
exceeding 1,5pg/mL, and may find a correlation between either direct mutagenic effects or propofol- 
exerted oxidative stress effects resulting in arrested cleavage. Continued biochemical investigation of 
propofol effects in the preimplantation embryo should also provide insight into the mechanism by which 
inhibition is exerted. DNA and RNA damage, interference with transcription and transcription factors, 
suppression of HSP expression, antimitotic effects and spindle formation, mitochondrial interactions, 
initiation o f the apoptotic cascade, interruption o f metabolism and nutrient uptake, or a combination of any 
of these factors should allow a greater understanding of the inhibition caused by propofol. Many of these 
factors may be investigated by experimentation in non-embryonic cells such as fibroblasts, mouse 
embryonic stem cells, mammalian micromass cell culture, or sperm cell viability, which would allow 
decreased expenses and animal use for abundant and timely data collection prior to testing effects in the 
preimplantation embryo. Future study of embryo transfer for implantation and fetal development may also 
provide evidence to support significant effects o f propofol on embryonic development does indeed exist 






The highest developmental sensitivity to barbiturates has been found during early stages of chick 
embryo development at subclinical levels, a period which may also be clinically relevant in mammals.81 
Short and long-term consequences of prenatal and neonatal exposure to barbiturates in humans include 
changes in the CNS and behavior;85 and congenital malformations associated with phenobarbital exposure 
include midface and digit hypoplasia,219 and microcephaly.216'219 The FDA classifies pentobarbital to be a 
class D potentially teratogenic medication,1 however little published research supports the potential of 
pentobarbital to be detrimental to development.14’81'84’252’253 Pentobarbital exposure during neural 
development has been found to significantly affect neurological physiology and behavioral function.84 
GABAmimetics such as barbiturates are capable of triggering neuroapoptosis in the developing brain.116 
Pentobarbital has the potential to destroy newly formed neurons resulting in behavioral and cognitive 
defects; and even early administration of the less potent barbiturate phenobarbital has been found to impair 
the rat hippocampus and cause extensive deficiencies in radial maze behavior and spontaneous alteration.85 
Prenatal exposure to barbiturates has been found to cause syndromes of neurobehavioral deficits, especially 
involving defects in septohippocampal cholinergic innervation-related behaviors.215 Eight-arm radial maze 
performance is the most common test of impairment to the septohippocampal pathways,217 and extensive 
deficiencies in radial maze performance and spontaneous alteration behaviors have been found to be 
associated with barbiturate administration during neural development.85
Documentation of the effects of barbiturates on preimplantation embryo development is sparse,14 and 
extensive search of the literature has revealed an absence of in vitro studies of pentobarbital effects in the 
preimplantation embryo. Most studies of developmental effects o f barbiturates focus on late-term exposure 
and are limited to teratological examination for visual determination o f major malformations in the 
offspring, and behavioral studies examining effects on neurological development. Effects o f sodium 
pentobarbital (NaPB) anesthesia on the preimplantation embryo have been investigated in rabbits, though, 
where female rabbits were injected intravenously at either 15 minutes or 6h after mating.14 Blastocysts 
were recovered from females at gestation day 6 and examined for chromosomal abnormalities; a greater 
frequency of chromosomally abnormal blastocysts was found in animals injected with pentobarbital than 
controls.14
The anesthetic use of barbiturates has diminished in recent years,15'23 30 33"43 however the long history of 
barbiturate use and research, as well as utilization for selective procedures or conditions, and potential for 
abuse compels continued barbiturate research. NaPB anesthesia remains prevalent in many undeveloped
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countries,82 and NaPB use continues as a second or third-line agent in first-world countries for a number of
applications.24'73,82,84‘87 The decades of use of NaPB, in addition to its generalized availability, low cost,
relatively rapid onset of anesthesia, and ease of injection to a variety of animals contributes to its sustained
68 81 8^  88 *widespread use for laboratory animals and for veterinary medicine. ' " " Few IV barbiturates are 
currently used, however NaPB and thiopental are common agents, and the availability issues of 
thiopental82 influenced the selection of NaPB as a representative of barbiturates for this study.
The focus of this study was to evaluate the preimplantation embryotoxicity of NaPB. Toxicity of long­
term exposure to NaPB in the 2-cell preimplantation embryo is previously unreported. The mouse system 
is valuable for screening the potential toxic effects o f any xenobiotic compound which may come in contact 
with a developing embryo,138 and the mouse embryo growth and development 72h bioassay is considered to 
be by the clinical reproductive industry the preferred assay for quality assurance/quality control (QA/QC) 
determination and validation of gamete and embryo research.153 The window during preimplantation 
development, and the dosage and severity o f embryotoxic effects which may be exerted by NaPB has not 
been previously evaluated. Early embryonic stages provide indications of potential induction of fetal and 
postnatal defects,157 and extended exposure allows determination of effects of later preimplantation 
development since some components have the ability to affect the development of the blastocyst and inner 
cell mass directly .151 Evaluation of extended drug exposure is necessary since some components causing 
failure o f the bioassay may compromise embryo development without being outright lethal.151 Extended 
exposure may also assist in evaluation of potential embryotoxicity of pharmaceutical agents subject 
prolonged use or habitual abuse.
This study was performed with the objective of evaluating the potential of NaPB to impair cleavage 
through the normal progression of in vitro embryonic development from the 2-cell to the blastocyst stage, 
and the developmental timing and extent to which damage may be exerted. Potential adverse effects of 
NaPB were assessed by individual culture of preimplantation 2-cell murine embryos with incremental 
concentrations of NaPB, starting with normal clinical concentrations and surpassing the normal clinical 
time of exposure. When extreme embryotoxicity was observed near the range of clinical concentrations for 
rodents (300pg/mL)93"96 during preliminary exploratory experimentation, the dosages o f NaPB were 
modified to a serial dilution of normal clinical anesthetic dose (30pg/mL, 3.0pg/mL, and 0.3pg/mL) to 
evaluate embryotoxicity in follow-up experimentation. Embryotoxicity was assessed by analysis of early 
cleavage and subsequent differentiation of 2-cell preimplantation embryos subjected in vitro to prolonged 
72h exposure of NaPB. Detection of abnormal embryo morphology including fragmentation, granulation, 
and degeneration of blastomeres provided indications of deleterious clastogenic damage capable of 




Embryos used in the study were produced on IACUC protocol #12-017. Embryos were obtained from 
female mice 6-18 weeks old (B6CBAF]F, purchased from Jackson Laboratories, Bar Harbor, Maine) 
crossed with outbred CD-I males 2-10 months old (Harlan Lab, Indianapolis, IN). This F2 hybrid mouse 
strain has proved to produce consistently high numbers of embryos with 100% development to blastula 
stage in 72h if all culturing variables are at an optimum. Mice were 4-6 weeks old when received and 
acclimated to the animal facility for at least 48h before use and were used within 12 weeks of purchase. 
Mice were maintained on a lighting regime of 14h light, lOh dark at 21°-25°C and given water and 
laboratory rodent chow (Harlan) ad libitum. Euthanasia was performed by cervical dislocation, approved 
by the Panel on Euthanasia of the American Veterinary Medical Association.
Superovulation And Mating
Female mice were selected at random for exogenously driven superovulation. Superovulation was 
achieved by intraperitoneal (IP) injection of gonadotropic hormones. IP injection was performed through 
the lower right quadrant o f the abdomen using a lmL syringe with a 'A inch 30 gauge needle. Beginning 
four days prior to use, the injection cycle consisted of two injections separated by 48h. The first injection at 
Oh was 0. lmL of a 50 international units (IU)/mL (5 IU) of pregnant mare serum gonadotropin (PMSG) 
(SIGMA, G4877, 106K1171; St. Louis) in phosphate buffered saline (PBS). At 48h after PMSG injection, 
O.lmL of a 50 IU/mL (5 IU) solution of human chorionic gonadotropin (hCG) (SIGMA, CG5, 075K1442; 
St. Louis) in PBS was administered. At the time of hCG injection, each female was caged with one proven 
fertile male CD-I mouse. Female mice go into estrous and mate within 6h o f hCG injection, with ovulation 
occurring between 10 and 12h after hCG injection. Between 8 AM and 10 AM (16h after hCG injection) 
the following morning, female mice were inspected for vaginal copulatory plugs and the result o f the 
performance o f each male was recorded. At this time mated and unmated females were segregated and 
marked appropriately with cage cards; only mated animals were used. Unmated animals were submitted to 
the same injection cycle after a two-week recovery period during which the pituitary gland is less sensitive 
to gonadotropins. Females cycled three times without successful mating were removed and euthanized by 
cervical dislocation.
Collection O f Embryos
Females with vaginal copulatory plugs were euthanized using cervical dislocation starting 
approximately 42h after the hCG injection (pregnancy day 0) and immediately prior to embryo collection. 
The abdomen of the mouse was entered by producing a small hole above the umbilicus then retracting the 
skin simultaneously down over the hind legs and over the forelegs in a process known as de-gloving. This 
technique leaves a sterile field for entry without any mouse hair and obviates use of antiseptic agents that
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may compromise embryo viability. Bilateral celiotomy was performed to expose the oviducts of pregnant 
animals. Salpingectomy was performed by gently stretching and tearing the mesosalpinx and mesometrium 
away from each oviduct and uterine hom, and then cutting between the oviduct and ovary at the cephalad 
end and the oviduct and the intramural junction at the caudal end with microsurgical scissors. The two 
oviducts were then placed in each sterile 35 x 10mm polystyrene culture dish (Nalge Nunc International) 
containing 2ml, of modified Krebs-Ringer-bicarbonate (mKRB) medium (See Appendix 1). A Zeiss 
dissecting stereomicroscope (Eastern Microscope Co, Raleigh, N.C.) at 20x magnification, watchmaker 
forceps (Dumont and Fils, Switzerland) was used to slide the fimbriated end of the oviduct onto a 30-gauge 
(FineJect, Henke Sass Wolf) sterile needle attached to a 1 mL sterile syringe (Norm-Ject). Embryos were 
irrigated from the oviducts with medium lightly expressed from the syringe. Each animal can be expected 
to produce an average of 15 embryos per successful mating (successful mating is approximately 1 per 2 
stimulated females = C/2)).
Embryos
Individual morphologically normal (judged by oval, bilateral symmetry of the two blastomeres with 
narrow perivitelline space and presence of two small polar bodies) 2-cell embryos was evaluated at 32x 
magnification and collected from the petri dish with a lOpL micropipette (Eppendorf) fitted with a sterile 
tip (Avant) and aseptically dispensed into 96 well U-bottom culture plates (Falcon, 35-3077) with one 
embryo per well. Embryos were cultured in a NuAire Autoflow IR Water Jacketed C 0 2 Incubator at 37°C, 
5% C 0 2 for 72h. Differentiation was evaluated every 24h at 40x and lOOx using a Nikon Diaphot inverted 
microscope. Each test medium was evaluated in triplicate cultures.
Solutions And Media
Media used was mKRB solution supplemented with 4mg bovine serum albumin (BSA) per mL (See 
Appendix 1) and conditioned at 37°C 18-24h. Sodium pentobarbital (NaPB) (60mg/mL) (Sigma, P3751) 
buffered with 20% glycerol 10% ethyl alcohol to improve miscibility was dissolved in mKRB media at 
designated concentrations and equilibrated for at least 12h before use. The dosage o f NaPB was adjusted to 
10"', 10'2, and 10‘3 relevant anesthetic dose (300pg/mL)9V96 following the extreme toxicity observed at 
300pg/mL in preliminary experimentation. The mKRB media containing the addition of 20% glycerol 
10% ethyl alcohol was used as the negative control for the pentobarbital experiments, since the initial 
pentobarbital positive control of mKRB media containing 20% glycerol 10% ethyl alcohol produced no 
significant effect.
Statistics
A 72 hour embryo culture endpoint with minimum development of 65% blastula and combined 
80% morula + blastula embryo morphology is necessary to report a passing score on the mouse embryo 
assay. Cell number and overall developmental stage of embryos in specific treatments were analyzed using
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one-factor fixed-effects randomized block analysis of variance (ANOVA) performed using IBM SPSS 20 
to test for overall significance among treatments. If significance was found, this was followed by Tukey’s 
HSD (honestly significant difference) test (for unequal sample sizes in treatment groups) for differences 
between means of specific treatments. The Shapiro-Wilk test of normality and Levene’s test of equality of 
variance were also used to evaluate whether samples were normally distributed and if there was statistically 
significant variation between treatments. The significant groups were then tested with x2 for homogeneity 
and difference o f proportions. Culture of at least 15 embryos is performed with each item that we test to 
meet the CLIA ‘88 federal law to establish toxicity for the tested item. This embryo number (15) was 
established by the R. J. Swanson Mouse Embryo Laboratory as the standard for their testing protocol.
RESULTS
Results of NaPB experiments are presented in Table 3 and Table 4. Significant inhibitory effects to 
mouse embryo differentiation were found at 300pg/mL and 30pg/mL pentobarbital concentrations (Table 
4). Preliminary experimentation of the rodent anesthetic dose (300pg/mL)93‘96 found NaPB to be 100% 
toxic to 2-cell mouse embryos, with 100% cleavage arrest of 2-cell embryos characteristic of the “2-cell 
block.” NaPB dosage was modified to 10"1, 10'2, and 10'3 ED for follow-up experimentation. Positive 
control experiments of the vehicle media (20% glycerol 10% ethyl alcohol with mKRB media containing 
BSA) were performed alongside mKRB media. Preliminary study of the vehicle produced a passing 
embryo score, with 100% of embryos reaching blastocyst when cultured in the positive control solution. 
Vehicle media was used as the negative control for follow-up experimentation.
Culture of embryos with NaPB significantly decreased differentiation to the blastocyst stage at 
30|ig/mL; however all lower concentrations did not significantly affect cleavage and differentiation to the 
blastocyst stage. Significant degeneration and visible nuclear fragmentation in 53.8% of embryos treated 
within the 30pg/mL NaPB group (x2, p<0.001) (Table 4) was observed. Only 30.7% of embryos within the 
degenerating/fragmenting group completed the second cleavage division by the 72h endpoint. In addition, 
at the 72h endpoint, 23.1% of embryos at 30pg/mL NaPB reached the compact morula stage, and only 
23.1% of embryos at this concentration reached the blastocyst stage. Effects o f NaPB on blastocyst 
development were also tested with x2 for homogeneity and difference of proportions within significant 
groups. Inhibition of blastocyst hatching compared with blastocyst formation was significant at 0.3pg/mL 
(X2, p<0.01), 3.0pg/mL (x2, p<0.001), and 30pg/mL NaPB (0% hatching) (Table 4).
Results of the one-factor fixed-effects randomized block ANOVA for overall significance among 
treatments found a significant effect between development groups (degenerating/ fragmenting, morula, and 
blastocyst) (F=8.494253, d/=2,9; P=0.008464), and a significant difference between treatment 
concentrations (F=6.013; d/=3,8; P=0.041). This probability is less than the alpha value of 0.05 associated 
with a 95% confidence level. Significant effects were present at the 30pg/mL concentration, however all 
lower concentrations were found to have no significant effects on differentiation. This analysis was
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followed by Post Hoc Tukey’s HSD test to evaluate differences between specific treatments. The Tukey’s 
HSD test did not reveal significant effect between specific blocks. The Shapiro-Wilk test of normality 
indicated that the samples were not normally distributed (P=0.034,0.062,0.024). Levene’s test of equality 
of variance fell outside of the critical realm (F=2.499; d/=3,8; P=0.134), indicating that NaPB did not have 
a significant effect on differentiation at concentrations below 30ug/mL.
Table 3. Sodium pentobarbital 72h effects on embryonic development: percentage of embryos reaching 
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Differentiation results of NaPB buffered with mKRB media+BSA. Degenerating refers to abnormal 
development or deterioration of the embryo before the compact morula stage. A control was performed 
using mKRB+BSA embryo culture media sans NaPB; however the NaPB used in these experiments was 
dissolved in 10% ethyl alcohol, 20% glycerol. Preliminary experimentation comparing effects o f the 
mKRB+BSA embryo culture media with mKRB+BSA+vehicle (10%EtOI I+20%glycerol) did not produce 
significant results (both yielded passing embryo scores). The mKRB+BSA+vehicle solution was used as 



















72h Differentiation of 2-Cell Mouse Embryos Exposed to  NaPB
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Fig. 10. 72h differentiation of 2-cell mouse embryos exposed to sodium pentobarbital. Effects of NaPB 
indicated by percentage reaching each embryonic stage o f differentiation. NaPB was buffered with mKRB 
media+BSA. Control solution contained mKRB+BSA+vehicle (10% EtOH+20% glycerol) sans NaPB. 
Blast refers to blastocyst (32+ cells).
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NaPB buffered with mKRB media+BSA was tested. Degenerating reters to abnormal development or 
deterioration of the embryo before the compact morula stage. Control solution contained 
mKRB+BSA+vehicle (10%EtOH+20%glycerol) sans NaPB. Blast refers to blastocyst (32+ cells).
72h Differentiation of 2-Cell Mouse Embryos Exposed to  Sodium 
Pentobarbital
J □  300
2-Cell 4- 12-Cell Morula Early Blast
Stage of Differentiation Reached
Hatching Blast
Fig. 11. Detailed 72h differentiation of 2-cell mouse embryos exposed to sodium pentobarbital. 
Differentiation effects indicated by percentage of embryos reaching specific stage of differentiation. NaPB 
was buffered with mKRB media+BSA. Control solution contained mKRB+BSA+vehicle (10% EtOH+20% 
glycerol) sans NaPB. Blast refers to blastocyst (32+ cells).
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30|ig/mL NaPB
■  2-cell 
□  4-cell
□  8- 12-Cell
Fig. 12. Differentiation progress of degenerating embryos following 72h exposure to 30pg/mL sodium 
pentobarbital. Percentages of embryos arrested at the 2-cell stage in comparison to embryos able to 
undergo at least one cleavage division before degenerating and/or fragmenting (4-cell and 8- 12-cell). 
Significance between stages of differentiation of degenerating embryos was only found at this 
concentration.
DISCUSSION
Results of this study suggest that the presence of NaPB produces dose-dependent inhibitory effects on 
in vitro cultured 2-cell mouse embryos. Cleavage and differentiation to the blastocyst stage of 
preimplantation mouse embryos at the 2-cell stage was impeded when exposed to extended culture at 
30pg/mL and 300pg/mL NaPB. At these concentrations, significant embryotoxicity was observed within 
the first 48h of culture and affected the first cleavages. The decreased progression of 2-cell embryos to 
blastocysts during 72h culture indicates embryonal arrest during the first cleavages (two- to eight-cell 
stage), and 100% blastomere degeneration and fragmentation during exposure to the highest dose is 
suggestive o f extreme embryotoxicity. Differentiation was completely inhibited in 100% o f 2 -cell embryos 
exposed to the highest concentration tested, 300pg/mL NaPB, where fragmentation and degeneration was 
present in all embryos cultured at this concentration. Although the industry standard for establishing 
embryotoxicity requires culture of at least 15 embryos per treatment, the 100% toxicity found in 10 
embryos during preliminary investigation o f embryotoxicity of the relevant clinical ED (300pg/mL) NaPB 
was sufficient indication o f a necessity to decrease concentration for additional study. This assumption was 
supported by the wide range of differentiation of embryos observed at the next lowest treatment (30pg/mL) 
once dosages were modified (Table 4; Fig. 11).
At 30(ig/mL NaPB, a significant percentage of embryos displayed a 2-cell block where no cleavage 
divisions occurred. A significant amount of embryos were, however, able to complete one or several 
cleavage divisions before arresting at this concentration (Fig. 11; Fig. 12), as well as a significant 
percentage able to reach the compact morula and early blastocyst stage. Though a significant percentage 
of embryos were able to reach later stages of development at 30pg/mL NaPB, the combined morula + 
blastula embryo morphology score of 46.2% fell well outside the necessary passing score of 75% for 
human IVF,144 and 80% for the mouse embryo bioassay.251 At Opg/mL and 3.0gg/mL (relevant human
56
anesthetic ED),24'73 the embryos degenerating at the 2 -cell stage (less than 4%) are not indicative of a 
significant effect. It is not uncommon for a small percentage o f embryos to fragment or degenerate even 
when cultured with specific embryo culture media.144
Statistical analysis was performed for embryo morphology groups commonly used to evaluate toxicity 
in the 72h mouse embryo bioassay, degenerating, morula, and blastocyst. Detailed examination of 
differentiation, however, produced compelling results when analyzed using %2 for homogeneity and 
difference of proportions. The degeneration and nuclear fragmentation in 53.8% of embryos treated at 
30pg/mL NaPB was significant (Table 4). An apparent significant effect between embryos degenerating at 
30(ig/mL, where 43% displayed a 2-cell block, 29% completed one cleavage division to arrest at the 4-cell 
stage, and the remaining 28% degenerated prior to reaching the morula stage falls outside the critical realm 
for significance (%2, p=0.1633). Significant effects were found between those degenerating, and those 
reaching the compact morula stage (23.1%) or the early blastocyst stage (23.1 %) (y2, p<0.001). This effect 
was statistically significant and is indicative of inhibition in response to embryonic exposure to 30pg/mL 
NaPB. The difference between the groups treated with 3.0pg/mL and 0.3pg/ml. NaPB, and control 
(mKRB+BSA+EtOH+Glycerol), was not found to be statistically significant. This study found insufficient 
evidence to support the assumption that the lower doses (<30pg/mL) of NaPB tested have a significant 
inhibitory effect on the ability of murine embryos to reach the blastocyst stage, however analysis of later 
cleavage stages reveals a fascinating trend. As the concentration of NaPB increases from 0.3gg/mL to 
30|tg/mL, the ratio of embryos reaching the hatching blastocyst stage to the early blastocyst stage 
significantly decreases (0.3pg/mL y l,  p<0.01; 3.0pg/mL y l ,  p<0.001). This effect is likely a result of 
NaPB interference with later embryonic processes involved with blastocyst development and maturation 
and will be discussed below.
The embryotoxicity of NaPB exposure in the current study may be attributed to a variety of 
biochemical mechanisms or a combination of deleterious effects. Exogenous compounds can affect 
development of the preimplantation embryo by increasing oxidative stress, and due to relatively weak 
antioxidant defense during early developmental stages,227 this stress often results in defective 
development.224 Oxidative stress, which has previously been found to produce a developmental block in 
mouse embryos cultured from the 2 -cell stage,224 is a likely factor impeding differentiation in embryos 
cultured in the higher concentrations of NaPB in this study. Although pentobarbital has previously been 
found to suppress free radical generation and increase antioxidant ability,239 NaPB has also been found to 
aggravate oxidative stress damage in some tissues.240
The ability of a significant percentage of embryos to complete at least one cellular division before 
degenerating at 30pg/mL, suggests that at this concentration, many embryos were able to endure toxic 
effects long enough to stagger through at least one additional cleavage. This survival effect may be 
attributed to moderate toxicity at 30fjg/mL NaPB only affecting select cellular processes, perhaps in 
combination with the capacity of embryonic endogenous mechanisms to preserve some normal functions in
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the presence of environmental insult. Embryonic repair may also have assisted in survival at this 
concentration; undifferentiated cells of the early embryo can make repair possible through multiplication of 
cells,4 even if development may still be compromised by non-lethal insults.'51-224
Induced expression of HSPs due to suboptimal culture conditions and constitutive HSP expression 
both represent an essential mechanism for successful embryo growth in an adverse environment, however 
inducible expression is not active until the morula or early blastocyst stage.178 Inadequate HSP expression 
at the time of initial NaPB contact may have contributed to inability of 2-cell embryos to recover from the 
chemical insult of exposure at 30pg/mL and 300pg/mL NaPB. Loss of heat shock factor function has 
previously been found to result in developmental arrest as early as the 2-cell stage197-225-246 similar to the 2- 
cell block at 30ug/mL and 300pg/mL NaPB recorded in this study. Early HSP expression may have also 
assisted in the survival and additional cleavage divisions of a significant percentage o f embryos at 
30pg/mL if this concentration did not overwhelm the minor protective effects of early HSP expression. 
Inducible HSP expression may have contributed to the trend of delayed later development of the embryos 
at 0.3, 3.0pg/mL, and 30pg/mL NaPB as well. This suggests that NaPB exposure affected later processes 
involved with formation and maturation of the blastocyst at 0.3pg/mL and 3.0pg/mL without interfering 
with early cleavage divisions. The induced expression of HSPs up regulated during the morula to 
blastocyst stage may have significantly assisted resistance to NaPB to allow later cleavage and blastocyst 
formation. Although inhibition o f early cleavage up to the morula stage was insignificant at 0.3pg/mL and 
3.0pg/mL, as NaPB concentration increments increased between 0.3pg/mL and 30pg/mL, later 
differentiation was significantly affected (Table 4, Fig. 11). The significant percentage of embryos delayed 
at the morula stage or only reaching the early blastocyst stage at 30pg/mL also supports this assumption.
Cellular fragmentation characteristic o f apoptosis was significant in embryos exposed to 30pg/mL and 
300pg/mL NaPB, and increased apoptosis or an imbalance of apoptotic proteins may have also contributed 
to delayed differentiation observed at 30pg/mL NaPB. In vitro induction of apoptosis may be attributed to 
suboptimal culture conditions, excessive ROS exposure, or chromosomal abnormalities,178 and high levels 
o f apoptosis have previously been detected in fragmenting preimplantation embryos.238 The fragmentation 
of blastomeres observed in this study in degenerating embryos at 30pg/mL and 300pg/mL NaPB was 
indicative of apoptosis, however the exact mechanism by which the apoptotic cascade was initiated is 
unclear. Multiple stimuli such as oxidant insults, pro-apoptotic BAX protein activation, intracellular Ca2+ 
overload, and direct activation of other caspases are capable of activating caspase enzymes to initiate
173apoptosis.
NaPB has previously been shown to increase oxidative stress,240 which is capable o f damaging 
mitochondrial membranes,198 the primary mechanism by which initiation of apoptosis occurs.173 
Mitochondrial damage or alteration of membrane and intracellular proteins can perturb metabolism, which 
could affect nearly every process critical to early development. Mitochondrial function is critical for the 
progression of early development,190 and in addition to initiation of apoptosis, disruption of mitochondrial
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function would primarily affect metabolism during pre-compaction stages, when energy production is
• 179 188 189 *nearly entirely dependent on the mitochondrial TCA cycle. ’ ' Alteration o f the TCA cycle would 
significantly interrupt the main mechanism of ATP production during early embryonic differentiation, 
potentially contributing to the significant degeneration and 2-cell block in embryos cultured at 30pg/mL 
and 300pg/ml, NaPB. The delayed differentiation and arrest of cleavage prior to reaching the blastocyst 
observed in embryos at 30ug/mL NaPB may also be attributed to inhibition o f early metabolism bv NaPB- 
induced mitochondrial damage. Mitochondria are responsible for providing the energy required to 
maintain cellular activity through oxidative phosphorylation and provision of intermediates for glycolysis, 
as well as affecting ion homeostasis, participating in amino acid metabolism, signal transduction, and 
apoptosis.196 In addition, ATP is necessary for embryonic compaction between the 8-cell and morula 
stage,173 as well as for active transport to internalize fluid for formation of the blastocoel165'169'171 to 
generate the blastocyst.165 The expansion of the blastocoel is crucial to the differentiation of the ICM and 
“hatching” of the embryo from the zona pellucida to prepare for uterine implantation. 152 165 174 Later 
delayed differentiation observed in embryos at 0.3pg/mL, 3.0pg/mL NaPB may also be attributed to 
defective mitochondria metabolic effects, depriving embryos of necessary ATP for mitotic divisions and 
blastocyst differentiation; however NaPB may also have affected the trophectoderm Na+/K+ pumps 
necessary for blastocoel expansion.173
Mitochondrial dysfunction may not be the only mechanism by which NaPB potentially interrupted 
metabolism to cause embryonic delay of later differentiation. Embryonic dependence on the TCA cycle 
prior to compaction shifts to a metabolism based on glycolysis between the morula and blastocyst 
stages.179,188,189 During the 8-cell to morula stage, glucose consumption increases dramatically and the 
embryo shifts its metabolism to depend on glycolysis,179 190 and by the blastocyst stage, glucose is utilized 
as the primary energy substrate.166 The glucose transporter GHJT1 is expressed throughout development 
and is thought to provide the embryo with its basal glucose requirements.193 Interference with facilitators 
o f glucose uptake such as GLUT 3 has been shown to result in a high rate of apoptosis at the blastocyst 
stage of murine embryos.244 This was attributed to hyperglycemia associated decreased glucose transport, 
acting as a cell death signal to trigger a BAX-dependent apoptotic cascade.244 This correlation between 
hyperglycemia and elevated apoptosis during the blastocyst stage was proposed to result key progenitor cell 
loss, potentially manifesting as resorption, malformation, or miscarriage,244 pregnancy outcomes increased 
in diabetic women.244'245
Pentobarbital has previously been found to interact directly with GLUT 1 and to inhibit glucose 
transport.48 Inhibition of glucose uptake previously found to be induced by pentobarbital in other tissues 
may also have similar apoptotic effects in the preimplantation embryo. This inhibition of glucose uptake 
by NaPB may have also interfered with the embryonic metabolic transition to glycolysis resulting in 
significant embryonic arrest between the 8-cell and morula stages at 30pg/mL NaPB (15.35%), as well as 
the significant percentage of embryos halted at the morula stage (23.1%) prior to blastocoel formation.
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Down regulation o f glucose transport may significantly contribute to the trend of embryonic delay of later 
differentiation between morula and blastula stages as NaPB dosage increments increased from 0.3- 
30pg/mL. As embryonic metabolism becomes dependent on glycolysis, inhibition of glucose transport may 
directly initiate apoptosis or significantly deprive the embryo of ATP necessary for differentiation and 
blastocoel development to slow or arrest progression.
The embryonic cell cycle can be modified either by introduction of new components, substrates, 
pathways, or altered interactions between them.232 Inhibitory effects found in delayed embryos at 30pg/mL 
NaPB and arresting embryos at 30pg/mL and 300pg/mL NaPB suggest significant modification to the cell 
cycle occurred. Antimitotic effects resulting from NaPB exposure to induce the 2-cell block in embryos at 
30pg/mL and 300pg/mL NaPB could be exerted by a number o f mechanisms. Cell cycle control proteins 
Cdc25 phosphatases235 may be inactivated by ROS, which has been found to lead to a block of the cell 
cycle progression.236 NaPB may also have induced improper attachment of kinetochores to microtubules, 
which would trigger the spindle assembly checkpoint (SAC).210 This effect would have prevented the onset 
of anaphase210 and arrested the cell cycle. At 30pg/mL and 300pg/mL NaPB, the SAC likely contributed 
to the arrest and subsequent degeneration of 2-cell embryos. Several local anesthetics (dibucaine, 
tetracaine, procaine, and lidocaine) have previously been found to significantly affect the organization of 
cytoskeletal components and plasma membrane attachment points223 and similar effect may be produced by 
a general anesthetic such as NaPB.
190 'v>7Oxidative stress is capable of directly causing DNA or RNA damage, "  which may interfere with 
zygotic gene activation (ZGA). The preimplantation embryo is particularly sensitive to oxidative stress 
during ZGA, and any condition which enhances ROS accumulation during ZGA can have detrimental
190 1 7 0  177consequences. Failure to undergo ZGA often results in arrested progression, comparable to the 2- 
cell block of embryos exposed to 30pg/mL and 300pg/mL NaPB. Chromatin remodeling is a necessary 
process for successful ZGA and embryonic differentiation.170 Chromatin remodeling uses energy from 
ATP hydrolysis to restructure or move nucleosome constraints to transcription to make the genome 
accessible to transcription factors, however defective transcription factor function can result in 
developmental arrest.197-225,246 Culture media has previously been found to directly affect gene expression 
(actin, G-3PDH, and Na+/K+ATPase housekeeping genes), transcription factors, and growth factors, as well 
as impacting the rate of degradation of mRNAs which can affect methylation and expression.228 
Interference with chromatin remodeling or transcription factors may have been another contributor to the 2- 
cell block of embryos exposed to 30pg/mL and 300pg/mL NaPB. The zygote and the 2-cell embryo are 
also susceptible to certain mutagens with a delayed expression of damage,157 which may have been another 
factor contributing to the embryonal delay in this study. Future experimentation is necessary to evaluate 
NaPB mutational effects of matemal-effect genes and ZGA, or oxidative stress exerted by any of these 
concentrations affected ZGA to delay differentiation or cause a developmental block at the 2-cell stage.
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The results of this study suggest that subclinical concentrations of NaPB affect preimplantation mouse 
embryo development by delaying or arresting early cleavage. NaPB at 30fig/mL and 300pg/mL 
significantly inhibited embryonic differentiation to the blastocyst stage. Lower concentrations 0.3pg/mL 
and 3.0pg/mL NaPB did not significantly inhibit blastocyst formation; however 3.0ug/mL exerted 
significant inhibitory effects on later differentiation including blastocyst maturation and hatching compared 
to controls and 0.3pg/mL NaPB. This should assist recommendations regarding the use of NaPB 
anesthesia during early pregnancy in humans since these later preimplantation inhibitory effects were 
observed at a concentration within the range of the relevant human ED (2-4mg/kg, 2.0-4.0pg/mL).24,73 
Further testing of concentrations between 0.3pg/mL and 300gg/mL NaPB should provide insight into the 
range of embryonic effects within the range relevant to veterinary/laboratory anesthesia and enable detailed 
analysis o f potential molecular mechanisms contributing to the inhibition of preimplantation embryonic 
development by NaPB.
Detailed examination of NaPB effects on preimplantation embryo biochemistry is necessary to confirm 
that apoptosis is indeed activated by NaPB exposure, that increased apoptosis contributed to inhibited 
differentiation, and to elucidate the mechanism(s) by which apoptosis is initiated. Additional mechanistic 
study is needed for characterization of the significant 2-cell block recorded at NaPB doses exceeding 
3.0pg/mL, and may find a correlation between either direct mutagenic effects or NaPB-exerted oxidative 
stress effects resulting in arrested cleavage. Continued biochemical investigation of NaPB effects in the 
preimplantation embryo should also provide insight into the mechanism by which inhibition is exerted. 
DNA and RNA damage, interference with transcription and transcription factors, suppression of HSP 
expression, antimitotic effects and spindle formation, mitochondrial interactions, initiation of the apoptotic 
cascade, interruption of metabolism and nutrient uptake, or a combination of any of these factors should 
allow a greater understanding of the inhibition caused by NaPB. Investigation of later differentiation may 
also provide insight into how either increased apoptosis or ATP deprivation resulting in insufficient energy 
to sustain further mitosis or power Na+/K+ pumps necessary for blastocoel development may affect the 
inhibition of blastocyst hatching in progressively increasing NaPB concentrations. Many o f these factors 
may be investigated by experimentation in non-embryonic cells such as fibroblasts, mouse embryonic stem 
cells, mammalian micromass cell culture, or sperm cell viability, which would allow decreased expenses 
and animal use for abundant and timely data collection prior to testing effects in the preimplantation 
embryo. Future study of embryo transfer for implantation and fetal development may also provide 
evidence to support significant effects of NaPB on embryonic development does indeed exist and may 
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Ketamine has been a widely used anesthetic in pediatrics, obstetrics, and veterinary medicine. *
The versatility of ketamine,21-26 in addition to positive hemodynamic profile,23-29 analgesic effects,73 and low- 
cost19- 27-29 contributes to its continued use in humans19 despite some associated undesirable emergence 
reactions.28 The psychomimetic effects28-31-32 of ketamine in combination with the abundant availability of 
ketamine contributes to its prevalent abuse.7-11-29-101-116 The widespread use o f ketamine and its potential for 
abuse make necessitates investigation of ketamine effects on embryonic and fetal development.
Ketamine easily crosses the placenta and is rapidly distributed in the fetal tissues,31-64 likely due to its 
relatively low molecular weight.31 Ketamine has also been found to produce uterine artery 
vasoconstriction, a fall in uterine blood flow, and eventual fetal deterioration,12 and umbilical cord 
ketamine concentrations have been found to be higher than maternal blood concentrations.31 Ketamine 
administration produces stimulating effects on the fetus, elevating fetal arterial pressure and heart rate;64 
however, no evidence of fetal hypoxia, metabolic acidosis, or arrhythmia has been found following 
ketamine application.12
Documentation of ketamine developmental defects has been limited to post-implantation 
development.7-11 Toxicity o f ketamine in the preimplantation embryo is previously unreported.
Observations of ketamine developmental effects in CF-1 mice have shown daily 50mg/kg doses from 
gestation day 6-15 to produce insignificant effects on skeletal and visceral anatomy, as well as no increased 
resorptions, dead fetuses, or decreased fetal weight.7 Further histological analysis of the heart, liver, and 
kidney effects, however, has revealed focal nuclear hypochromatosis, interfibrillary edema, parenchymal 
cell degeneration, and proximal convoluted tubule degeneration,7-11 and degenerative effects were found to 
be dose and treatment duration dependent.11
The focus of this study was to evaluate preimplantation embryotoxicity of ketamine HC1. Toxicity of 
long-term exposure to ketamine HC1 in the 2-cell preimplantation embryo is previously unreported. The 
window during preimplantation development, and the dosage and severity of embryotoxic effects which 
may be exerted by ketamine HC1 has not been previously evaluated. Early embryonic stages provide 
indications of potential induction of fetal and postnatal defects,157 and extended exposure allows 
determination of effects of later preimplantation development since some components have the ability to 
affect the development of the blastocyst and inner cell mass directly.151 Extended exposure is valuable for 
the evaluation of potential embryotoxicity of pharmaceutical agents subject prolonged use or habitual
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abuse, and analysis of extended effects is necessary to assess the effects of compounds which may 
compromise embryo development, causing failure of the bioassay without being outright lethal .151
This study was performed with the objective of evaluating the potential of ketamine HC1 to impair 
cleavage through the normal progression of in vitro embryonic development from the 2-cell to the 
blastocyst stage, and the developmental timing and extent to which damage may be exerted. Potential 
adverse effects of ketamine HC1 were assessed by individual culture of preinplantation 2-cell murine 
embryos with incremental concentrations o f ketamine HC1, starting with a range encompassing and 
exceeding normal clinical concentrations, and surpassing the normal clinical duration of exposure. When 
extreme embryotoxicity was realized at concentrations exceeding the normal clinical ED during 
preliminary experimentation, the dosage of ketamine HC1 was modified to a range of moderate effects near 
the relevant anesthetic dose in mice (50-lOOmg/kg, or 50-100pg/mL)105 for follow up experiments. 
Embryotoxicity was assessed by analysis of early cleavage and subsequent differentiation of 2-cell 
preimplantation embryos subjected in vitro to prolonged 72h exposure of ketamine HC1. Detection of 
abnormal embryo morphology including fragmentation, granulation, and degeneration of blastomeres 




Embryos used in the study were produced on IACUC protocol #12-017. Embryos were obtained from 
female mice 6-18 weeks old (B6CBAF]F, purchased from Jackson Laboratories, Bar Harbor, Maine) 
crossed with outbred CD-I males 2-10 months old (Harlan Lab, Indianapolis, IN) This F2 hybrid mouse 
strain has proved to produce consistently high numbers of embryos with 100% development to blastula 
stage in 72h if all culturing variables are at an optimum. Mice were 4-6 weeks old when received and 
acclimated to the animal facility for at least 48h before use and were used within 12 weeks of purchase. 
Mice were maintained on a lighting regime of 14h light, lOh dark at 2 1°-25°C and given water and 
laboratory rodent chow (Harlan) ad libitum. Euthanasia was performed by cervical dislocation, approved 
by the Panel on Euthanasia of the American Veterinary Medical Association.
Superovulation And Mating
Female mice were selected at random for exogenously driven superovulation. Superovulation was 
achieved by intraperitoneal (IP) injection of gonadotropic hormones. IP injection was performed through 
the lower right quadrant o f the abdomen using a lmL syringe with a lA inch 30 gauge needle. Beginning 
four days prior to use, the injection cycle consisted of two injections separated by 48h. The first injection at 
Oh was 0. lmL of a 50 international units (IU)/mL (5 IU) o f pregnant mare serum gonadotropin (PMSG) 
(SIGMA, G4877, 106K1171; St. Louis) in phosphate buffered saline (PBS). At 48h after PMSG injection,
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O.ImL of a 50 IU/mI. (5 IU) solution ofhuman chorionic gonadotropin (hCG) (SIGMA, CG5, 075KI442; 
St. Louis) in PBS was administered. At the time of hCG injection, each female was caged with one proven 
fertile male CD-I mouse. Female mice go into estrous and mate within 6h of hCG injection, with ovulation 
occurring between 10 and 12h after hCG injection. Between 8 AM and 10 AM (16h after hCG injection) 
the following morning, female mice were inspected for vaginal copulatory plugs and the result o f the 
performance of each male was recorded. At this time mated and unmated females were segregated and 
marked appropriately with cage cards; only mated animals were used. Unmated animals were submitted to 
the same injection cycle after a two-week recovery period during which the pituitary gland is less sensitive 
to gonadotropins. Females cycled three times without successful mating were removed and euthanized by 
cervical dislocation.
Collection O f Embryos
Females with vaginal copulatory plugs were euthanized using cervical dislocation starting 
approximately 42h after the hCG injection (pregnancy day 0) and immediately prior to embryo collection. 
The abdomen of the mouse was entered by producing a small hole above the umbilicus then retracting the 
skin simultaneously down over the hind legs and over the forelegs in a process known as de-gloving. This 
technique leaves a sterile field for entry without any mouse hair and obviates use of antiseptic agents that 
may compromise embryo viability. Bilateral celiotomy was performed to expose the oviducts of pregnant 
animals. Salpingectomy was performed by gently stretching and tearing the mesosalpinx and mesometrium 
away from each oviduct and uterine horn, and then cutting between the oviduct and ovary at the cephalad 
end and the oviduct and the intramural junction at the caudal end with microsurgical scissors. The two 
oviducts were then placed in each sterile 35 x 10mm polystyrene culture dish (Nalge Nunc International) 
containing 2mL of modified Krebs-Ringer-bicarbonate (mKRB) medium (See Appendix 1). A Zeiss 
dissecting stereomicroscope (Eastern Microscope Co, Raleigh, N.C.) at 20x magnification, watchmaker 
forceps (Dumont and Fils, Switzerland) was used to slide the fimbriated end of the oviduct onto a 30-gauge 
(FineJect, Henke Sass Wolf) sterile needle attached to a 1 mL sterile syringe (Norm-Ject). Embryos were 
irrigated from the oviducts with medium lightly expressed from the syringe. Each animal can be expected 
to produce an average of 15 embryos per successful mating (successful mating is approximately 1 per 2 
stimulated females = (Z)).
Embryos
Individual morphologically normal (judged by oval, bilateral symmetry of the two blastomeres with 
narrow perivitelline space and presence of two small polar bodies) 2-cell embryos was evaluated at 32x 
magnification and collected from the petri dish with a lOpL micropipette (Eppendorf) fitted with a sterile 
tip (Avant) and aseptically dispensed into 96 well U-bottom culture plates (Falcon, 35-3077) with one 
embryo per well. Embryos were cultured in a NuAire Autoflow IR Water Jacketed C 0 2 Incubator at 37°C, 
5% C 0 2 for 72h. Differentiation was evaluated every 24h at 40x and lOOx using a Nikon Diaphot inverted
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microscope. Each test medium was evaluated in triplicate cultures.
Solutions And Media
Media used was mKRB solution supplemented with 4mg bovine serum albumin (BSA) per ml. (See 
Appendix 1) and conditioned at 37°C 18-24h. Ketamine HC1 (100 mg/mL) (Hospira, Inc. RL-0065) was 
dissolved in mKRB media at various concentrations and equilibrated for at least 12h before use. Control 
solutions included mKRB media for the ketamine HC1 experiments, since during preliminary experiments 
the positive control containing the vehicle (0. lmg/mL benzethonium chloride pH 3.5-5.5) did not produce a 
significantly different result from media solution. Exploratory study was performed with an array of 
concentrations below and exceeding the relevant anesthetic dose (25-100mg/kg, or 25-100gg/mL for a 25g 
mouse) at 1.0,10, 50, 100, 500, 1000, and 5000pg/mL ketamine HC1. A second set o f experiments testing 
20 ,40 ,60 ,80 ,100 , 250}ig/m L ketamine HC1 was then performed to test the range below 100% toxicity 
where inhibition was present.
Statistics
A 72h embryo culture endpoint with minimum development of 65% blastula and combined 80% 
morula + blastula embryo morphology is necessary to report a passing score on the mouse embryo assay.251 
Cell number and overall developmental stage of embryos in specific treatments were analyzed using one- 
factor fixed-effects randomized block analysis of variance (ANOVA) performed using IBM SPSS 20 to test 
for overall significance among treatments. If significance was found, this was followed by Tukey’s HSD 
(honestly significant difference) test (for unequal sample sizes in treatment groups) for differences between 
means of specific treatments. The Shapiro-Wilk test o f normality and Levene’s test of equality of variance 
were also used to evaluate whether samples were normally distributed and if there was statistically 
significant variation between treatments. The significant groups were then tested with for homogeneity 
and difference of proportions. Culture of at least 15 embryos is performed with each item tested to meet 
the CLIA ‘88 federal law to establish toxicity for the tested item. This embryo number (15) was 
established by the R. J. Swanson Mouse Embryo Laboratory as the standard for their testing protocol.
RESULTS
The results of ketamine HC1 experiments are presented in Table 5 and Table 6. Ketamine HC1 did not 
produce any significant inhibitory effects on embryonic development up to and including a concentration of 
50pg/mL during initial studies. At all concentrations greater than 50jig/mL ketamine IlCl, significant 
inhibition of differentiation was observed, with fragmentation and degeneration in 100% of embryos 
cultured at concentrations exceeding lOOpg/mL. All concentrations cultured at greater than 50fig/mL 
ketamine HC1 resulted in a failing mouse embryo assay morula + blastocyst embryo score. The Ong/mL 
ketamine HC1,0.1 mg/mL benzethonium chloride pH 3.5-5.5 control solution produced effects not 
significantly different from control mKRB media, and for follow up experimentation mKRB media was
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used as the control solution. During preliminary experimentation a wide array of concentrations including 
a serial dilution of ketamine HC1 was evaluated. This was performed with the objective o f determining a 
more precise dosage range in which moderate toxic effects were exerted to allow more detailed analysis for 
follow-up experimentation. At 5(XX)ug/mL ketamine HC1, 100% of embryos exhibited a 2-cell block and 
degenerated at the 2-cell stage without completing any cleavage divisions. At concentrations of 
lOOOpg/mL 500gg/mL, and 250pg/mL ketamine HC1, 100% of embryos tested degenerated before 
reaching the blastocyst stage, however within these groups a significant percentage (13.3%) of embryos 
were able to complete at least one cleavage division (Table 5; Fig. 13) (x2, p<0.001).
In the second set of experiments, the concentrations of ketamine HC1 dosages were modified to the 
area within which inhibition was present but not 100% toxic to development (1.0-100pg/mL ketamine 
HC1). Ketamine HC1 dosage increments of 20pg/mL were investigated, ranging from Ong/ml,-1 OOgg/ml., 
and significant inhibitory effects were recorded at concentrations >60pg/mL (Table 5, Table 6). Significant 
degeneration and visible nuclear fragmentation was recorded for 31.5% of embryos treated at lOOpg/mL 
ketamine HC1 (%2, p<0.01). Although the degeneration observed at lOOpg/mL ketamine HC1 was 
significant, 67% of embryos within the degenerating/fragmenting group (21% total) were able to complete 
several cleavage divisions to arrest between the 8-cell stage and just prior to morula by the 72h endpoint 
(Fig. 13 , Fig. 14). This suggests that ketamine IICl inhibitory effects on differentiation may not be limited 
to the first cleavages, but also affects later stages of differentiation. Later inhibition was supported by the 
significant percentage of embryos reaching the compact morula stage (26.3%) and blastocyst stage (42.1%) 
at 1 OOpg/mL ketamine HC1. At SOpg/mL ketamine HC1, significant degeneration and nuclear 
fragmentation was detected in 33.3% of embryos (y l, p<0.001). Similar to the results o f the lOOpg/mL 
group, 60% of degenerating embryos (20% total) completed at least one cleavage division (Fig. 13; Fig.
14). By the 72h endpoint, a significant percentage of embryos at 80pg/mL reached the morula (40%) or 
blastocyst stage (26.7%), however the combined total resulted in a failing embryo score for this 
concentration.
The 60pg/mL ketamine HC1 concentration did not exert effects causing degeneration or fragmentation, 
all embryos at this concentration reached the morula or blastocyst stage. A significant effect was found 
between embryos reaching the morula stage (40%) and those reaching the blastocyst stage (60%) (y l, 
p<0.01), though, suggesting that 60gg/mL ketamine HC1 may have an inhibitory effect to delaying later 
differentiation of the preimplantation embryo. This concentration was also the lowest dosage to result in a 
failing morula + blastocyst embryo score. At 40|ig/mL ketamine HC1 a significant effect (y l , p<0.01) was 
found between embryos reaching the blastocyst stage (66.6%) and those delayed at the morula stage 
(26.7%). A significant inhibitory effect was also present at the lowest concentration tested, 1.0pg/mL 
ketamine IICl, where only 66.7% of embryos at this stage were able to reach the blastocyst stage, 13.3% 
reached the compact morula stage, and 20% degenerated at the 4-cell to 12-cell stage (6.7% at 4-cell). 
Inhibition of development to blastocyst was significant at 1.0pg/mL (x2, p<0.05), although this
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concentration yielded a passing embryo score. At the next highest concentration, lOpg/mL, 93.3% of 
embryos reached the blastocyst stage with 6.7% exhibiting a 2-cell block.
Results o f the one-factor fixed-effects randomized block ANOVA for overall significance among 
treatments found a significant effect between developmental stage groups (degenerating/fragmenting, 
compact morula, and blastocyst) ((F=3.988; d/=2,36; P=0.0273), however a significant difference between 
concentrations was not found. This analysis was followed by Post Hoc Tukey’s HSD test to evaluate 
differences between specific treatments. The Tukey’s HSD test did not reveal a significant effect between 
specific blocks, except between the morula and blastocyst groups (P=0.025). The Shapiro-Wilk test of 
normality indicated that the samples were not normally distributed (P=0.003,0.005,0.010). Levene’s test 
of equality of variance was statistically significant (P=0 .001), indicating a significant effect on 
differentiation by ketamine HC1.
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Ketamine HC1 buffered with mKRB media + BSA was tested at the above concentrations to ascertain 
potential for embryotoxicity. Degenerating refers to abnormal development or deterioration of the embryo 























■  Morula 
□  Blast
Control 1 10 20 40 50 60 80 100 250 500 1000
Concentration Ketamine HO (pg/mL)
Fig. 13. 72h differentiation o f 2-cell mouse embryos exposed to ketamine hydrochloride. Effects of 
ketamine HCI indicated by percentage of embryos reaching specific stage o f differentiation at 72h. 
Ketamine HCI buffered with mKRB media+BSA was tested at the above concentrations. Control solution 
contained mKRB+BSA embryo culture media sans ketamine HCI. Blast refers to blastocyst (32+ cells).
Table 6. Ketamine hydrochloride 72h effects on embryonic development: percentage of embryos reaching
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Ketamine HCI buffered with mKRB media + BSA tested at the above concentrations to ascertain potential 
for embryotoxicity. Degenerating refers to abnormal development or deterioration o f  the embryo before 
the compact morula stage, Blast refers to Blastocyst. Control solution contained mKRB+BSA embryo 
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Fig. 14. Differentiation progress of degenerating embryos following 72h exposure to ketamine 
hydrochloride. Percentages of embryos arrested at the 2-cell stage in comparison to embryos able to 
undergo at least one cellular division before degenerating and/or fragmenting (4-Cell and 8-Cell-12-Cell).
Fig. IS. Degenerating/fragmenting embryos following 72h exposure to ketamine hydrochloride.
Composite image of degenerating/fragmenting mouse embryo morphology following 72h of culture at 
1000jjg/mL ketamine HCI (A) and (B), 500pg/mL ketamine HCI (C), and 250pg/mL ketamine HCI (D). 
(A) Irregular shape of blastomeres and cellular fragments are indications of extensive degeneration and 
apoptosis. (B) Very similar appearance to that o f normal 2-cell embryo, however blastomeres have a more 
granulated appearance than a normal 2-cell embryo. At 72h this morphology is demonstrative of the “2- 
cell block.” (C) 6-8-cell embryo, exhibiting irregular cleavage, and minor fragmentation. (D) 8-cell embryo 
with more compact organized structure than (C), however blastomeres are slightly granulated and 
fragments are visible within the zona pellucida at right. Photomicrographs taken using DIC Optics at 200x,
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Fig. 16. Morula stage embryos following 72h exposure to lOOpg/mL ketamine hydrochloride. 
Photomicrograph taken using DIC Optics at 200x.
Fig. 17. Blastocyst stage embryos following 72h exposure to 50pg/mL ketamine hydrochloride. Expanded 
blastocyst (A) and early blastocyst (B) both categorized as early blastocyst for statistical analysis.
Fig. 18. Expanded blastocyst stage embryos following 72h exposure to ketamine hydrochloride. Effects of 
20gg/mL (A) and lOpg/mL (B) ketamine HCI indicated above.
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Fig. 19. Hatching blastocyst stage embryos following 72h exposure to ketamine hydrochloride. Blastocyst 
stage embryos “hatching” from the zona pellucida following 72h culture at l.Opg/mL ketamine HCI (A) 
and (B), and control mKRB media + BSA (C) and (D).
DISCUSSION
The results of this study suggest that preimplantation murine embryos exposed to ketamine HCI in 
extended in vitro culture exhibit dose-dependent inhibitory effects. Statistical analysis was initially 
performed for embryo morphology groups used for toxicity evaluation in the 72h mouse embryo bioassay 
(degeneration, morula, and blastocyst). Follow-up tests for homogeneity and difference of proportions to 
analyze specific differentiation stages following completion of experimentation found compelling effects. 
Ketamine HCI completely inhibited differentiation to the blastocyst stage at high concentrations 
(250pg/mL, 500gg/mL, lOOOgg/mL, and 5000gg/mL). At these concentrations, significant embryotoxicity 
was observed within 48h of culture and affected the first cleavages, and 100% of embryos arrested and 
degenerated before reaching the morula stage. Detailed analysis of the degeneration within these groups, 
however, showed 5000pg/mL ketamine HCI to be the only concentration to induce a 2-cell block in 100% 
of embryos. A significant percentage of embryos at 250pg/mL, 500pg/mL, lOOOpg/mL were able to 
complete at least one cleavage division before arresting {’f l ,  p<0.001). At lower concentrations 
(<50gg/mL), ketamine HCI produced no significant inhibitory effects on embryonic development (Table 
6), with the exception of 1 Ofig/mL. Since effects o f ketamine HCI on in vitro preimplantation embryo 
differentiation are previously unreported, testing of a wide array of concentrations was necessary to 
determine a more precise range for follow-up experimentation. The concentrations of ketamine HCI 
dosages were modified to include the range found to be inhibitory but not prohibitive to differentiation to 
the blastocyst stage (0-100pg/mL) in exploratory experiments. The coincidence that inhibitory effects were 
observed in embryos cultured near the range of the anesthetic ED for mice (25-100mg/kg, or 25- 
lOOpg/mL) is significant and suggests a concomitant effect.
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Significant degeneration and visible nuclear fragmentation was present in 31.5% of embryos treated 
with lOOpg/mL ketamine HCI. While significant degeneration was observed, only 10.5% of embryos at 
this concentration were arrested at the 72h endpoint, with 21% able to undergo at least one cellular division 
(Fig. 13; Fig. 14). This result suggests that the inhibition of differentiation was not limited to a cleavage 
block at the 2-cell stage, since a significant percentage was able to complete several cleavage divisions 
before arresting (x2, pO.OOl). Signs of embryonic delay were also displayed by embryos treated at this 
dosage, with a significant percentage (26.7%) reaching the compact morula stage, and 42.1% reaching the 
blastocyst stage (x2, p=0.0062). At 80pg/mL ketamine HCI, significant degeneration and visible nuclear 
fragmentation was detected in 33% of embryos (x2, pO.OOl), however a significant difference between 
degenerating, morula, and blastocyst groups was not detected. Further analysis found similar results to 
those of the JOOpg/ml. ketamine HCI group, 20% o f embryos tested (60% of those degenerating, Fig. 14) 
were able to complete at least one cleavage division (x2, p=0.0217). Analysis o f effects on later cleavage 
found no significant effect between embryos reaching morula, early blastocyst, or hatching blastocyst 
stages. Both lOOpg/mL and 80pg/mL ketamine HCI concentrations resulted in similar failing morula + 
blastula embryo scores (68.5% at lOOpg/mL; 66.7% at 80pg/mL ketamine HCI).
Embryos cultured at 60pg/mL ketamine HCI exhibited no significant degeneration, visible nuclear 
fragmentation, or indication o f  early delay or arrest before the morula stage. Although 100% o f embryos at 
60pg/mL ketamine HCI were able to reach at least the morula stage, similar to higher concentrations, a 
failing embryo score resulted since less than 65% reached the blastocyst stage.251 In addition, a significant 
effect was found between embryos reaching the morula stage (40%) and those reaching the blastocyst stage 
(60%) (x2, p=O.0455), as well as between those reaching morula, early blastocyst, or hatching blastocyst 
(x2, pO.OOl). This result suggests that 60pg/mL ketamine HCI exerts inhibitory effects to slow later 
stages of preimplantation embryonic development. At all concentrations below 60pg/mL ketamine HCI, a 
passing embryo score was calculated. Significant differences between degenerating, morula, and blastocyst 
groups were calculated within this range, as well as significant differences between later differentiation 
stages (x2, pO.OO 1). Although the lowest concentration tested resulted in a passing embryo score,
1.0pg/mL ketamine HCI induced a significant degeneration in 20% of embryos (x2, pO.OOl). At this 
concentration, no embryos were blocked at the 2-cell stage, however 20% were arrested between the 4-cell 
and 12-cell stages, 13.3% reached the compact morula stage, and 66.7% reached the blastocyst stage.
While this effect was significant, the early inhibition may not necessarily be attributed to exposure to 
ketamine HCI, since 93.3% of embryos reached the blastocyst stage at the next highest concentration 
tested, lOpg/mL. Problems with culture medium preparations which fail to support adequate embryo 
development are often traced to technician error,141 however only 30-50% of human embryos reach the 
blastocyst stage in vitro, with causes commonly attributed to chromosome abnormality and genetic 
defects.178 In addition, it is not uncommon for a few 2-cell embryos to fragment or degenerate during 
culture with Kreb’s media specifically prepared for toxicity testing and culture of mouse embryos.144 These
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effects may potentially account for the early fragmentation and degeneration found at l.Opg/mL, 10pg/mL, 
20pg/mL, and 40pg/mL ketamine HCI, and conceivably the inhibition of some embryos at higher 
concentrations (>60pg/mL).
The embryotoxicity of ketamine HCI exposure in the current study may be attributed to a variety of 
biochemical mechanisms or a combination of toxic effects. Exogenous compounds can affect development 
of the preimplantation embryo by increasing oxidative stress, and due to relatively weak antioxidant 
defense during early developmental stages,227 this stress often results in severe embryonic damage or 
arrest.190,224'227 Oxidative stress has previously been found to produce a developmental block in 2-cell 
mouse embryos,224 and is a likely factor contributing to impeded differentiation in embryos cultured at 
concentrations above 60pg/mL ketamine HCI in this study. Oxidative stress is also capable of affecting 
development via numerous secondary effects such as directly causing DNA or RNA damage,190,227 as well 
as affecting nutrient uptake and metabolism,198 mitosis,236 and apoptosis.178 Oxidative stress may be 
intensified by autocatalytic effects; free radicals can damage mitochondrial membranes and generate new 
sources of ROS.198 Environmental agents that elevate levels of free radicals may also affect the developing 
embryo by increasing lipid peroxidation and protein oxidation.227 Ketamine has previously been found to 
increase ROS production, induce expression o f oxidative stress-related genes, and dose- and time- 
dependently cause cell death in other tissues;103 similar effects may be exerted by ketamine I ICl in the 
preimplantation embryo.
Induced expression o f HSPs due to suboptimal culture conditions and constitutive HSP expression 
both represent an essential mechanism for successful embryo growth in an adverse environment, however 
inducible expression is not active until the morula or early blastocyst stage.178 A cellular response to 
oxidative stress or chemical insult is increased expression of HSPs.225 HSPs are regulated by heat shock 
factors,170,246 but loss of heat shock factor function has previously been found to result in developmental 
arrest as early as the 2-cell stage. I97-22S-246 Inadequate HSP expression at the time of initial ketamine HCI 
contact may have contributed to inability of 2-cell embryos to recover from the chemical insult of exposure 
at >60pg/mL ketamine HCI and arrest during early cleavage. Early HSP expression may have also assisted 
in the survival allowing additional cleavage divisions of embryos not blocked at the 2-cell stage if this 
concentration did not overwhelm the minor protective effects of early HSP expression.
Inducible HSP expression may have also contributed to the delay o f later development in embryos 
cultured at lower concentrations of ketamine HCI (<60|ig/mL), where inhibited formation and maturation 
of blastocysts occurred without significant interference to cleavage prior to compaction. Induced 
expression of HSPs up regulated during the morula to blastocyst stage may have significantly assisted 
resistance to ketamine HCI to allow later cleavage and blastocyst formation, possibly at concentrations up 
to lOOpg/mL. The significant percentage of embryos delayed at the morula stage or early blastocyst stage 
at concentratioas between 1.0 and lOOpg/mL ketamine HCI (except 80pg/mL) also supports this
73
assumption, however below 40pg/mL effects of inhibition of blastocyst do not significantly differ from 
those recorded in control solutions.
The ability of a significant percentage embryos to complete at least one cellular division before 
degenerating at concentrations up to lOOOpg/mL ketamine HCI demonstrated that even at high 
concentrations, some embryos were able to endure toxic effects long enough to stagger through at least one 
additional cleavage. This capacity for survival was especially significant at concentrations <100pg/mL 
ketamine HCI, and may be attributed to moderate toxicity at lower concentrations only affecting select 
cellular processes, perhaps in combination with the capacity of embryonic endogenous mechanisms such as 
HSPs (even basal expression) to preserve some normal functions. Embryonic repair may also have assisted 
survival; undifferentiated cells of the early embryo make repair possible through multiplication of cells,4 
even if development may still be compromised by non-lethal insults.151224
Blastomeres o f embryos cultured at concentrations above 60pg/mL ketamine HCI displayed substantial 
fragmentation indicative o f clastogenic damage and apoptosis likely contributing to significant inhibition of 
early cleavage. This result is consistent with results previously found with another anesthetic NMDA 
antagonist nitrous oxide,66 where 2-cell, 4-cell, and morula stage embryos were exposed to doses of nitrous 
oxide determine effects on subsequent development following short-term exposure.2 All groups were 
exposed for 30 minutes, but significant effects were only observed in 2-cell embryos treated within 4h of 
expected cleavage. Exposure of the 2-cell embryos to nitrous oxide resulted in significant inhibition of 
blastocyst development compared to control groups. In addition, the majority of affected embryos were 
halted at the 2-cell stage with no further cellular division,2 comparable to the significant 2-cell block 
recorded for embryos cultured at concentrations greater than lOOgg/mL ketamine HCI in this study.
Cellular fragmentation characteristic of apoptosis was significant during early cleavage of embryos 
exposed to concentrations greater than 60pg/mL ketamine HCI, and increased apoptosis or an imbalance of 
apoptotic proteins may have also contributed to delayed differentiation observed during later cleavage of 
embryos cultured between 1 Opg/mL and lOOpg/mL ketamine HCI (with the exception of 80pg/mL). 
Multiple stimuli such as oxidant insults, pro-apoptotic BAX protein activation, intracellular Ca2+ overload, 
and direct activation o f other caspases are capable of activating caspase enzymes to initiate apoptosis,173 
and in vitro induction of apoptosis may be attributed to suboptimal culture conditions, excessive ROS 
exposure, or chromosomal abnormalities.178 High levels of apoptosis have previously been detected in 
fragmenting preimplantation embryos,238 however determination of the mechanism responsible for 
induction of apoptosis in this study requires further investigation.
Alteration of the redox-balance has the potential to induce oxidative stress-mediated damage to 
mitochondrial proteins and result in mitochondrial dysfunction.198 Ketamine has previously been found to 
have significant deleterious mitochondrial effects in neurons, including induced mitochondrial 
ultrastructural abnormalities, decreased inner mitochondrial membrane potential (ATm), and increased 
mitochondrial cytochrome c release, resulting in toxicity by the mitochondrial apoptotic pathway.103
74
Ketamine HCI may also have profound effects on mitochondrial Junction in the preimplantation embryo, 
which would significantly contribute to the inhibition of differentiation observed in this study.
Mitochondrial function is critical for the progression o f early development,190 and mitochondrial 
damage or alteration of membrane and intracellular proteins can perturb metabolism or many other cellular 
processes such as oxidative phosphorylation and provision o f intermediates for glycolysis, affect ion 
homeostasis, signal transduction, and apoptosis.196 In addition to initiation o f apoptosis, disruption of 
mitochondrial function would affect metabolism during pre-compaction stages, when energy production is 
nearly entirely dependent on the mitochondrial TCA cycle.179'188 189 Damage from oxidative stress has 
previously been found to cause cells to shift from oxidative use of pyruvate in the full TCA cycle to use of 
the segment of the TCA cycle involving succinate and succinate dehydrogenase.198 Alteration o f the TCA 
cycle can significantly interrupt the main mechanism of ATP production during early embryonic 
differentiation, potentially contributing to the significant inhibition and degeneration during the first 
cleavage divisions in embryos cultured at concentrations greater than 60pg/mL ketamine HCI. The 
significantly delayed differentiation and arrest of cleavage prior to reaching the blastocyst observed in 
embryos cultured at concentrations between 60-100pg/mL ketamine HCI may also be attributed to 
interrupted metabolism by ketamine-induced mitochondrial damage. ATP is necessary for embryonic 
compaction between the 8-cell and morula stage,173 as well as for active transport to internalize fluid for 
formation of the blastocoel.165'169'171 Expansion of the blastocoel is essential for ICM differentiation as well 
as for embryonic hatching from the zona pellucida.152'165'174 Later delayed differentiation observed in 
embryos at lower ketamine concentrations may also be attributed to metabolic effects resulting from 
mitochondrial dysfunction, depriving embryos of necessary ATP for mitotic divisions and blastocyst 
differentiation; however the trophectoderm Na+/K* pumps necessary for blastocoel expansion may have 
also been affected by ATP deficiency.173 Ketamine-induced oxidative damage to mitochondrial 
membranes may have also contributed to later inhibition by depriving embryos of glycolysis intermediates.
Embryonic dependence on the TCA cycle during pre-compaction stages shifts to a metabolism based 
on glycolysis between the morula and blastocyst stages.179 188 189 Prior to compaction, glucose is not 
utilized as the main energy source,166 but between the 8-cell to morula stage, glucose consumption 
increases dramatically179'190 and glucose is utilized as the primary energy substrate by the blastocyst 
stage.166 Glucose uptake has previously been found to be interrupted by ketamine,48 and the inhibitory 
effect of ketamine HCI on glucose transport may be involved in the delay of later differentiation between 
the morula and hatching blastocyst stages observed in this study. Although the TCA cycle is dominant 
during early cleavages, the glucose transporter GLUT 1 is has been detected at every stage o f development 
and is believed to satisfy basal glucose requirements o f the embryo.193 In addition, interference with 
facilitators of glucose uptake such as GLUT 1 have previously been shown to result in a high rate of 
apoptosis during the blastocyst stage.244 The inhibition of GLUT 1 and associated decreased glucose 
transport previously found to be induced by ketamine may have a similar apoptotic effect on the mouse
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embryo. Once embryonic metabolism becomes dependent on glycolysis, ketamine HCI induced inhibition 
of glucose transport may significantly slow cellular processes and result in arrest before the blastocyst stage 
similar to that observed in embryos cultured at 40ug/mL, 60gg/mL, 80pg/mL, and lOOpg/mL. Increased 
apoptosis resulting from interference with facilitators of glucose uptake by ketamine HCI may have also 
contributed the later inhibition at 40pg/mL, 60pg/mL, 80pg/mL, and lOOpg/mL.
In the embryo, the cell cycle can be modified either by introduction of new components, substrates, 
pathways, or altered interactions between them.232 At different phases of the cell cycle, the embryo may be 
more resistant or sensitive to environmental factors. Inhibitory effects found in the highest concentration 
groups suggest there significant modification to the cell cycle, possibly due to differences in sensitivity to 
ketamine HCI at various points within the cell cycle during initial exposure. During the G 1 phase of the 
cell cycle, preimplantation embryos are particularly susceptible to environmental factors.15 The timing of 
teratogen exposure during the cell cycle is consequently very important to embryonic survival, and 
embryotoxic effects during early cleavage have previously been attributed to cell cycle differences.15 At 
the time of initial ketamine HCI contact, affected embryos may have been at the sensitive G1 phase or at a 
transition in stages of the cell cycle, which could differ between embryos depending on the timing of 
insemination.15 This could potentially contribute to the significant variation in sensitivity to ketamine HCI 
found at 80pg/mL and lOOpg/mL (Table 6; Fig. 13; Fig. 14).
Antimitotic effects resulting from ketamine HCI exposure to induce the 2-cell block in embryos at 
80pg/mL and lOOpg/mL ketamine HCI, and especially 2-cell block of embryos between 250-5000pg/mL 
ketamine HCI could be exerted by a number of mechanisms. Cell cycle control proteins Cdc25 
phosphatases235 may be inactivated by ROS, which has been found to lead to a block of the cell cycle 
progression.236 Ketamine HCI may also have induced improper attachment of kinetochores to 
microtubules, which would trigger the spindle assembly checkpoint (SAC).210 Activation o f the SAC can 
prevent the onset o f anaphase210 to arrest the cell cycle. At higher concentrations, especially above 
lOOpg/mL ketamine HCI, the SAC likely contributed to the arrest and subsequent degeneration of 2-cell 
embryos. Several local anesthetics (dibucaine, tetracaine, procaine, and lidocaine) have previously been 
found to significantly affect the organization of cytoskeletal components and plasma membrane attachment 
points223 and similar effect may be produced by a general anesthetic such as ketamine HCI.
The preimplantation embryo is particularly sensitive to oxidative stress during ZGA, and any condition 
which enhances ROS accumulation during ZGA can have detrimental consequences.190 Failure to undergo 
ZGA often results in arrested progression,170 177 comparable to the 2-cell block of embryos exposed to 
80pg/mL, lOOpg/mL, and especially between 250-5000pg/mL ketamine HCI. Chromatin remodeling, a 
process requiring competent transcription factor function, is necessary for successful ZGA and embryonic 
differentiation,170 and defective transcription factor function can result in developmental arrest.197-225'246 
Culture media has previously been found to directly affect gene expression (actin, G-3PDH, and 
Na+/K+ATPase housekeeping genes), transcription factors, and growth factors, as well as impacting the rate
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of degradation of mRNAs which can affect methylation and expression.228 Interference with chromatin 
remodeling or transcription factors may have been another contributor to the 2-cell block of embryos in 
higher concentrations. The zygote and the 2-cell embryo are also susceptible to certain mutagens with a 
delayed expression of damage,157 which may have contributed to the embryonal delay observed in embryos 
at 60|ig/mL, 80pg/mL, and lOOpg/mL ketamine HCI. Future experimentation is necessary to determine 
whether the higher doses of ketamine HCI (>60pg/mL) induced a direct mutation o f maternal-effect genes 
and affected or prevented ZGA, or oxidative stress exerted by any of these concentrations affected ZGA to 
delay differentiation or cause a developmental block at the 2 -cell stage.
The results of this study suggest that exposure to ketamine HCI near and exceeding clinical 
concentrations affects preimplantation mouse embryo development by delaying or arresting early cleavage. 
Ketamine HCI at concentrations within the range of the clinical ED (>60pg/mL ketamine HCI) 
significantly inhibited in vitro differentiation to the blastocyst stage. Concentrations below 60pg/mL 
ketamine HCI, however, did not significantly affect differentiation to the blastocyst stage. Further testing 
of concentrations below and within the range of relevant clinical dose o f ketamine HCI (25-100pg/mL) 
should enable detailed analysis of potential molecular mechanisms contributing to the inhibition of 
preimplantation embryonic development by ketamine HCI.
Detailed examination of ketamine HCI effects on preimplantation embryo biochemistry is necessary to 
confirm that apoptosis is indeed activated by ketamine HCI exposure, that increased apoptosis contributed 
to inhibited differentiation, and to elucidate the mechanism(s) by which apoptosis is initiated. Additional 
mechanistic study is needed for characterization of the significant 2-cell block recorded at ketamine HCI 
doses exceeding 60pg/mL, and may find a correlation between either direct mutagenic effects or ketamine- 
exerted oxidative stress effects resulting in arrest of cleavage. Continued biochemical investigation of 
ketamine HCI effects in the preimplantation embryo should also provide insight into the mechanism by 
which inhibition is exerted. DNA and RNA damage, interference with transcription and transcription 
factors, suppression of HSP expression, antimitotic effects and spindle formation, mitochondrial 
interactions, initiation of the apoptotic cascade, interruption of metabolism and nutrient uptake, or a 
combination of any o f these factors should allow a greater understanding of the inhibition caused by 
ketamine HCI. Investigation of later differentiation may also provide insight into how either increased 
apoptosis or ATP deprivation resulting in insufficient energy to sustain further mitosis or power Na+/K+ 
pumps necessary for blastocoel development may affect the inhibition of blastocyst hatching in 
progressively increasing ketamine HCI concentrations. Many o f these factors may be investigated by 
experimentation in non-embryonic cells such as fibroblasts, mouse embryonic stem cells, mammalian 
micromass cell culture, or sperm cell viability, which would allow decreased expenses and animal use for 
abundant and timely data collection prior to testing effects in the preimplantation embryo. Future study of 
embryo transfer for implantation and fetal development may also provide evidence to support significant
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effects o f ketamine HCI on embryonic development does indeed exist and may potentially result in a 




The potential teratogenic risk of anesthetic medications is difficult to assess in vivo.5 Pregnant patients 
requiring surgery often have an infection or fever which may be detrimental to development in addition to 
hemodynamic changes and metabolic disturbances related to the surgery itself.5 Data from in vitro assays 
of tissue, cellular and biochemical functions from animal models are useful for evaluation o f human safety 
risks.156 The limitations o f extrapolating potential for human risks from in vitro and animal studies are 
largely attributed to lack of cross-species translation.156 Differences in biological pathways and 
pharmacokinetics between species156 combined with the complexity of mammalian reproduction, makes 
modeling and characterization of complete chemical effects on mammalian reproduction impossible.144 In 
vitro culture may never be able to encompass all aspects of prenatal development; however the lack of 
validated alternative tests of embryonic development from gamete maturation to embryo implantation, 
makes animal testing and in vitro culture the only current option to assess the possible effects of exogenous 
agents to development.149,162 Breaking down mammalian reproduction to biological components allows 
functions to be studied individually or in combination,162 and isolation of components can assist in 
classification of chemicals as harmful to development.149-162 Whether sufficient information can be derived 
from the results of these tests to label agents toxic to the developing embryo is debatable, and one must be 
cautious when attempting to translate the results o f laboratory embryotoxicity studies to humans. Culture 
of the mammalian preimplantation embryo in vitro is associated with decreased viability,254 however 
blastocyst morphology provides a good indicator of embryonic potential for implantation and subsequent 
development.152 The results o f  the current study o f  the effects o f prolonged exposure to propofol, NaPB, 
and ketamine HCI to early mouse embryonic development suggest potential risks during early pregnancy.
The results o f this study also suggest that concentrations near the clinical ED for propofol and 
concentrations well below the ED of NaPB inhibit development of the preimplantation mouse embryo by 
delaying and arresting embryonic cleavage. The results o f this study also suggest that exposure to ketamine 
HCI near and exceeding clinical concentrations delays or arrests early cleavage, and ketamine HCI at 
concentrations within the range of the clinical ED (>60pg/mL ketamine HCI) significantly inhibited in vitro 
differentiation to the blastocyst stage. Ketamine I ICl also exerted 100% inhibition of differentiation to 
blastocyst at concentrations above lOOpg/mL. Lower test concentrations o f all three compounds (< 
3.0gg/mL NaPB, <60pg/mL ketamine, and <2.0pg/mL propofol), did not significantly affect differentiation 
to the blastocyst stage. Further testing o f concentrations below and within the range o f relevant clinical 
dose o f propofol (human 1.5-2.5pg/mL, 1.5-2.5mg/kg), veterinary conentrations of ketamine HCI (mouse 
25-lOOpg/mL, 25-100mg/kg), and below relevant concentrations of NaPB (0-300pg/mL, 0-300mg/kg 
depending on species) should enable detailed analysis and characterization of potential molecular
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mechanisms contributing to the inhibition of preimplantation embryonic development by all three 
compounds.
Detailed examination of propofol, NaPB, and ketamine HCI effects on preimplantation embryo 
biochemistry is necessary to confirm that apoptosis is indeed activated by exposure to these anesthetics, 
that increased apoptosis contributed to inhibited differentiation, and to elucidate the mechanism(s) by 
which apoptosis is initiated. Additional mechanistic study is needed for characterization of the significant 
2-cell block recorded at higher concentrations of these drugs, and may find a correlation between either 
direct mutagenic effects or drug-induced oxidative stress effects resulting in arrest of cleavage. Continued 
biochemical investigation o f anesthetic effects in the preimplantation embryo should also provide insight 
into the mechanism by which inhibition is exerted. DNA and RNA damage, interference with transcription 
and transcription factors, suppression of HSP expression, antimitotic effects and spindle formation, 
mitochondrial interactions, initiation of the apoptotic cascade, interruption of metabolism and nutrient 
uptake, or a combination of any of these factors should allow a greater understanding of the inhibition 
caused by propofol, NaPB, and ketamine HCI. Investigation of later differentiation may also provide 
insight into how either increased apoptosis or ATP deprivation resulting in insufficient energy to sustain 
further mitosis or power Na+/K+ pumps necessary for blastocoel development may affect the inhibition of 
blastocyst hatching in progressively increasing anesthetic concentrations.
Probing for receptors or specific biochemical responses may be accomplished using radiolabelling with 
substances such as radioactive amino acids (e.g. [35S]methionine), however the radioactivity itself may 
damage chromatin, DNA, or other vital cellular components.235
Many of these factors may be investigated by experimentation with non-embryonic cells such as 
fibroblasts, mouse embryonic stem cells, mammalian micromass cells, or testing sperm cell viability.
These tests would decrease expenses, time, and animal use to maximize data collection prior to testing 
effects in the preimplantation embryo. Results of these tests would serve as preliminary indicators of 
effects, not as a replacement for study of embryo culture; sufficient information may not be derived from 
alternative tests to allow classification of chemicals as toxic to embryonic development.’49162 
Understanding the mechanisms underlying the inhibition induced by these drugs would greatly assist in the 
prevention of teratogenesis caused by exposure to these anesthetics.
Future study of embryo transfer for implantation and fetal development may also provide evidence to 
support significant effects of propofol, NaPB, or ketamine HCI on embryonic development does indeed 
exist and may potentially result in a decrease in live pup births (embryo or fetal resorption) or an increase 
in teratogenesis/birth defects. In addition to analysis o f neonatal pups, ultrasound study o f embryonic and 
fetal effects of anesthetic exposure at various developmental stages may provide valuable information of 
potential for teratogenesis. Selection of specific time points during development is necessary since real­
time study of embryonic development is a difficult, tedious, and expensive endeavor, requiring use of more 
animals and equipment,155 or collective culture of embryos which may also affect results. Additional study
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of alternative agents such as thiopental, etomidate, IV anesthetic cocktails, and inhalation agents may also 
be performed once model experiments using propofol, NaPB, and ketamine HCI have concluded.
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APPENDIX 1 











BSA (Bovine Serum Albumin) 0.4000g
Pen/Strep 1.0 mL if 5000 IU
Osmolarity Range: 270-300 mOsm/kg H20  
pH Range: 7.4-7.8
For preparation of lOOmL mKREBS solution. After composition, media is checked for a pH value between 
7.6 and 7.8 (before C 02 equilibration); filter-sterilized into 150 mL red-necked, 0.22 pm filter units 
(Nalgene), dispensed into the tissue culture tubes, and incubated at 37°C in 5% C 02 in air for at least 18h 
before use.
Lactate, Pyruvate, BSA in refrigerator 
Pen/Strep in freezer
Other reagents in desiccator under vacuum
Place approximately 125 mL ultra-pure water into beaker with stir-pellet 
Use sterile 2 mL pipette for Pen/Strep
Be careful not to create bubbles (stir too fast) when adding BSA 
Carefully drop Pen/Strep onto BSA to facilitate dissolving
96
APPENDIX 2 
TWO-DIMENSIONAL CHEMICAL STRUCTURES OF COMPOUNDS 
DESCRIBED IN INTRODUCTION
Fig. 20. GAB A chemical structure. Gamma-aminobutyric acid C4H9NO2 M.W. 103.11976 g/mol.256 
National Center for Biotechnology Information. PubChem Compound Database; CID=119, 
http://pubchem.ncbi.nlm.nih.g0v/compound/l 19
'V .
Fig. 21. Glutamate chemical structure. L-glutamic acid C5 H9 NO4  M.W. 147.12926 g/mol.256 National 
Center for Biotechnology Information. PubChem Compound Database; CID=33032, 
http: //pubchem. ncbi. nlm. nih. gov/compound/3 3032
97
Fig. 22. NMD A chemical structure. A'-mcthyl-D-aspartate C5H9NO4M.W. 147.12926 g/mol.256 National 
Center for Biotechnology Information. PubChem Compound Database; CID=22880, 
http://pubchem.ncbi.nlm.nih.gov/compound/22880
Fig. 23. Propofol chemical structure. 2,6-Diisopropylphenol C I2H |8() M.W. 178.27072 g/mol.256 
National Center for Biotechnology Information. PubChem Compound Database; CID=4943, 
http://pubchem.ncbi. nlm. nih. go v/compo und/4943
Fig. 24. Sodium pentobarbital chemical structure. Sodium;5-ethyl-5-[(2R)-pentan-2-yl]pyrimidin-3-ide- 
2,4,6-trione C nIIn^N aC b  M.W. 248.254049 g/mol.256 N ational C enter for B iotechnology Inform ation. 
PubChem Compound Database; CID=23692753, http://pubchem.ncbi.nlm.nih.gov/compound/23692753
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It
Fig. 25. Ketamine hydrochloride chemical structure. 2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1. 
one .hydrochloride C ijH 17C12NO M.W. 274.18618 g/mol.256 National Center for Biotechnology 
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